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SUMMARY 
THE BIOSYNTHESrs OF TETRAHYDROBIOPTERrN IN THE RAT 
De novo tetrahydrobiopterin biosynthesis has been studied in vitro 
using rat brain supernatants. G. T. P. was shown to be the best precursor 
for the biosynthetic pathway. NADPH, magnesium ions, pyrimidine 
antagonists and 5-methyltetrahydrofolic acid, particularly when coenzyme 
B12 was present, were shown to stimulate tetrahydrobiopterin production. 
Tne de novo biosynthesis of tetrahydrobiopterin was inhibited by metal ions, 
particularly lead, purine antagonists and a range of dihydrofolate reductase 
inhibitors which led to the postulation of a feedback control mechanism of 
its biosynthesis by tetrahydrobiopterin. 
The activity of dihydropteridine reductase has been measured by an 
in vitro assay after purification from rat liver by affinity chromatography 
using sodium 1, 2-naphthoquinone-4-sulphonate as the ligand. The enzyme 
was purified 900 fold over the original supernatant and quinonoid dihydro-
biopterin and NADH were found to be the best substrates with apparent Km 
values of 9.2. l0- 6 M and 3.2. 10-SM respectively. Dihydropteridine 
reductase was inhibited by a range of dihydrofolate reductase inhibitors, 
aromatic amino acids, phenylalanine metabolites, neurotransmitters and 
metal ions. The enzyme was shown to exhibit co-operativity and to have 
more than one binding site per enzyme molec14.le.. Dopamine and noradren-
aline are probably feedback inhibitors of dihydropteridine reductase to 
control their own biosynthesis and inhibit by binding to an allosteric site. 
It is suggested that this enzyme may be a regulatory point for dopamine 
biosynthesis. Phenylalanine and phenyl.pyruvate inhibit dihydropteridine 
reductase at concentrations which occur in untreated phenylketonurics and 
could be the cause of the neurological defects associated with this di sease 
due to decreased catecholamine neurotransmitter production as a result of 
decreased cellular tetrahydrobiopterin levels. 
A model for the regulation of cellular tetrahydrobiopterin levels was 
proposed and discussed in the light of the results of in vivo studies as 
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Naturally-occurring derivatives of the parent com pound 2-am lno-
4-oxodihydropteridine (1) are called pterins and are a widely distri buted 
class of compounds. The num0ering of foe r ings is as shown in figure 








extracted a yellow pigment from )utterfly wings (Hopkins 1889). This 
was followed in 1925 by the isolation of yellow and white pigments by 
Wleland and Schopf. (1925) Pumnan finally determined the structures 
of these natural pigments after much experimental difficulty in 1940- 1. 
They were named xanthopterin (2), leucopterin (3) and isoxanthopterin 
0 H 
HN 




(4). (Purrman 1940a, Purrman 1940b, Purrman 194i) . 
- 1 -
Much work on pterins has concerned their isolation and iren tif -
ication from butterflies: moths and other insects. (Zeigler and 
Harmsen 19 69) Other extens ively studied groups of pterins are those 
(3) 





Pterins are only present in small concentrations in organisms 
and some are chemically, vezy lablle. Thus working with them and 
their identification from natural sources presents great difficulties. 
The compounds isolated could be analytical artlfacts as suggested 
with regard to xanthopterin (2) from Drosophila eyes (Koschara 19 36, 











The method by which pterins are extracted from their natural 
sources depends on the solubility and lability of the pterin in question. 
Relatively soluble pterins such as biopterin (6), neopterin (7) and 
HN 





seplapteri.n (8) can be isolated from trichloroacetic acid extracts. 
Labile hydrogenated pterins are stabilized under these acidic conditions. 
Acid insoluble pterins such as isoxanthopterin (4) and leucopterin (3). 
0 
HN 
HNA 2 N 
(7} 
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can be extra c ted in bas ic s olvents . In order to prevent degradat ion 
of the re du ce d ac id-ins oluble pterins, me rcaptoethanol must )e added 
to t he ba s ic solvent . (Lagowski a nd Fornut 19 67) 
(B) 
Once the pterins have been isolated they can be purified by 
chromatograph ic or ele ctrophoretic methods (Rem bold and Gyure 19 72) 
and then identified using a v ariety of methods including ultra-violet 
absorption spectrometry, (Blakley 19 69) fluorescence emission s pec t-
rometry, (Uyeda and Rabinowitz 1963) chromatograph ic behav iour, 
(Blakley 1969) enzyme tests, (Guroff 1971) colour tests, (McNutt 1964) 
mass spectrometry, (Van der Have-Kirchberg, de Moree, Van Laar, 
Gerwig, Versluis and Ebels 1977) gas chromatography, (Haug 1970, 
Lloyd, Markey and Weisner 19 71) high performance liquid chromato-
graphy (Fu kushima and Nixon 19 78) and microbiologic al assays such 
as Lactobacillus easel, Streptococcus faecalis and Pediococcus 
cerevista e for folate derivatives (Blakley 1969) and Crithidia fasci c ulata 
for unconjugated pterins. (Dewey and Kidder 19 71) 
Because of their electronegative nature the nitrogen a t oms of the 
pterin rings corn pete with the TI electrons of the system and partially 




localise the latter. X-ray analysis of pteridine (9) has indicated a 
planar arrangement of the atoms. Bond angle and bond len gth 
measurements have shown that pteridine (9) is not centrally symmetric. 
(1 O) Pterins exist in tautomeric forms but the one favoured at equilibrium 









exist in the form of the true cyclic amides (11) and do not have the 
vinylogous amide structure (12 , 13). (Pfleiderer 1964) 
- 5 -
(12) ( I I) (13) 
Biopterin (6) was isolated from human urine in 1956 by Patterson 
and his colleagues. (Patterson, Von Saltza and Stokstad 1956) Th is 
pterin bears a dihydroxypropyl side-chain on carbon atom 6. The 
possession of such a side-chain means that there are two chiral 
carbon atoms at positions l' and 2' and therefore four optical 
isomers of ,biopterin. (14) The erythro and threo isomers can be 
conveniently separated from -one another by chromatography . The erythro 






















I I 3 
H OH 
L-threo 
R. "' 2 amino-4-hydroxypteridine group 
(14} 
- 6 -
more acti V(; th:m the D form. For further identification of the threo series 
lt is necessary to measure optical rotations. (Green and Rembold 1966) 
The correct isomeric form is very important in biological systems a , 
enzymes are able to utilize only certain isomers. For example , the L 













synthesis of folic acid (16) in L. plantarum but also is an effective 
inhibitor of the D erythro form utilization. (Rembold and Gyure 1972) 
0 0 ~ 1ooH HN C-N-CH I I I N CH H CH 
X 2 I 2 CH I 2 ~ H COOH 
(I G) 
A very important biochemical property of pterins is their ability 
to form dihydro- and tetrhydro- .derivatives for example, 7, 8 dihydro-
biopterin (1 7) and 5, 6, 7, 8 tetrahydrobiopterln (18). 












In the tetrahydro- form there is yet another chiral carbon atom, 
at position 6 . There are therefore two diastereoisomers of the natur-
ally occurring isomer, the L erythro form of tetrahydrobiopterin (18) 
0 ~ ~ 
~~C-C-CH 





There have recently been separated using high performance liquid 
chromatography. (Bailey and Ayling 1978) The natural isomer is 
probably the [S] isomer as it ls formed by the enzyme dlhydrofolate 
reductase in mammals. This enzyme has recently been shown to 
reduce 7, 8 dihydrofolic acid (19) and 6 methyl 7, 8 dihydropterin (20) 
stereos pecifically to the [s] configuration. (Arm are go, Waring and 
















act as cofactor for phenylalanine hydroxylase with identical Km values 
the natural isomer gave a faster V value and also stimulated sub-
max 






Biopterin derivatives have been measured in human and rat tissues 
and fluids, (Baker, Frank,Bacchi and Butner 1974) including blood, 
serum (Frank, Baker and Saboka 19 63) and urine. (Fukushima and 
Shiota 1972,.Fabst and Rembold 1966) It is difficult to exactly 
identify the derivatives present in tissues because the reduced forms 
are so reactive. (Blair and Pearson 1974) Biopterin (6) isolated 








( 2 I) 
the dihydro- or tetrahydro- forms because the oxidation of S, 6, 7, 8-
tetrahydrobiopterin (18) proceeds rapidly to 7, 8 dihydrobiopterin (17) 
and then to biopterin (6). (Blair and Pearson 1974, Metzyer, Rembold 
and Gutensohn 1971) However a variety of methods are now available 
for measuring biopterin derivatives. One method which is useful for 
large numbers of samples and yet at the same time ls sensitive and 
specific is gas chromatography/mass fragmentography. The pterins 
have to be converted to thelr trimethylsllyl derivatives lnitially to make 
them volatlle enough for gas chromatography separation. (Rother and 
Karobath 1976) An extremely sensitive method is reverse-phase high 
performance liquid chromatography following lnltial iodine oxidation 
and separation by ion-exchange chromatography. This method was 
used recently to show that biopterin is present in mammalian tissues 
predominantly in the tetrahydro- form. (Fukushima and Nixon 1980) 
Tetrahydrcibiopterin (18) can be assayed enzymatically by measuring 
phenylalanine hydroxylase activlty as this enzyme exhiblts an 
absolute cofactor requirement fortetrahydrobiopterin (18). (Guroff, 
- 10 -
a nd Abramowitz 196 7) Th is method is therefore very specific for tet -
rahydrob iopterin a lone but if t he assay medium contains dihydropterid-
ine re ducta s e and NADH there i s a pos s ibillty that reduction of endo-
gen ous quin~:moid dihydrob iopterin (22) may contribute t o the activity 
me asure d. This a ssay has b e e n u sed to demonstrate the regional 
distribution of t e trahydrobiopterin ( 18) in ra t bra in . (Bulla rd , Guthrie, 
0 H H 
I I 
HN ~ HOH OH 3 N~C-C-CH 
HN~N~ N ~ 
H 
(22) 
Russo and Mandell 19 78) The Crithidia fasci cula ta assay has proved 
itself to be an invaluable tool for me asuring biopterin derivatives in 
animal tissues and flu ids. This protozoon is e x tremely selectl ve in 
the pterins it can use for growth. Biopterin (6) and its re duced 
derivatives dihydrobiopterin (17) and tetrahydrobiopterin (18) are t h e 
best pterln sources and only L-Neopterin (7) and pteroic acid (2 3) 





Hf~ N~ H 
(23) 
- 11 -
approach their growth - stimulating capacity. (Baker, Frank, Bacchi 
and Hutner 1974, Leeming and Blair 1974) This assay is also very 
sensitive as well as specific because Crithldia fasciculata responds 
to very low concentrations of the Crithidia-active pterins. This 
method can be supplemented with t!'iin-layer or paper chromatography 
in a range of solvent systems in order to establish the identity of the 
particular pterins being utilized by Crithidia fasciculata. (Blakely 
1969, Leemlng 1975) 
The reduced pterin forms are very reactive and can serve as 
specific reductants and can also participate in cellular electron trans-
port reactions. 
Evidence for the participation of unconjugated reduced pterins 
in the photosynthetic process has been put forward (Fuller and Nugent 
1969) and it is suggested that they are the primary photochemical 
electron-acceptors for photosystem I in higher plants and for the single 
primary photochemical act in bacterial photosynthesis. However, 
pterins have not been clearly demonstrated in chloroplasts and the 
standard reduction potential for tetrahydropterins is + 0. 15 V. 
(Archer and Ser im ge our 19 7 0) Since that of ferredoxin ls -0. 42 V 
the expected reaction would be a reverse sequence of the electron flow 
proposed. (Rembold and Gyure 1972) 
- 12 - I 
However, the function of pterins in mitochondria is much clearer. 
Tetrahydrobiopterin (18) has been found in the mitochondrial matrix in 
concentrations similar to those of the cytochromes. (Rembold and 
Metzger 19 6 7) Mitochondrial respiration can be stimulated by reduced 
pterins at physiological concentrations and the utilization of oxygen is 
linearly proportional to the amount of tetrahydrobiopterin (18) present. 
Cytochrome C is readily reduced by tetrahydrobiopterin (18) according 
to its more positive redox potential of + 0.22 V. (White, Handler 
and Smith 1973) A soluble electron tr2.nsport system can be formed 
but the tetrahydrobiopterin-catalysed respiration is not coupled to ATP 
production. The pathway would be of importance if cells must regen-
erate pyridine nucleotides under high hydrogen pressure without the 
production of ATP but the physiological significance of this pathway is 
not really known. (Rembold and Buff 1972a, Rembold and Buff 1972b, 
Rembold 1975) 
The best-studied reductant function of tetrahydroblopterin (18) ls 
its role in the oxidation of aromatic am lno acids. Tetrahydrobiopterin 
(18) was shown to be the natural cofactor for the enzymes phenylalanine 
hydroxylase, (Kaufman 195 7, Kaufman 1958) tyrosine hydroxylase 
(Nagatsu, Mizutani, Nagatsu, Matsura and Sugimoto 19 72) and 
tryptophan -hydroxylase. (Hoseda and Gluk 19 66) Other reductants 
such as ascorbate, glutathlone, ferrous ions etc. cannot replace tetra-
hydrobiopterln (18), therefore, it has been established as the s peciflc 
cofactor for these aromatic amino acid hydroxylations. Of the four 
- lJ - I 
isomers of reduced biopterin, the L erythro form, the naturally-occurr-
ing one, has been shown to be the best cofactor. (Osanai and 
Rembold 1971) Other tetrahydropteridine-dependent oxygenase 
reactions ar~ cinnamic acid hydroxylation, (Nair and Vining 1965' 
Cinnamic acid+ PtH4 + 0 2





and the oxidation of long chain alkyl ethers of glycerol to fatty acids 
and glycerol. (Tietz, Lindberg and Kennedy 19 64) Others have been 
reported but not conclusively proved and need validation especially as 
OH 
CH2 0-CH -R CH OtHR 










glyca-ol + RCHO 
reduced pterins can indirectly catalyse an enzyme reaction by protect-
ing the enzyme from inactivation (Zamoni, Brown and La D .u 1963) 
Phenylalanine hydroxylase catalyses the conversion of phenyl-
alanine (21) to tyrosine (24). Certain regulatory features displayed by 




2 --->~ Tyrosine + q BH2 + H 2 O 
- 14 - I 







site for tetrahydrobiopterin (18) on phenylalanine hydroxylase as well 





N H 3 
H 
(25} 
Tyrosine hydroxylase catalyses the conversion of tyrosine (24) to 





(Figure 27} (Levitt, Spector, Sjoerdsman and Udenfriend 19 65) It has 




































been shown that the amount of tetrahydrobiopterin (18) is the rate-
limiting factor for this reaction. (Kettler, Bartholini and Pletscher 
19 74) Other controlling factors are end-product inhibition by 
catecholami_nes competing for the pterin site and activation of the 
enzyme by allosteric changes. (Costa and Meek 1974) 
Tryptophan hydroxylase catalyses the conversion of tryptophan 





---> 5 hydroxytryptophan + q BH2 + H 2 0 




Tetrahydrobiopterin (18) is again present in limiting concentrations for 








rate-limiting factor. (Costa and Meek 19 74) 
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q,BH + H 0 
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As tetrahydrobiopterin ( 18) plays such an important role in neuro-
transmitter biosynthes is the metabolism of tetrahydrobiopterin (18) itself 
and anything which effects it is of great significance. 
During the reactions catalysed by the hydroxylase enzymes 
tetrahydrobiopterin (18) is converted to quinonoid dlhydrobiopterin (22) 
which has no cofactor activity for the hydroxylases. Therefore, a 
method of regeneration of the active cofactor fonn or a constant supply 
of tetrahydrobiopterin (18) is required. 
Dlhydropteri.diI'le reductase is the enzyme which converts 
quinonoid dihydrobiopterin (22) back to tetrahydroblopterin (18) and 
thereby provides the means of regenerating the active cofactor ensuring 
that the hydroxylase reactions can proceed. (Craine, Hall and Kauf-
man 1972) If the qulnonoid dihydrobiopterin (22) is not converted to 
tetrahydrobiopterln (18) it undergoes a non- enzymatic tautomerlzation 
into 7, 8 dihydroblopterin (17). (Figure 32) This is not a substrate 
for dihydropteridine reductase and therefore it cannot be converted to 
the active cofactor by this route. The levels of 7, 8 dihydrobiopterln 
then build up in the cell, move out into the serum and are excreted in 
the urine. (Leeming 19 79) 
The dihydropteridine reductase reaction is rapid and provides a 
so- called salvage pathway for quinonoid dihydrobio_pterin thereby main-
taining the tetrahydrobiopterin (18) levels in the cells. (Craine, Hall 
- 19 - , 
N 
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HN N~ C- t I C-CH 
HN~ ~OH OH 3 
2 N W'K~ H H 
7,8, Dihydrobiopterin 
and Kaufman 1972) 
Besides this salvage pathway the other possible sources of tet-
rahydrobiopt~rin (18) to the cell are from the diet or de novo biosy1 thesis. 
Although potentially great amounts of pterins could be obtained 
from the diet, experiments have shown that tetrahydrobiopterin (18) is 
poorly absorbed from the gut. (Rembold and Metzger 1967, Blair, 
Ratanasthien, Leeming, Melikian and Cooke 1974) Biopterin (6) is 
more readily absorbed and retained from the gut although only its 
reduced forms are known to have any metabolic activity. (Rembold and 
Metzger 1967) Parentally administered tetrahydrobiopterin (18) is taken 
up by the tissues and retained but radioactive biopterln (6) g iven in 
this way was rapidly totally excreted in the ur-ine. (Rembold and Metzger 
1967) This suggests that biopterin (6) is reduced during intestinal 
transport . Due to its poor intestinal absorption the diet does not 
provide a major source of tetrahydrobiopterin (18). 
By feeding several generations of rats on a biopterln-free diet 
and finding that the urinary excretion of biopterin (6) remained constant 
at about 30 }19 per day, Pabst and Rembold established that the bio-
synthet ic route to biopterin (6) was present in mammals. (1966) 
Purines had long been considered as potential starting materials 
for the biosynthesis of the pterin ring because of structural similarities. 
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When purine precursors such as formate (33) or glycine (34) or purines 
HO 
----~-CH-CH 





and their derivatives such as adenosine (35), guanine (36), guanoslne 
(37) or guanylic acid (38) were injected or fed to rats they produced 
(33) 






This synthesis of biopterin was 
increased with the simultaneous injection of actinomycin D to 
(35) OH OH 
reduce the flow of purines and their precursors into nucleic acid 
synthesis. (Rembold and Gyure 1972) Other evidence supporting 
(36) 
purines or their derivatlves as the precursors of pterin biosynthesis is 
- 22 - • I 
14 
l>J'l·,ve.--so..\\~ 
t hat C from labelled guan ine (3 6) was shown to be incorporated in-
/\ 
t o 2 am ino - 4 - hydroxypteridine - 6 - carboxyllc acid (5) . (Ziegler-
(37) OH OH 






guanosine triphosphate (GTP) (39) was the most efficient substrate for 
pterin biosynthesis. (1965) All the initial biosynthetlc work was 
carried out studying the biosynthesls of the pterin ring of _folic acid (1 6) 






(Shiota 1971, Eto, Fukush ima and Shiota 1976) 
Unconjugated pterin biosynthe sis has now been studied in a varie ty of 
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animal cells including the skin of bullfrog tadpoles (Fukushima 19 70), 
Drosophila melanogaster (Brown and Fan 1975}, rat tissues (Fukushima, 
Eto, Mayumi, Richter, Goodson and Shiota 1975, Lee, Fukushima and 
Nixon 1978), mouse neuroblastoma clones (Buff and Dairman 1975,·), 
Chinese Hamster ovary cell cultures (Fukushima and Shiota 1974) and 
even the intact rat (Buff and Dairman 19 75b) and has been shown to 
follow the same general scheme of reactions as in bacteria. The bio-
synthesis proceeds from guanosine triphosphate (39) to L erythro- 7,8 
dihydrobiopterin (17) via D erythro 7, 8 dihydroneopterin triphosphate 
(40). Seplapteri.n (8) has also been proposed as an intermediate in this 
pathway. (Eto, Fukushima and Shiota 1976) 7, 8 dihydrobiopterin 
(1 7) can be converted to 5, 6, 7, 8 tetrahydrobiopterin (18) by the enzyme 
dihydrofolate reductase (Abelson, Spector, Gorka and Fosburg 1978 
Pollock and Kaufman 1978, Spector, Levy and Abelson 1977, Spector, 
Fosburg, Levy and Abelson 1978) and hence the active cofactor Ls 
OH OH 





formed. This biosynthetic pathway is probably a rather slow process 
and performs a topping-up function of the cellular levels of tetrahydro- . 
biopterin (18). 
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The catabollsm of pterins is more fully understood than any other 
section of their biochemistry. Rembold and his coworkers shoW=d 
that tetrahydrobiopterln (18) is degraded in vltro uslng rat liver homo-
genates and in vivo after intraperitoneal injections into the rat, i1 a 
similar manner, by a series of deaminations and oxidations to yield 
lumazine derivatives and hydroxylated pterin species. Principally two 
enzymes are involved : xanthine oxidase and a specific pterin deamin-
ase. (Rembold and Gutensohn 19 68, Rembold, Metzger, Sudersham 
and Gutensohn 1969) More recent studies in mice receiving intra-
peritoneal injections of a variety of pterins with and without the 
xanthine oxidase inhibitor, allopurinol suggest that aldehyde oxidase 
can also play a part in pterin oxidation. (Knipe and McCormack 1977) 
These enzymes plus non-enzymatic degradations provide not only a 
catalytic pathway for unconjugated pterins but also a pathway for the 
production of simple lumazines and ring hydroxylated pterins. (Rembold, 
Metzger and Gutensohn 1971) 
The importance of tetrahydrobiopterin (18) metabolism is demon-
strated by the genetically transmitted diseases, phenylketonuria and 
lts variants. Phenylketonuria is characterised by high levels of phenyl-
alanine (21) and its metabolites in the blood and urine. It is due to a 
lack or deficiency of the enzyme phenylalanine hydroxylase and is 
transmitted by a recessive gene. Although the disease is not fatal 
it causes mild to severe mental retardation if untreated. Treatment is 
by a controlled low-phenylalanine diet. (Woolfetel 1951) 
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Cases of 
phenylketonuria where the plasma phenylalanine (21) levels were 
easily controlled by the low-phenylalanine diet but where the neuro-
logical defects were progressive and terminated life ln early childhood 
have been _described. (Smith, Clayton and Wolff 1975 a and b) }. .ore 
recently the same syndrome was re ported where the children were shown 
to have biochemical lesions at one of two sites, elther in dlhydrop-
teridine reductase (Kaufman, Holtzman, M ilstien , Butler and Krumholz, 
1975, Rey, Harpey, Leeming, Blair, Aicardi and Rey 1977, Grobe, 
Bartholome, Milstien and Kaufman 19 78) or in the biosynthetic path-
way for 7, 8 dihydrobiopterin (17). (Leeming, Blair and Rey 1976, Rey, 
Blandin-Saroja and Rey 1976, Kaufman, Berlow, Summer, Mllstien, 
Schulman, Orloff, Spielberg and Pueschel 1978) In both these types 
of syndrome, named malignant hyperphenylalan inaem ia, the neurolog-
ical defects are similar but the two types may be distlnguished by 
measuring their Crithidia factor response to an oral phenylalanine (21) 
load (Rey, Harpey, Leeming, Blair, Aicardl and Rey 1977, Kaufman, 
Berlow, Summer, Mllstien, Schulman, Orloff, Spielberg and Pueschel 
19 78) and their serum dihydrobiopterin (17) levels. These children 
with a metabolic block in the tetrahydrobiopterln blosynthetlc pathway 
from guanosine triphosphate (39) had low serum levels of dihydrobiop-
terin of 0. 4 pg/L compared to the normal level of 1. 78 pg/L. (Leeming 
and Blair 1980 b) Those children lacking the dihydropteridine reductase 
salvage pathway had higher than normal serum dihydrobiopterin (17) 
levels of 4. 9 pg/L. (Leeming and Blair 1980 b) Treatment of both 
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types of the syndrome is by a low phenylalan ine diet with the admin-
istration of L-DOPA (2 6), carbid o pa (4 1) and 5 hydroxytryptophan (29) . 
(Bartholome and Byrd 1975) It ha s been s h own that the hyperphenyl -










hydrobiopterin (18). (Danks, Cotton and Schleis inge r 19 75, Schaub , 
Daumling, Curtius, Niederweiser, Bartholom, ic; , Vis c ont inl, Sch iniks 
and Biers 19 78) 
The study of these variants of phenylke tonuria prov ide s an in v ivo 
demonstration of tetrahydrobiopterin (18) metabolism. Other studies 
of serum and urine levels of biopterin (6) and its derivatives have been 
undertaken for a number of different disease states. Raised blood or 
serum levels of biopterin derivatives have been re ported in tumour 
patients (Kokolis and Ziegler 1977) classical phenylketonurlcs, patients 
with kidney disfunction and patients taking the drug methotrexate (42). 
(42) 
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whereas lowered serum levels have been demonstrated ln pernicious 
anaemics, schizophrenics, rheumatoid arthritics patients with regional 
enteritus, leukaemia, (Leeming, Blair, Melikian and O'Gorman 197 6) 
malignant carcinoid disease, senile dementia, coeliac disease and 
lead poisoning. (Leeming and Blair 198Oa, Leeming and Blair 198 0 b) 
No significant difference of serum biopterin derivative levels were 
found in Parkinson 's Disease, Epilepsy and cirrhosis. (Leeming, 
Blair, Melikian and O'Gorman 1976) Similar results are reflected in 
studies of urinary levels of biopterin derivatives where epileptics, 
rheumatoid arthritics (Leeming and Blair 1974) and patients with kidneydls-
functlon all had lowered levels whereas in schizophrenics there was 
no significant change. (Leeming, Blair, Melikian and O'Gorman 1976) 
The major role that tetrahydrobiopterin (18) plays in the production 
of catecholamine neurotransmitters indicates that changes in brain 
levels of tetrahydrobiopterin (18) in disease could have a significant 
effect. Tetrahydrobiopta-in(l 8) ls not effectively transported across 
the blood-brain barrier, (Kettler, Bartholini and Pletscher 1974} so the 
relevance of these serum and urine measurements with respect to brain 
levels must be regarded with caution. Levels in cerebral spinal fluid 
may provide a better indication of brain concentrations and recently 
measurements of this kind have been reported. (Leeming 1979) How-
ever there are also reports of differentials in regional brain levels 
(Leeming, Blair, Melikian and O'Gorman 1976, Gal, Hanson and 
Sherman 19 76, Bullard, Guthrie, Russo and Mandell 1978) which 
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indicates that even cerebral spinal fluid measurements are not an ideal 
indication of the biopterin status of the various brain regions. 
For e_thical reasons, only so much information can be obtaim d 
from the in vi vo measurement studies. Yet this information can be 
supplemented by that obtained from in vitro studies such as those 
reported in this thesis. 
The de novo biosynthes is of tetrahydrobiopterin (18) from guanosine 
triphosphate (39)_ in rat brain homogenates will be measured using the 
Crithidia fasciculata as say. (Leeming and Blair 1974) Isolated 
enzyme studies may also add information to the ln vivo results. 
Methods exist for the isolation of dihydropteridine reductase from 
mammalian liver (Cheema, S oldin, Knapp, Hofman and Scrimgeour 1973, 
Hasegawa 1977, Webber, De its, Synder and Whiteley 1978, Aksnes, 
Skotland, Flatmark and Ljores 1979) and its actiyity can be measured 
using a spectrophotometric assay. (Craine, Hall and Kaufman 1972) 
An affinity chromatographic method using a sodlum naphth cx:iuinone 
sulphonate adsorbent will be used to prepare dihydropteridlne reductase 
from rat liver. (Cotton and Jennings 1978) 
These two systems isolated in vitro will therefore be used to 
look at the effect of a number of drugs, metabolites and other compounds 
on the de novo biosynthesis of tetrahydrobiopterin (18) and its main-
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tenance in the reduced form by the dihydropteridine reductase salvage 
pathway. These studies should provide more information about tetra-
hydrobiopterin (18) metabolism and how it is controlled. The results 
obtained c~rn then be used together with the in vivo measurements to try 
to explain the changes observed in diseases., though extrapolation 
of results from animals to humans must be limited because of the 
metabolic differences involved. Comparison of the changes in biop-
terin derivative levels observed when drugs are administered to patients 
with the effects of the same drugs in the in vitro experiments will 
indicate which metabolic pathway of tetrahydrobiopterin, if any, is 
being affected by the drug. Hence these studies may give an indicat-
ion of how the drugs are acting to control the disease or produce side-
effects associated with the drug. These results may also provide 
further insight into the underlying biochemical processes and how these 
are altered in disease. 
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CHAPTER TWO 
THE IN VITRO MEASUREMENT OF THE BIOSYNTHESIS OF BIOPTERIN 
DERIVATIVES 
INTRODUCTION 
The de novo biosynthesis of biopterin derivatives from 
guanosine trlphosphate has been demonstrated ln many different 
mammalian tissues such as rat brain, hamster kidney, liver and brain 
(Lee, Fukushima and Nixon 1978, Fukushima, Eto, Saliba and Shiota 
1975, Fukushima, Eto, Mayumi, Richter, Goodson and Shiota, 1975) 
and also in cell cultures of rat lung and ovary, hamster kidney, lung 
and ovary and mouse kidney, lung, ovary and neuroblastoma clones . 
(Fukushima, Eto, Mayuml, Richter, Goodson and Shlota, 1975, 
Fukushima and Shiota, 1974, Buff and Dairman, 1975B.). 
Figure 2-1 shows the steps wh lch have been postulated for the 
biosynthetic pathway from guanosine triphosphate (I) to L erythro 7, 8 
dihydrobiopterin (VII). The flrst step consists of opening of the 
imadazole ring between carbon 8 and nitrogen 9 followed by removal of 
carbon 8 as a one carbon compound identified as formic acid by Shiota 
and Palumbo, (1965). The ribose moiety of the compound formed (III) 
then ~nclergoes an Amadorl rearrangement resulting in the formation of 
a deoxypentulose derivative (IV). This compound contributes lts 
carbons l' and 2' to fonn the pterin ring as carbons 7 and 8 respect-
ively. The remaining ribose carbons fonn the pterin side chain at 
- Jl - I 
Figur e 2-1 Postulated ·Bios;vnthetic Pathway of Dihydrobiopterin 
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position 6, thus forming D erythro 7, 8 dihydroneopterin triphosphate 
(IV)• In mltro-organisms it has been postulated that only one enzyme 
is responsible for catalysing all these reactions although none of the 
proposed intermediates have ever been detected. (Shiota and Palumbo, 
1965, Dahal and Gots 1965, Cone and Guroff, 1970, Kobashl, Hariu 
and {wai, 1976). This enzyme was named guanosine triphosphate 
cyclohydrolase by Burg and Brown (19 68) and it was suggested that 
the intermediates have not been identified because they are enzyme-
bound. (Wolf and Brown, 1969). [t was demonstrated that the 
Amadori rearrangement occurs by use of 7 methyl guanosine triphos-
phate (1) as substrate. The methyl group at position 7 prevents the 
ring closure step and the methy lated deoxypentulose derivative (2) 
OH OH 
(I ) 
formed readily reacts with phenylhydrazine to give a phenylosazone of 
ribose, (Wolf and Brown 1969) this latter reaction being typical of 
Am.adori rearrangement products. 
14 
Universally C labelled guanosine 
triphosphate yields labelled D erythro 7, 8 dihydroneopterin triphosphate 
whereas guarrosine triphosphate specifically labelled at carbon 8 yields 
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(2) 
CH H H 
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radioactive formic acid and unlabelled D erythro 7, 8 dihydronaopterin 
triphosphate. (Reynolds and Brown 1964). Hence, it was shown 
that it is carbon 8 which is lost from guanosine triphosphate (I) by 
the action of guanos ine tri phosphate cyclohydrolase. 
It has been indicated that the same steps as catalysed by GTP 
cyclohydrolase in bacteria occur in hlgher animals and again one 
enzyme is responsible which has been isolated from chicken liver 
(Fukushima, Richter and Shiota 1977). The enzyme was named 6-(D 
erythro 1 '-2 '-3 '-trihydroxypropyl)-7, 8 dihydropterin triphosphate 
synthetase and was shown to have no apparent homology with GTP 
cyclohydrolase from E. coll using immunological studies. However, 
Gal and co-workers have characterized two enzymes responsible for 
these steps in rat brain. The first enzyme they named GTP cyclo-
hydrolase which catalyses the hydrolysis of guanosine triphosphate 
(I) to formamidopyrimidine ribotide, (II). The second enzyme converts 
the formamidopyrim idine ribotide (II) to D erythro 7, 8 dlhydroneopterln 
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triphosphate (V) and was called D erythro 7, 8 dihydroneopterin tri-
phosphate synthetase. (Gal, Nelson and Sherman 1978). 
The rest of the biosynthetic pathway from D erythro 7, 8 dihydro-
neopterin tri phosphate (V) to L erythro 7, 8 dlhydrobiopterin (VII) hd s 
not been fully elucidated yet. Non-phosphorylated neopterins are 
not converted to biopterin derivatives but sepiapterin (VI) is . (Eto, 
Fukushima and Shiota 1976). Therefore, the immediate fate of D 
erythro dihydroneopterin triphos phate (V) is not the removal of the 
triphosphate ester to form dihydroneopterin. (3) 
14 
If universally C-






sepiapterin (VI) the amount of biopterin produced increases but the 
incorporated radioactivity decreases compared to if the labelled GTP 
ls used alone. (Fukushima and Shiota 19 74) Thls indicates that 
seplapterin (VI) is probably a biosynthetic intermediate of biopterin. 
It was shown that NADPH was required for the conversion of D 
erythro 7, 8 dihydroneopterin triphos phate (V) to L erythro 7, 8 dihydro-
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. 
biopterin (VII) (Eto, Fukushima and Shiota 1976) and it was suggested 
that sepiapterin reductase whlch is known to requlre NADPH may be 
lnvolved. This e nzyme catalyses the converslon of seplapterin (VO 
to L eryt~ro 7, 8 dihydroblopter in (VII). (Nag a l and Matsubara IS 68, 
Matsubara, Katoh, Aklno and Kaufman, 19 66). But also an enzyme 
which was named L erythro 7, 8 dlhydroblopterln syntr.etase has been 
isolated from rat brain and shown to catalyse the whole step from D 
erythro 7, 8 dihydroneoipte rin trlphosphate (V) to L erythro 7, 8 d ihydro-
biopterin (VII). (Gal, Nelson and Sherman, 19 78). 
It has been shown that L erythro 7, 8 dlhydrobiopterln (VII) can 
be converted to 5, 6, 7, 8 tetrahydrobiopterln (VIII) by the e.nzyme 
dihydrofola te reductase. (Figure 2-2). This enzyme also requ ires 
NADPH as cofactor and has been isolate d from rabbit and rat brain. 
(Abelson, Spector, Gorka and Fosburg, 1978, Pollock and Kaufman, 
1978). 
The importance of this· biosynthetlc pathway ls clearwl--i<1n the 
consequences due to its absence in the rare conditlon, malignant 
hyperphenylalanlnaem la are considered. (Leem lng, Blalr and Rey, 
1976, Rey, Blandin-Saroja and Rey 1976 , Kaufman, Berlow, Summe r, 
Milstien, Schulman, Orloff, Spielberg and Pueschel, 1978). Tetra-
hydrobiopterln ls the cofactor required for the rate-limiting steps for 
the production of both the catecholamine neurotransmitters, dopamine 
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}972, Le vitt, Spe ct©r , Sjoerdsma and Udenfriend, 1965 , Naga tsu, 
Levitt a nd Udenfr ie nd, 19 64), a nd serotonin , (Hosoda and Gllck, 
19 66) cata lysed by tyros ine hydroxylase and tryptophan hydroxylase 
respectively. Te tra hydrobiopterin has been shown to be present In 
rate-limiting concentrations for tyrosine hydroxylase. (Kettler , 
Bartholini and Ple t s cher, 19 74) . Therefore, anyth ing which effects 
this biosynthetic pathway of tetrahydrobiopterin in any way could 
have significant conseque nces on t he central nervo us system . 
MATERIALS AND METHODS 
Guanosine triphosphate, nicotina mide ad e nine dinucleotlde , 
reduce d nicotinam ide adenine dinucle otlde , n icot inam ide adenine 
dinuc°Botide phosphate, reduced nicotlnamide a de nine dinucleotide 
phosphate, adenoslne trlphosphate, guanosine dlphosphate , guanoslne 
monophosphate and Tris (tris(hydroxymethyl)amlnomethane) we re 
purchased from the Slgma Chemical Company. Blopte rin was a gif t 
from Roche Products Limited. Liver fra ct ion L was from the Nutrlt lon 
Biochemical Company and vitamin-free casamino aclds was from the 
Difeo Laboratories. All other chem Lcals were of analytical grade a nd 
were purchased from B.D.H. Chemlcals Limited. 
Preparation of Tissue Extracts 
Brain tissue was removed from fre shly kille d male Wista r ra t s 
and 25% homogenates were prepared in 0.0lM Tris/ HCl, 0.04M KCl 
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buffer pH 8. These homogenates were centrlfuged at o0 c at 19,000 x g 
in a M. S .E. Superspeed SO centrifuge for 1 hour. The superna tants 
were collected and used in the incubations. Protein was measured 
by the Blt~ret method. (Layne 195 7). 
Incubation Methods 
The incubation mixture contained the followlng in a total volume 
3 






75 Jlmolesof Tris/HCl buffer pH 8. 
Guanos ine triphos phate (GTP) at various concentrations 
to provide substrate for biopterin biosynthesls. 
3 
0 . 1 cm supernatant (added last to lnitlate the reactlon). 
0.1 cm
3 
additlves ( if included) 
Distilled water to make up the right volume. 
The tubes were incubated in a water bath at 3 7°C ln the dark 
for 3 hours. The reaction was terminated by addition of 2 cm
3 
of 
0. IM HCl. Any reduced pterins formed were oxidised to their more 
stable forms by addition of O. 01 cm 
3 
of iodine solutlon (2g of KI and 
3 
lg of iodine ln 100 cm of distilled water) in the presence of one drop 
of 1 % starch solution. After 15 minutes the excess iodine was reduced 
using O. IM ascorbic acid. (Fukushima, Eto, Mayurr,i, Richter, Goodson 
and Shiota 1975). The mixture was then assayed for biopterin 
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derivatives using the Crlthldia fascicu lata assay . (Leeming 1975 , 
Leeming and Blair 1974}. The re s u lts we re calculated as ng biopterln 
per mg of protein. 
The incubation period was varied to discover a n a pproprlate 
length of time. 
Other substrates were tested such as ade nosine triphos pha te 
(ATP), guanosine monophosphate (GMP) and guanosine di phos pha te 
(GDP) to discover which was the be st precursor for blopterln blo-
synthesis. 
+ The effect of nicotinamide adenine dlnuc leotlde (NAD ) , reduce d 
nicotinamide adenine dlnucleotide (NADH) , nlcotlnamide adenine 
+ 
dinucleotide phosphate (NADP ) and reduced nicotinam lde adenine 
dinucleotlde phosphate (NADPH) on the biosynthesls of blopterin 
derivatives was tested by including a range of concentrations of these 
pyridine nucleotides in the incubations. 
Simllarly the effect of magnesium Lons and ATP was investigate d. 
Crithidia Fasciculata Assay 
Crithidia fasciculata culture (American Type culture collection 
No. 12857) was supplied by Dr. S. H.Hutner of Hoskins Laboratory, 
Pace College, New York, U.S.A. and maintained .by Dr. R. J. Lee ming, 
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General Hospltal, Blrrningham. 
This was subcultured weekly into maintenance medium prepared 
as summarized in Table 2-1. 0 It was lncubated for two days at 29 C 
in the da~k and then placed in the refrigerator at 4 °c. Preventio,1 of 
contamination was assisted by the addltion of 1 mg/cm 3 amplclllln 
when inoculating and this did not affect the growth of the flagellate. 
The stock assay medlum and the double strength assay medium 
were prepared as summarlzed in Tables 2-2 and 2-3. The inoculum 
was prepared by aseptically adding 1 drop of a two day culture to 
15 cm
3 
of single strength assay medium. This was incubated at 29°c 
for four days to exhaust the endogenous pterldine s. (Dewer and Kidder 
3 3 
1971) 0.2 cm of the resultant growth was added aseptically to 20cm 
of single strength medium. It was found to be advantageous to add 
500 mg of amplclllln to thls Lnoculum. One drop of the lnoculum 
was added to each assay tube using a sterlle pasteur pipette. 
The samples to be assayed for biopterin derivatives were 
diluted approprlately wlth O. 2 M phosphate buffer pH 5. Dilutions 
were determined by a method of trial and error. 0. 5 cm 
3 
of the 
diluted sample was added to each of three sterlllzed rimless 12 x 75 
3 3 
mm assay tubes containing 1. 5 cm of distilled water. 2 cm of 
double strength assay medium was then added to each assay tube to 
3 
make a total volume of 4 cm . Two standard curves were also set 
up ln tripllcate and were included with each batch of samples. The 
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standard curve cons isted of eleven tubes containing a range of standard 
biopterin solutions from O - O. lng in O. S cm 3 of O. 2 M phosphate 
buffer pH S. These standards were treated exactly the same as the 
other samples. Where additives were included in the incubationr, 
these were also tested to see if they had a direct effect on the growth 
of the Crithidia fasciculata itself. For these control tests 0 . OS ng 
of biopterin standard in O. 25 cm 
3 
of O. 2 M phosphate buffer .pH S 
was added to each assay tube ln triplicate together with 0.25 cm 3 
containing the amount of the additive corresponding to that included 
in the incubations but appropriately diluted as before . All the assay 
tubes were then autoclaved at 11s0 c for 5 minutes using a steam 
pressure autoclave and inoculated aseptically as described above, 
The samples were incubated at 29°c for a period of 72-90 hours. The 
growth of Crithidia fasciculata in each tube was measured turbido-
metrically using a Gilford micro-sample spectrophotometer 300 with 
direct digital concentration read-out. This instrument was equipped 
with sample changer and chart recorder for automatic read-out of 
growth as described by Leeming and Portman-Graham, (19 73). All 
assays were read as absorption at a wavelength of 590 nm against 
uninoculated medium. The amount of biopterin in each sample was 
. 3 
calculated using the standard curve ln ng bloptenn/cm . 
Chromatography 
Paper chromatography was performed to identify the pterin 
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n-butanol/acetic acid/water 4 :l :1 
3 % ammonium chloride 
n-propanol/1 % ammonia solution 2 :1 
(Goto, Forrest, Dickerman and Urushlbara 19 65, 
Viscontini, Schoeller, Loeser, Karrer and Hadorn, 1955) 
- 43 - I 
TABLE 2-1 
PREPARATION OF MAINTENANCE MEDIUM 
Yeast extract (Oxoid) 
Trypticase 
Sucrose 
Liver Fraction L 
Haemin (5 mg/cm
3 
in 50% triethanolamine) 
Distilled water 
The pH was adjusted to between 6.8 - 7.6. 
0 . 3 g 




0 .5 cm 
3 
100 cm 
The medium was 
0 0 
autoclaved at 120 C for 15 minutes and stored in the refrigerator at 4 C. 
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TABLE 2 - 2 
PREPARATION OF STOC K ASSAY MEDIUM 
PART A 
L-arginine hydrochloride 






























































6 . 5g 
1.5g 
Continued •• ; . 
TABLE 2-2 (Continued .. ) 
PREPARATION OF STOCK ASSAY MEDI UM 
PART A 











This mixture was steamed at 100°c for 20 minutes to dissolve the 
constituents and then distributed into sterile bottles and stored ln the 





N icotinic acid 
Pyridoxamlne dihydrochlorlde 









These vitamins were ground together and stored dry ln the refrigerator 
0 




in 50% triethanolamlne 
This was prepared freshly as required. 
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fABLE 2-2 (continued .. ) 
PART D 
Folic acid 3 100 ng/cm 
This was prepared freshly as required . 
- 47 -
TABLE 2 - 3 
PREPARATION OF DOUBLE STRENGTH ASSAY MEDIUM 
3 
For 100 cm 
Distilled water 
Stock assay medium part A 
Stock assay medium part B 
Vitamin-free casamino acids 
Triethanolam ine 
(must be added before part C) 
Stock assay medium part C 





4. 8 mg 




1. 0 cm 
3 
0 .5 cm 
This was adjusted to pH 7. 5 with concentrated sulphuric acid. 
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RESULTS 
A typlcal standard curve for the growth of Crlthldla fasciculata 
with a range of different biopterin concentrations is shown in Flgure 
2-3. 
The effects of varying the GTP concentration is shown in Table 
2-4. It can be seen that guanos ine tri phosphate alone did not 
produce any biopterin but whe n the brain supernatant was present as 
well there were biopterin derivatives produced. As the concentratlon 
of guanoslne triphosphate was increased the amount of biopterin 
derivatives produced also increased until it levelled off at approx-
imately 6mM GTP. Simllar results were obtained by varying the 
guanosine triphosphate concentrations in the presence of 1 mM NADPH. 
(Figure 2-4) 3mM was chosen as a convenient concentration of GTP 
to use in the standard incubation. 
The results from varying the incubation time are shown in 
Figure 2-5 and demonstrate that the maximum amount of biopterln was 
produced at around 2 hours. However, three h0urs was chosen as 
the standard incubation time to ensure that the reaction was corn plete. 
These results also show that without GTP in the incubation the endo-
genous blopterin breaks down after about 1 hour. 
Table 2-5 shows the effect of different substrates on the prod-
uction of biopterin derivatives. Guanosine triphosphate was found 
to be the best substrate in brain sup.ernatanl for b:oplerin syn~:1esis . 
The results using the various f'jridine nucleotide addltives 
are shown in Tables 2-6, 2-7, 2-8 and in figure 2-6 in the presence 
of a constant concentration of GTP (3mM) . They all stimulated tne 
production of biopterin derivatives significantly (p < 0. 001) and it 
was decided to include a p~r idine nucleotide, NADPH ln the standard 
incubation mixture. 
As can be seen from Table 2-9 adenos ine tri phosphate had no 
significant effect on the production of biopterin derivatives from GTP . 
The effect of magnesium chlorlde on the synthesis of biopterln 
derivatives is shown in Table 2-10. Magnesium increased the pro-
duction of biopterin from GTP and this was a signlficant effect lf 
-5 
concentrations of 10 M or above were used in the presence of lmM 
NADH. There was still a signlficant stimulation by magnesium chloride 
if the NADH was left out of the incubation. 
The paper chromatography showed that a compound was produced 
when GTP was included in the incubations which co-chromatographed 
with standard biopterin in the three solvent systems used. However, 
if boiled supernatant plus GTP or supernatant alone were used ln the 
incubations, this compound could not be detected. 
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Figure 2-4 EFFECT OF GUANC6INE TRIPH03PHATE CONCENTRATION ON THE 
SYNTHES IS OF BIOPTERIN IN 'IRE PRESENCE OF 1 mM NADPH 
2 6 8 10 
GTP Concentration mM 
. . - .52 - ' 
TABLE 2-4 
THE EFFECT OF CONCENTRATION OF GTP ON THE SYNTHESIS OF 
BIOPTERIN DERIVATIVES in vltro 
Components 
Minus supernatant+ 3.0 mM GTP 
Supernatant alone 
Supernatant + 1 • 2mM GTP 
Supernatant + 2. 4mM GTP 
Supernatant + 3. 0 mM GTP 
Supernatant + 3. 6 mM GTP 
Supernatant + 4. 8 mM GTP 
Supernatant + 6. 0 mM GTP 
Supernatant + 7. 2 mM GTP 


















0.78 ng - 0.01 
+ l. 50ng- 0.03 
2.00 ng± 0.01 
2.06ng± 0.02 
2 .13 ng ± 0.01 




0. 70 ng - 0.01 
TABLE 2-5 
EFFECT OF SUBSTRATE TYPE ON SYNTHESIS OF BIOPTERIN DERIVAT[VES 
in vltro 
+ 
Substrate No . of Mean - SD/mg 
Observations protein 
Supernatant alone 6 
+ 
0. 78ng - 0.01 
Supernatant + 3mM GTP 6 
+ 
2.0 6ng - 0.02 
Supernatant + 3mM GDP 5 + 1. 32ng - 0. 01 
Supernatant + 3mM GMP 5 + 1. 00ng - 0.03 
Supernatant + 3mM ATP 5 + 1. 03ng - 0.03 
TABLE 2-6 
EFFECT OF NICOTINAMIDE ADENINE DINUCLEOTIDE ON BIOPTERIN 
SYNTHESIS FROM GTP 
NAD 
+ 
Concentration No . of 
+ 
Mean - SD/mg 
Observations protein 
+ 
0.03 None 6 2. 1 Ong -
0.5 mM 6 
+ 
2.87ng - 0.02 
1.0mM 6 
+ 
3.7lng - 0.08 
1.SmM 6 
+ 
3. 68ng - 0.05 
2.0 mM 6 
+ 
3.58ng - 0.07 
3.0 mM 6 
+ 
3.64ng - '.).02 
4.0 mM 6 
+ 
3. 50ng - 0.06 
+ 
1 mM minus GTP 6 0.88ng - 0.02 
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1ABLE 2-7 
EFFECT OF REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE ON 
BIOPTERIN SYNTHESIS FROM GTP 
NADH Concentration 
No . of 
+ 




2 .l0ng - 0.03 
+ 
0.05 0.5 mM 6 3. 4 7ng -
1.0mM 6 
+ 
4. 00ng - 0 .07 
+ 0.01 1.5 mM 6 4.70ng -
2. 0 rnM 6 
+ 
3. 9 3ng - 0.0 6 
+ 0.07 3. 0 rnM 6 3.85ng -
+ 
4. 0 rnM 6 3.98ng-0.02 
+ 
1 rnM minus GTP 6 0.85ng-0.03 
-5£,- , 
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TABLE 2. 8 
EFFECT OF NICOTINAMIDE ADENINE D[NUCLEOT[DE PHOSPHA'IE ON 
THE SYNTHES1S OF BIOPTERIN FROM GTP 





2 .1 Ong - 0.03 
+ 
0.01 0.5 mM 5 3.34ng -
1.0 mM 5 
+ 
3.97ng - 0.06 
1.SmM 5 
+ 
4.37ng - 0 . 06 
+ 0.02 2.0 mM 5 4.25ng -
+ 0.05 3.0 mM 5 4. 34ng -
+ 
0.03 4.0 mM 5 4.2lng -
TABLE 2-S 
EFFECT OF ADENOSINE TRIPHOSPHATE ON SYNTHESIS OF BIOPTERIN 
FROM GTP 
ATP Concentration No. of 
+ 




2. 07 - 0.02ng 
1 mM 6 
+ 
2.00 - 0.03ng 
3 mM 6 
+ 
2. 05 - 0.02ng 
6 mM 6 
+ 2. 03 - 0.0lng 


























lliE EFFECT OF NADPH CONCENTRATION ON 'IliE PROOOCTION 






Concentration of NADPH, mM 
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TABLE 2-10 
EFFECT OF MAGNESIUM CHLORIDE ON THE PRODUCTION OF 




GTP + 10 M MgC1
2 
GTP + NADH 
GTP + NADH + 10-6 M MgC1
2 
GTP + NADH + 10-S M MgC1
2 
-4 
GTP + NADH + 1 Q M MgC12 
-3 
GTP + NADH + 10 M MgC12 
-3 
GTP+NADH+2.10 MMgC12 
* p < 0. 001 
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+ 
Mean - SD/mg 
prote ln 
+ 
l.92ng - 0.09 
+ 
2. 24ng - 0. 02 * 
+ 




2.57ng - 0.03** 
+ 
2. 63ng - 0. 07** 
+ 
2. 54ng - 0. 08 * 
+ 
2.63ng - 0.03 * 
DISCUSSION 
The results obtained here for the biosynthesi s of blopterin in 
rat b a· r m supernatants do not differ substantially from results obtained 
with di ffere nt mammalian tissues (Fukushima, Eto, Mayunl, Richter, 
Goodson and Shiota, 1975, Eto, Fukushima and Shiota 1976, 
Fukushima, Eto, Saliba and Shioto, 1975) and cell cultures . (Buff 
and Dainnan 1975a, Fukushima and Shiota 1974). 
GTP was found to be the best precursor of the purine derivat-
ives tested for rat brain biosynthesis of biopterin as in hamster liver. 
(Fukushima, Eto, Saliba and Shiota 1975). 
Although not absolutely necessary for biopterin biosynthesis 
in rat brain, the addition of pyridine nucleotides was found to be 
stimulating as in hamster liver and kidney. (Fukushima, Eto, 
Mayuml, Richter, Goodson and Shiota, 1975 , Eto , Fukushima and 
Shiota 1976). Since this work was done, the requirement forNADPH 
by rat brain for tlopterln biosynthesis has been published (Lee , 
Fukushima and Nixon 1978) but this was using a different assay 
system where GTP ,~<.loh~~rolase from E.coli was used with the rat brain 
supernatant. Of the pyridine nucleotides used, NADPH was found to 
be the best stimulator for blopterin blosynthesis . This has also 
been shown for hamster kidney where NADH or NADPH was shown to 
be essential for the conversion of D erythro dihydroneopterin tri phos-
phate to biopterin and of the two, NADPH was the more efficlent. 
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(Eto, Fukushima and Shiota 1976). It seems likely from these results 
that a reduced pyridine nucleotide is required at one or more points 
along the biosynthetic pathway for blopterin ln rat brain . There are 
several possible points where these reduced pyridine nucleotides may 
be involved assuming the biosynthetic pathway ls slm llar to that ln 
bacteria. These c ofactors may keep the D erythro dihydroneopterln 
triphosphate in the dihydro form, protecting it from belng converted 
to an ~nactive form. They may be required by the enzyme seplapl:e..rih 
reductase which catalyses the conversion of seplapte.r;nto dlhydrobio:-
pterin and requires the cofactor NADPH (Nagal 19 68, Matsubara, Katsh, 
Akino and Kaufman 1966) and has been shown to be present in rat 
brain. (Rembold and Metzger 1963). This assumes that th ls enzyme 
ls necessary for the biosynthesis of biopterin in rat braln . Or the 
cofactors might be required for unknown enzyme reactions which are 
inv olved in this pathway. 
Magnesium chloride was also found to be stimulating for the 
production of biopterin in rat braln as in hamster kidney biopterln 
biosynthesis (Eto, Fukushima and Shlota , 1976) and using the mlxed 
assay for rat brain blosynthesls. (Lee, Fukushima and Nlxon 1978). 
Magnesium Lons could be required for the efficient activity of one or 
more of the enzymes involved in this pathway. 
These results indicate that the btosynthe tic pathway for biop-
terin is present in rat brain and that GTP is necessary for this 
- 6J - I 
synthesis. Pyridine nucleot ides and magnesium ions were shown to 
stimulate this pathway. 
These results enabled a standard incubation mixture for biopterin 
b iosynthesls to be assembled which included GTP as substrate, 
NADPH and magnesium ions. 
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CHAPTER THREE 
THE EFFECT OF METAL IONS, DRUGS AND OTHER COMPOUNDS ON 
THE IN VITRO BIOSYNTHESIS OF BIOPTERIN DERIVATIVES 
INTRODUCTION 
Tetrahydrobiopterin is an essential cofactor for tyrosine hydroxy-
lase (Nagatsu, Mizutani, Nagatsu, Matsura and Sugimoto, 19 72) and 
for tryptophan hydroxylase, (Rosada and Glick 1966) the rate-limiting 
steps in catecholamine biosynthesis (Levitt, Spector, Sjoerdsma and 
Udenfriend 19 65, Nagatsu, Levitt and Udenfriend 19 64) and serotonin 
biosynthesis (Costa and Meek 1974) respectively. Tetrahydrobiopterin 
is present in tissues at concentrations lower than the Km value for 
tyrosine hydroxylase and therefore its concentration is rate-llmlting in 
controlling the activity of this enzyme (Kettler, Barthollni and Pletscher 
1974) and hence catecholamine biosynthesis. (Cote et al., 1975) 
Tetrahydrobiopterin is also present ln rate-limiting amounts for trypto-
phan hydroxylase activity (Costa and Meek 1974) but tryptophan 
concentrations are an important controlling factor for this enzyme. 
(Jequier, Lovenberg and Sjoerdsma 1967) Obviously tetrahydrobiopterln 
concentrations are going to have important consequences on the product-
ion of these neurotransm ltters . The lm portance of the biosynthe tic 
pathway of tetrahydroblopterin i s demonstrated by the neurological 
defects which occur in the form of malignant hyperphenylalaninaem la 
where there is a lesion in this pathway. (Leeming, Blair and Rey 1976, 
Rey, Blandin-Saroja and Rey 1976, Kaufman, Berlow, Summer, Mllstien 
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Schulman, Orloff, Spielberg and Pueschel 1978) 
Anything which affects the biosynthesis of tetrahydrobiopterln in 
any way would therefore cause considerable change s in neurotransmitter 
biosynthesis and hence, have serious implications on the central 
nervous system. 
Reduced pyridine nucleotides stimulate the biosynthesis of biopterin. 
(Chapter 2) Therefore, the supply of these nucleotides could 
consequently cause changes in the amount of blopterin produced. 
NADPH can be provided by various methods such as glutamate dehydro-
genase and the pentose phosphate pathway. (Le hninger 19 70) 
Glutamate dehydrogenase is a pyridine-linked enzyme which catalyses 
the deamination of glutamate. 
+ 
L- glutamate + NADP 
+ + 
It can use either NAD or NADP • 
+ 




As well as unloading the amino groups ln. the form of NH
4 
Lt serves as 
a supply of NADPH. The pentose phosphate pathway (Figure 3-1) is 
also a good source of reduced nicotinamide adenine dinucleotlde 
phosphate. The enzymes of the pentose phosphate pathway are cytos-
olic but are not present in large amounts in brain tissue. (Glock and 
McLean 1954) Assuming that glutamate dehydrogenase and the enzymes 
of the pentose phosphate pathway are present in the brain supernatant 
preparations, addition of the substrates, glutamate and glucose-6-
phosphate might have an effect on blopterln biosynthesls by stimulating 
NADPH production. Addition of these substrates with the cofactor 
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NADP and in the case of glucose-6-phosphate some glucose-6-
phosphate dehydrogenase as well, which is the rate-limiting enzyme 
for the pentose phosphate pathway may al so stimulate blopterin 
production. Glucose ls the ultimate precursor for the pentose pho , phate 
pathway and ls phosphorylated by hexokinase ln order to enter the path-
way. There is little intracellular glucose in the brain and the only 
supply is from the blood as glycogen levels are also low. (Bachelard 
and Mcilwain 1969) Obviously in isolated supernatants this supply 
has been term lnated so addition of glucose to the incubations may also 
stimulate NADPH production and hence effect biopterin biosynthes ls. 
The other major me tabolic pathway which usesglucose-6 -phosphate 
is the glycolytic pathway (Figure 3-2) which aga in consists of 
cytosolic enzymes. Addition of inhibitors of glycolysis may therefore 
direct the glucose-6-phosphate down the pentose phosphate pathway 
rather than the glycolytic pathway. High concentrations of ATP or 
citrate from the TCA cycle feedback and inhibit phosphofructoklnase. 
{Webb 1966a, Webb 1966b) Iodoacetate lnhlbits gl yceraldehyde-3 -
phosphate dehydrogenase which is an enzyme with free thlol groups. 
(Webb 1966c, Velick and Furfine 1963) Fluoride ions inhibit the 
enzyme, enolase especially if phosphate and magnesium Lons are also 
present due to the formation of a magnes ium-fluoride -phosphate complex 
(Wold I 971) and phenylalanine inhibits pyruvate klnase. (Boye r 19 62) 
As the biosynthetic pathway includes the elimination of a one 
- 68 -
FIGURE 3-2 THE GLYCOLYTIC PA1HWAY 
Dihyd:roxyacetone 
phosphate 
Glucose 1 Hexokinase 
Glucose-6-phosphate 
1 lFhosphoglucose isomerase 
Fructose-6-phosphate l Fhosphorructokinase 
Fructose-1,6-diphosphate l l Aldolase 
Glyceraldehyde-J-
Triose phosphate phosphate 
isomerase 

















carbon fragment after the initial ring-opening step (Buff and Dairman 1975) 
the addition of a one carbon unit acceptor might have an effect on blop-
terin biosynthesis. Tetrahydrofolate and its derivatlves have a 
major role iT: the biochemistry of one carbon fragment metabolism (8 akely 
19 69) and could be used for this purpose. However, tetrahydrofolates 
are very easily oxidised so an antioxidant must be included wlth them. 
(Wittenberg, Noronha and Silverman 1962, Bertino, Perkins and Johns 
1965) Vitamin B12 cofactor must also be included as lt ls a requirement 
for the regeneration of the active one carbon fragment acceptor. (Brot 
and Weissbach 1966) 
+ Pyridine nucleotides are degraded by the enzyme NAD nucleo-
sidase, especially in brain. (Mann and Quastel 1941a) Nicotinamide 
+ 
has been shown to inhibit NAD nucleosidase (Mann and Quastel 1941a, 
Mann and Quastel 1941b) and inclusion of nicotinamlde in the incubat-
ions may indirectly stimulate blopterin blosynthesls by lnhlbltlng the 
breakdown of the pyridine nucleotides included. 
Almost every heavy metal ls toxic to the central nervous system if 
present in excess and many metals have been suggested as neurotoxlc 
agents such as lead, aluminium, mercury and copper. 
Any effect of these metals on tetrahydrobiopterln synthesis could 
be important in the study of the symptoms of metal poisoning and even 
perhaps, give informatlon on the causes. 
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Exposure to high levels of lead has been shown to cause ne uro-
toxicity. (Byers and Lord 1943, Chisolm 1971, Rutter 1980) 
Behavioural changes and hyperactivity occur in animals (Sauerhoff and 
Michaelson _1973, Silbergeld and Goldberg 1974) and humans (Davi I, 
Clark and Voeller 1972, Baloh, Stunn, Green and Gleser 1975, Beevers, 
Erskini, Robertson, Beattie,Campbell, Goldberg, Moore and Hawthorne 
19 76) when blood lead levels are greater than at least 80pg/dl. At 
pre sent no biochemical explanation for the neurological effects of lead 
has been presented and the few studies on the interaction of neuro-
chemical components and lead have produced conflicting results. 
(Sauerhoff and Michaelson 19 73, Silbergeld and Goldberg 1975, Golter 
and Michaelson 1975, Michaelson, Greenland and Roth 1976, Satija 
and Seth 1978, Shih and Hanin 1978) Children are more susceptible to 
lead poisoning than adults. (Byers 1959) Lead poisoning can arise in 
a variety of situations (Guinea 1972) due to its ubiquitous use. Lead 
in paint and lead water pipes present a major hazard, (Egan 1972, 
MAFF 1972, MAFF 1975, Campbell 1977, Barltrop 1969, Airborne Lead 
in Perspective 1972) and lead from petrol fumes ls thought to be an 
environmental problem. (National Inventory Alr Pollution Emission and 
Control, 1 9 7 0) 
Aluminium has recently become a neurotoxlc issue due to the high 
levels which have been found in the brains of patients suffering from 
Dialysis Dementia. (dialysis associated with encephalopathy}(Flendrlg, 
Kruis and Das 1976,Alfrey, LeGendre and Kaehny 1976, Parkinson, Ward, 
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Feest, Fawcett and Kerr 1979, Wing, Brunner, Brynger, Chantler 
Donckerwolcke, Gurland, Jacobs, Kramer and Selwood 1980) [n this, 
usually fatal disease, aluminium in the brain was shown to be accum-
ulated to levels about six times the concentration found in undialy~ ?d 
controls during haemodialysis for renal fallure. (Alfey, LeGendre and 
Kaehny 1976) The levels of aluminium in patients who had dialysis 
-4 
dementia were about 1 .18 . 10 M compared to those of undialysed 
controls which were about 2 . 0. 10-SM whereas non-demented dialysis 
-5 
patients had levels of about 3. 2 6. 10 M. (McDermott, Smith, Ward, 
Parkinson and Kerr 1978) Aluminium has also been implemented in 
Alzheimer's disease where raised aluminium concentrations in the brains 
of patients dying from this form of dementia have been reported. 
(Crapper, Krishman and Quittkat 1976, Crapper, Krishman and Dalton 
I 9 73) In normal subjects the mean concentration of aluminium in grey 
matter was I. 9 ± 0. 7 }19/9 and in the patients with Alzheimer's disease 
+ 
it ranged from 2. 8 ± 2. 7 to 4 .. 3 - 1. 8 }19/9. (Crapper, Krishman 
and Quittkat 1976) Intracranial injection of alumin ium salts to cats 
produced cerebral function disorders such as impaired short-term 
acquisition and retention of conditional behavioural responses. (Crapper, 
Dalton 1973a, Crapper and Dalton 1973b) The degree of functional 
disorder was related to the number of neurofibrillary tangles and the 
amount of aluminium present in the cerebral cortex. (Crapper and 
Dalton I973b) Neurofibrillary tangles are a striking histological feature 
of the brain in Alzheimer's disease. 
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Mercury is associated with severe CNS toxicity . (Fllnk 19 75, 
Cumings 1959) The symptoms of mercury poisoning are fatlgue, lnco-
ordination, acrodynia, los s of memory, vlsual disturbances and there 
are microsc~pic changes in cerebellar and ganglionic cells . (Flinr 
19 75, Hirschman, Feingold and Boyler 19 63) Mercury poisoning may 
arise as an occupationa l hazard, from house paint or environmental poll-
ution. (Joselow, Louvia and Browder 1972, Hirschman , Feingold and 
Boyler 1963) Mercury damages the blood-brain barrier and this leads 
to incorporation of mercury into the brain quite readily. (Magosl968) 
The mean mercury concentration in seventeen post-mortem brain 
specimens was O. 28 pg/g in the cerebellum (Glomski, Brody and Pulay 
1971) but leve ls of 1 or 2pg/g have been reported. (Olszewski, 
Pillay, Glomski and Brody 1974) 
Cadmium poisoning ls mainly caused by exposure from manufact-
uring industries and is rarely fatal. Its symtoms include headaches 
and pulmonary oedema. (Flink 1975) 
Copper is normally present in the central nervous system at con-
centrations of approximately 100 )191 9 dry we ight. (Scheinberg 1978) 
Copper is an essential e lement for llfe but ls a lso potentially toxlc . 
Therefore, mechanisms for the conservation when uptake is low and 
homeostasis of copper have had to be evolved a long with mechanisms 
to exclude unwanted excess copper. These homeostatic processes 
are not well understood and ln fact thetr existence is only known from 
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patients in whom one of the mechanisms ls defective or genetically 
absent. For example , a fat a l int racellular deflclency of copper known 
as Menkes' Disease (Nat. Acad. Sc l. Washington D . C . 1977) ls 
caused by a defect in transporting copper across membranes . Another 
rare genetic defect causes chronic copper toxicity known as Wilson's 
Disease (Wilson 1912, Nat. Acad. Sc i. Washington D . C . 1977) due 
to a fault in normal excretory pathway for dally copper balance . The 
toxic symptoms of copper are haemolysi s , he patlc necrosis, hypotension 
and convulsions. (Scheinberg and Ste inlieb 19 76) Brain level s of 
copper of 3. 65 pmol/g have been re ported . (Hamlyn , Gollan , Douglas 
and Sherlock 1977) Reduced pte ridine s are s e ns itive to catalytic 
oxidation by low concentrations of copper. (Blair and Pearson 19 7 4) 
So the effect of copper on tetrahydrobiopte rin b ios ynthe sl s could prove 
to be an important effect. 
Phenylalanine given in phenylalanine-loadlng test s cause s s e rum 
levels of dihydroblbpterin to rise. (Leemlng, Blalr, Green and Ralne 
19 76) The levels of serum dlhydrobiopterin appear to correlate with 
those of serum phenylalanine but seem to be inde pende nt of serum tyrosine 
(Leeming 1975) and tryptophan levels. (Leeming 1979) In hyperphe nyl-
alaninaemia the levels of phenylalanine are ra ised dramatically. 
(Letendre, Nagaiah and Guroff 1980) 
an affect on biopterin biosynthesis. 
Hence phe nylala nine ma y ha ve 
The drugs, methotrexate (ame thopte rin) a nd c o-trlmoxazole 
(sulphamethoxazole with trimethoprim) have both be en shown to cause 
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rises in serum dihydrobiopterin levels of patients treated wlth them . 
(Leeming, Blair, Melikian and O'Gorman 19 76) Co-trimoxazole and 
methotrexate were further shown to interfere with phenylalanine metab-
olism by reducing its clearance after an oral load. (Andrews, Purk .s s, 
Chalmers and Watts 1976, Goodfriend and Kaufman 1961) Methotexate 
and one component of co-trimoxazole, trimethoprlm have been shown to 
inhibit dihydrofolate reductase (Futterman and Silverman 1957, Osborn 
& Huennekens 1958, Buchal! and Hitchings 1965) whlch could be 
involved in the l ast step of tetrahydroblopterin biosynthesls . (Chapter 
2) Other drugs which inhibit dihydrofolate reductase are amlnopterln, 
( Osborn and Huennekens 1958) tetroxoprim, (Burchell 19 79) trlampterene 
(Bertino, Perkins and Johns 1965) a'potassium sparlng' dluretic and 
pyrimethamine (Waxman and Herbert 1969, Hltchlngs 1972) a drug used 
to treat malaria (Covell 1953) toxoplasmosis (Grisham 1962) and poly-
cythaemia. (Issacs 1954) The effect of any of these drugs on biop-
terin biosynthes is may help to disclose their site of action. 
6-mercaptopurine, azathioprlne and thioguanine are all drugs 
whlch interfere with purine synthesis and hence may interfere ln the 
supply of guanine nucleotides for biopterln biosynthesis . (Stebbins, 
Scott and Herbert 19 73) 
MATERIALS AND METHODS 
L-phenylalanine, L-tyroslne, L-tryptophan and nlcotlnamlde 
(niacinamide ) were purchased from the Sigma Chemical Company. 
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Sulphamethoxazole, trimethoprim and mercaptopurine were obtained 
from Burroughs Wellcome. Upjohn Limited supplied cytosine arabino-
side and thioguanine was obtained from the Wellcome Foundatlon . 
Fluoro-uracil was a gift from Roche Products Limited. Aminopterln, 
triampterene, tetroxoprlm, pyrimethamine and azathioprlne were gifts 
from Dr. R. J. Leeming of the General Hospital, Birmingham . Metho-
trexate (amethopterin) was purchased from Lederle Laboratories. All 
other chemicals were of analytical grade and purchased from B. D. H. 
Chemicals Limited, or as described in Chapter 2. 
Brain supernatant from freshly killed male Wistar rats was prepared 
as described in Chapter 2. 
The standard incubatlon mixture now contained the following 
3 







7511moles of Tris/HCl buffer pH 8. 0. 
3,Pmoles of G.T.P. as substrate. 
1 J-lmole of NADPH. 
211moles of MgC12 . 
O.l cm 3 of additive (lf required). 
o. 1 cm 3 of brain supernatant (added last to lnitlate the 
reaction). 
(vii) Distilled water to make up the volume and replace any com-
ponent which was omitted. 
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TABLE J-1 continued 
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The tubes were incubated in a water bath at 37oC in the dark for 
3 hours when the reaction was terminated by the addition of 2 cm 3 of 
0.1 M HCl. Any reduced pterins formed were oxidised by the Iodine 
meth0d as described in Chapter 2. The samples were then assayed for 
biopterin derivatives using the Crithidt'a fas i 1 t 1 c cu :=t a assay a so as 
described in Chapter 2 and the results were calculated in rx.;i of blopterln 
per mg of protein• Appropriate controls for the effect of the various 
additives used in order to test the effect of these compru nds on the 
growth of Crithidia fasciculata itself were also included. 
The compounds tested for their effects on blopterln blosynthesls 
are listed in Table 3-1. (The Pharmaceutical Codex 1979) 
RESULTS 
The results of the tests of the agents used to stimulate NADPH 
production are shown In Table 3-2. Glutamate only gave a slgnlflcant 
+ increase in biopterin biosynthesis when NADP was present also , 
However, this increase was not as great as that produced wlth NADPH 
+ alone. Glutamate and NADP wlth NADPH did not glve an addltlve 
effect so the NADPH could be sparing the glutamate and NADP+ . 
Glucose - 6-phos phate alon2 did not change the amount of biopterln blo-
synthe sis and also glucose-6-phosphate dehydrogenase alone only 
increased the biopterin biosynthesis slgnlflcantly lf 7 units of the 
enzyme were provided. However, together they gave a slgnlflcant 
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increase in biopterin biosynthesis with 2. 5 units of the enzyme . 
Providing NADP + 'th 1 
WL g ucose-6-phosphate and glucose-6-phosphate 
dehydrogenase gave a further stimulation to biopterin biosynthesis whlch 
increasErlwith increasing NADP+ concentrations. Again thls mlxtur~ 
did not produce an effect of the same magnitude as NADPH although 
they did not give an additive result if NADPH was provided as well. 
Glucose significantly inhibited the in vitro production of biopterin and 
the inhibition increased as the glucose concentration increased . 
The results of the glycolytic inhibitors are shown in Table 3-3. 
All three compounds gave significant increases in biopterin biosynthesis 
and as the concentration of inhibitor was raised the effect also 
increased. · Iodoacetate and sodium fluoride raised the synthesis of 
biopterin by about 20% whereas citrate only increased the synthesis 
by about 8% which is much less than the approximately 130% increase 
with NADPH. Again these reagents did not glve additive results wl th 
NADPH. 
Table 3-4 shows the results from the addltlon of ascorbate, 5-
methyl tetrahydrofolic acld and coenzyme B12 to the standard assay 
mixture. Ascorbate increased the blosynthesls of blopterln signlflcant-
ly by as much as 50% and the degree of rise corresponded to the amount 
of ascorbate added. However, there was no additive effect with ascorba.te 
and NADPH together. 5-methyl tetrahydrofollc acld had no effect alone 
but with ascorbate there was an additional rlse and the amount of blop-
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terin fonn e d increase d as the amount of 5-methyl tetrahydrofolate added 
increased. 5-methyltetrahydrofolate also gave an additional lncrease 
when NADPH was prese nt as we ll as corn pared to NADPH alone . Co-
enzyme B12 ~ad no effect a lone or addltlonal effect with ascorbate . 
However, if ascorbate and 5- methyltetrahydrofolate were added wlth 
coenzyme B12 there was a further increase to give an approximate 
doubling of biopterin biosynthe sis. If coenzyme s
12 
was added with 
5-methyltetrahydrofolate and NADPH there was a further increase in 
biopterin biosynthesis of approxim ately 50% . 
The results of adding n icotinam ide to the standard assay mixture 
are shown in Table 3-5. The significant increases in biopterln biosynth-
esis shown are related to the nicotinamide concentration used and the 
maximum increase achieved was about 20 % with 10-l M nicotinam ide . 
Table 3-6 shows the results of the metalllc salts on blopterln blo -
synthsis. The most dramatic effect was the decrease caused by the 
- 8 lead acetate which was signlflcant a t concentrations as low as 10 M . 
The maximum effect with lead acetate was a 45 % reduction of biopte r ln 
blosynthesis. All the other metals also showed s ignlflcant decreases 
in the biopterin produced but to le s ser extents except for llthlum carbon-
-2 ate in which 1 0 M was require d to produce a decrease s ignlflcant at 
the 1 % level. 
The results for the drugs are shown ln Table 3- 7. All the dlhydro-
folate reductase inhibitors incre a se d the amount of blopterln produced . 
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Of 
th
ese, methotrexate appeared to be the most potent glvlng an Increase 
of 1 35 % at 1. 1. 1 o-4M. 
All the purine inhibltors gave s ignlficant decreases ln the amount 
of biopterin fonned. The pyrimidine inhibitors gave lncreases ln t.1e 
amount of biopterin produced, that of cytosine arabinoslde being 
significant and that of fluoro-uracil not being significant by the student 
't' test. 
Table 3-8 shows the effect of the aromatic amino acids on blop-
terin biosynthesis. Tryptophan had no effect but both tyroslne and 
phenylalanine significantly increased the amount of blopterln fanned. 
No inhibitory or stimulatory effect on the growth of the Crlthidia 
fasciculata itself was measured with any of these compounds used as 
additives at the concentratlons used ln these experiments. 
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TABLE 3-2 
EFFECTS OF AGENTS USED TO STIMULATE NADPH PRODUCTION OF BIOPTERIN BIOSYNTHESIS IN VITRO 
The lncubatton tubes contained the standard Lncubatlon mlxture minus NADPH unless stated otherwlse. The 
control was the standard Lncubation mlxture minus NADPH and the amount of blopterln produced ln the control was 
2 .10 ± 0. 03 ng/mg protein which was taken as 100 % 
Additive and No. of Mean ± S.D % of 
Student 't' test results 
Concentration Observattons ng/mg protein Control 
10-3M NADPH 12 4_77± 0.05 227.1 p = <0.001 




6 + 100 --..J 2.10 M glutamate 2 .10 - 0. 04 
-3 
2 .10 M glutamate 6 
+ 
2. 16 - 0 . 04 102.8 p = <o. 01 
-5 
2 .10 M glutamate + 
2.l0-3M NADP+ 
+ 
6 2.07 - 0 . 02 98.6 p = <o .1 
-4 
2. 10 M glutamate + 
-3 + 
2 .10 M NADP 6 
+ 
2. 23 - 0.08 106 . 2 p = <o. 01 
-3 
2 .1 0 M glutamate + 
-3 + + 
2. 10 M NADP 6 2.43-0.05 115.7 p = <0.0025 
-3 
2.10 Mglutamate+ 
2 . 1 0 - 3M N ADP + + 1 0 - 3M 6 4 . 65 ± 0.03 221 . 4 p = < 0 . 001 
NADPli 
TABLE 3-2 (continued) 
Add i tl ve and No. of Mean 
+ - S. D % of 
Concentration Observations ng/mg protein Control 
Student 't' test results 
-5 
2 .10 M glucose - + 
6-phos phate 12 2.08 - 0.04 99.1 p = <o .1 
1 unit of glucose-
6-phosphate de- + 
hydrogen a se 6 2.10 - 0.02 100 
3 units of glucose-
6-phos phate de hydro- + 
genase 12 2.08 - 0.05 9~.l p => 0 .1 
~ 
5 unlts of glucose-6- + 
phosphate dehydrogen- 6 2.15 - 0 . 08 102 . 4 p = <0.1 
ase 
7 units of glucose-6-
phosphate dehydrogen- + 
ase 6 2.16 - 0. 05 102.9 p = <O. 05 
-5 
2 10 M glucose-6-
phosphate + 1 unit of 
glucose-6-phos phate 
dehydrogenase 6 2.15 ± 0. 08 102.4 p = <o .1 
-5 
2 .10 M glucose-6-
phosphate + 2. 5 units 
of glucose-6-phosphate 6 2.21 + 0.08 105.2 p = <O . 01 
de hydrogen a se 
TABLE 3-2 (contlnued) 
Addltlve and No. of Mean 
+ 
S.D - % of 
Concentration Observations ng/mg protein Control 
Student 't' test results 
-5 
2.10 M glucose-
6-phos phate + 
3 unlts of glucose-
6-phos phate dehydro-
genase 12 2.23 + 0.10 106.2 p- =<0.005 
-5 
2.10 M glucose-6-
phosphate + 5 unlts 
I of glucose-6-phos phate 
CX> dehydrogenase 12 2.30 ± 0 . 06 1 O!:l. S p = < 0 . 0025 '0 
-5 
2 . 10 M gluoose-6-
phosphate + 7 un lts 
of glucose-6-
phosphate de hydro- + 
genase 6 2.26 - 0. 04 107 . 6 p = <0.0025 
- 5 
2.10 M glucose-6-
phosphate + 2 .1 0 M 
~ 0 . 05 NADP+ 12 2.13 101 . 4 p = < 0 . 05 
5 unlts of glucose-6-
phosphate de hydro-
- 3 genase + 2. 10 M 









5 unlts of glucose-
6-phos phate dehyd-
rogenase + 2.l0-5M 
glucose-6....:phos phate 
+ 2. 10-SM NADP+ 
5 unlts of glucose-6-
phos phate dehygro-
genase + 2 . 10 M 
glucose - 6-phos pha te 
+ 2. 1 o-4 M NADP+ 
5 unlts of glucose - 6-
phos phate dehydro-
genase + 2 .1 o-5M 
g lucose-6 - phosphate 
+ 2. 10- 3M NADP+ 
5 unlts of glucose-6-
phos phate dehydro-
genase + 2 . 1 o-5M 
glucose - 6- phos phate 
+ 2. 10-3M NADP+ 





+ Mean - S. D. 
ng/rng prote ln 
+ 2.21 - 0.08 
+ 2.24 - 0.0 3 
+ 2. 45 - 0 . 04 





116 . 7 
225.7 
Student 't' test results 
P = <0.01 
P = <0 . 00 25 
P = <o . 001 
P = <o . 001 
I 
'° I-' 
TABLE 3-2 (continued) 
Addltlve and No. of Mean + - S. D· % of 
Concentratlon Observatlons ng/mg protein Control 
Stude nt 't' t e st re sults 
-4 
6.10 M glucose 6 1.89 ± 0,08 90.0 p = < 0.005 
-3 
6.10 M glucose 6 1. 81 ± 0. 02 86.2 p = < 0.002 5 
-2 
6.10 M glucose 6 1. 77 ± 0 .10 84.3 p . = < 0.0025 
-2 
6. 10 M glucose + 
10-3M NADPH 6 4. 77 ± 0. 07 227.1 p = < 0 . 001 
l un lt of glucose - 6-phos phate dehydrogenase ls the enzyme actlv ity which transforms I11mole of glucose-6-




EFFECT OF G_LYCOLYSIS INHIBITORS ON IN VITRO BIOSYNTHESIS OF BIOPTERIN 
The incubation tubes contained the standard incubation mixture minus NADPH unless otherwise stated. The 
control was the standard incubation mixture minus NADPH and the amount of biopterin produced ln the control 







3 .10 M cltrate 
-5 
3 . 10 M c ltrate 
-4 
3 .10 M citrate 
-3 
3 . 1 0 M cl tra te 
-2 
3 . 10 M citrate 
-2 -3 
3 • l 0 M cl tr ate + l 0 M 
NADPH 
-6 
3. l 0 M Iodoacetate 
-5 










Mean ± S . D. 
ng/mg prote ln 
4. 77 + O. 05 
+ 2.12 - 0.03 
+ 













1.93 - 0 . 12 
+ 












Student 't' test results 
P = < 0 . 001 
P = < 0 . 1 
P = < 0 .1 
P = <0 . 0025 
P = < 0 . 005 
P = < 0. 0025 
p = < 0. 00 1 
P = < 0 .025 
P • <0. l 
TABLE 3-3 (continued) 
Additive and No. of Mean ± S D . . % of 
Concentration Observations ng/m g prate in Control Student 't' test results 
-4 




3 .10 M Iodoacetate 2.56 - 0. 09 121.9 p = < 0.0025 
-2 




M Iodoace tate 
6 4.77 = 0. 03 = < 0 . 001 + 10 M NADPH 227.1 p 
-c - 4 + 
\...) 10 M Sod Lum fluorLde 12 2.26 - 0. 06 107 .6 p = < 0.0025 
I -3 + 
l O M Sod Lum fluorlde 12 2.29 - 0 . 05 109 . 1 p = < 0 . 0025 
- 2 
10 M Sodium fluorLde 12 2 .52 ± o. 02 120 . 0 p = < 0. 002 
- 2 
l O M Sodlum fluoride 
+ l0 - 3M NADPH 6 4 . 77 ± 0 . 01 227 . 1 p = < 0 . 01 
TABLE 3-4 
EFFECT OF AS80RBATE, 5 METHYLTETRAHYDROFQLIC A~Il2 AND CQENZYME B12 Ol\I T.HF. IN VITBQ 6IQSYNIHESrs 
OF BIOPTERIN 
The incubatlon tubes contained the standard incubation mixture minus NAD~H un less otherwise stated and this 
was the control. The amount of blopterin produced in the control was 2 .10-0. 03 ng/mg protein and thls was taken 
as 100%. 
Addltlve and No. of Mean + - S. D. % of 
Concentratlon Observations ng/mg protein Control Student 't' test results 
l0-3M NADPH 12 4.77 ± o. 03 227.1 p = < 0.001 
-4 
2.8.10 M + 
ascorbate 12 2.19 - 0. 12 104.3 p = < 0. 05 
'i 
5. 7 10-4 M 
ascorbate 18 2.23 ± 0. 09 106.2 p = < 0.0025 
-3 
1.1 10 M 
ascorbate 12 2.25 ± 0.11 107 .1 p = < 0 . 005 
2.3 10-3M 
:!: o. 07 ascorbate 12 2.28 108 . 6 p = <0.0025 
4.610-3M + 
ascorbate 6 2. 30 - 0. OG 109.5 p = <0.0025 
2. 8 l0-2M 
ascorbate 6 2 . 78 ± o. 04 132.4 p = <0.0025 
2.8 10-lM 
ascorbate 6 3 . 15 ± 0. OS 150 . 0 p = < 0 . 002 
TABLE 3-4 continued •• 
Addltlve and No. of Mean + - S. D. % of 




:- 0. 07 10 M NADPH 6 4.76 22 6. 7 p = < 0.001 
-4 
1.110 M5methyl 
t e trahydrofollc acld 
(5 CH
3 
THFA) 6 2.14 + 0.06 101. 9 p = < 0 .1 
I 
10-3M NADPH ~ + 
1 .1 10-4 M 
5 C H
3 
THFA 6 5. 4 2 ± o. 02 258. 2 p = < 0 . 001 
-7 
1. 1 10 MB12 
6 2.04 ± 0 . 08 97 . 1 P = < 0 . l 
2 . 8 10-lM 




6 3 . 15 
+ - o. 08 150 . 0 p = < 0 . 001 
2 . 8 10-l M 
ascorbate + 
1. 1 10-?M 
S CH3THFA 
6 3 . 15 ± o. 02 150 . 0 P = < J . 001 
TABLE 3-4 continued •• 
Addltlve and No. of Mean + - S. D. % of 
Concentration Observations ng/mg protein Control Student 't I te s t results 
2.8 10-lM 
a scorbate + 1 • 1 
10-ISM 5 CH
3 + 
THFA 6 3.28 - 0. 01 156.2 p = < 0.001 
2.8 10-lM 
as'::~rbate + 1. 1 
6 3.39 ± 0. 03 161. 4 10 M 5 CH3 THFA p = < 0 .001 
I 
'8,. -1 2. 8 10 M ascorbate 




THFA 12 3.46 + 0 . 05 164 . 8 p = < 0 . 001 
-1 
2. 8 10 M ascorbate 
+l . 110-4 M5CH 
THF A + 1. 1 1 0 - ik £\ 2 6 4 . 36 ± 0. 05 207.6 p ::: < 0. 001 
10-3M NADPH 2.8 
-1 





THFA 6 .45 ± 0.03 307 . 1 p = < 0 . 001 
-7 
+1.110 M s12 6 
TABLE 3-5 
EFFECT OF NICOTINAMIDE ON THE IN VITRO BIOSYNTHESIS OF BIOPTERIN 
The Lncubatton tubes contalned the standard incubatton mixture which was the control. The amount of b io pterin 
produced ln the control was 4. 77 ± 0. 06 ng/mg protein and this was taken a s 100% 
Concentratton of No. of Mean 
+ 
% of - S.D. 
nlcottnamlde Observations ng/mg prote Ln Control Student 't' test re sult s 
10-7M 6 4,39 ± 0. 16 92.0 p = < 0. 005 
1 0- 6M 6 4.58 ± 0. 12 9 6 .0 p = < 0 . 01 
I 
10- 5M + 
\() 12 4.70 - 0 . 08 9 8 . 5 p = < 0 . 01 
-.J 
I 10-4 M 12 5 , 07 ± 0 . 11 106 . 3 p <0 . 0025 = 
10-3M 24 5 .24 + - 0 . 04 109 . 8 p = <0.001 
-2 + 
112 . 0 10 M 12 5 . 34 - 0 . 04 p = <0.0025 
10-lM 12 5 . 72 ± 0 . 04 119. 9 p = <0.001 
M 6 5 . 63 ± 0 . 06 118. 0 p = < J • ..1025 
TABLE 3-6 
EFFECT OF METAL IONS ON THE IN VITRO BIOSYNTHEStS OF BtOPTERIN 
The incubation tubes contained the standard -incubation mixture which was t aken as the control a nd wh Leh produced 
4.77 :!." 0.08 ng/mg protein of biopterin which was taken as 100 % 
Addltlve and No. of Mean + - S.D % of 
Concentration Observations ng/mg protein Control Student 't ' tes t re sults .. 
-9 
10 M lead acetate 6 4.48 + 0.32 9 3. 9 p = < a.as 
-8 
12 4.15 + 0.38 87.0 = < 0 . 005 10 M lead acetate - p 
-7 
10 M lead acetate 
' 
30 3.58 + 0.35 75.0 p = < 0. 001 
'° CD -6 10 M lead acetate 24 3.10 ± 0. Z-5 65 .0 p = < 0 . 001 
-5 
1 0 M le ad a cetate 24 2.86 + 0 . 22 60 . 0 p = < 0 . 001 
-4 
1 0 M lead acetate 6 2. 62 ± o. 05 54 . 9 p = < 0 . 001 
-3 
1 0 M lead acetate 6 2. 67 ± 0 . 12 56 . 0 p = < 0 . 001 
-7 
10 M alumlnlum 
:!_- 0 . 18 sulphate 6 4 . 83 101. 3 p = > !) • 1 
-5 
10 M alumlnlum 
:!_- 0 . 29 sulphate 6 4 . 71 98 . 7 p = > ~ . 1 
- 3 
10 M alumlnlum 
± 0 . 14 sulphate 6 4 . 40 92 . 2 p = < 0 . 005 
TABLE 3-6 (continued) 
Addtttve and No. of Mean 
+ 
- S.D % of 
Concentratlon Observations ng/mg prote ln Control Student 't ' test results 
-7 
10 M mercurlc 
chlorlde 6 4.88 + 0.18 102.3 p = < 0 .1 
-5 
1 0 M mercurlc 
chlorlde 6 4.51 + 0.15 94.5 p = < 0 . 01 
-3 10 M mercurlc 
+ chlorlde 6 4.23 - 0.09 88.7 p = < 0 . 001 
-7 
10 M cadmlum 
~ chlorlde 6 4.75 + 0 .12 99.6 p = > 0.1 
-5 
10 M cadmlum 
chlorlde 6 4 . 47 :!:° 0.16 9 3. 7 p = < 0. 005 
-3 
10 M cadmlum 
chlorlde 6 4.27 ± 0 .12 89.5 p = <0 . 0025 
-7 
10 M copper 
sulphate 6 4 . 64 ± o. 21 97 . 3 p = < 0.1 
-6 10 M copper 
4.46 ! sulphate 12 0 . 32 93 . 5 p = < 0. 01 
TABLE 3-6 (continued) 
Addltlve and No. of Mean + - S .D . % of 
Concentration Observations ng/mg protein Control Stude nt 't I te s t re s u lt s 
-5 12 4.22 + 0.12 88.5 = < 0.0025 10 M copper - p 
sulphate 
-4 
10 M copper 
sulphate 12 4.00 ± 0 .16 83.8 p = < 0.0025 
-3 
10 M copper 
+ sulphate 6 3.77 - 0.13 79.0 p = < 0.001 
-
I 10-4 M llthlum .... carbonate 6 4.94 -t. 0.22 10 3 . 6 p = < 0 . 1 0 
0 
l 0- 3M llthlum 
carbonate 6 4.58 + 0 . 3 2 96 . 0 = > 0 . 1 - p 
10-Z M llthlum 
+ 
carbonate 6 4 . 31 - 0 . 31 9 0 . 4 p = < 0. 01 
TABLE 3-6 (continued) 
Addltlve and No. of Mean ± S.D % of 
Concentration Observations ng/ mg protein control Etudent 't I test results 
-4 
10 M gallium 
+ 
chloride 6 4.84 - 0.18 101. 4 p = > 0 .1 
-3 . 
10 M galllum 
± 0 .1 8 chlorlde 6 4.88 102.3 p = < 0 .1 
-2 
10 M galllum 
+ 
chlorlde 6 4.46 - 0 .1 5 9 3. 5 p = <.0.005 
I -2 
I-' 2 .10 M gall1.um 
~ + chlorlde 6 4.39 - 0 .14 92.0 p = < 0. 005 
TABLE 3-7 
EFFECT OF A VARIETY OF DRUGS ON IN VITRO BIOPTERIN BIOSYNTHESIS 
The lncubatlon tubes contalned the standard assay mixture which was taken as the cont rol. Thls control 
produced 4 • 7 7 + 0. 06 ng/mg proteln of blopterln and this was taken as 100% 
Addltive and No. of Mean + S.D % of -
Concentratlon Observations ng/mg protein Control Student "t II test resu lts 
5.5 l0-
6M 
methotrexate 12 4.53 + 0.45 94.9 p = < 0. 1 -
1.1 l0-
5M 





methot rexate 18 6. 69 + 0 .11 14 0.3 p = < 0 . 001 
1.1 10-
4 M 
methotrexate 12 11 . 2 1 ::!: 0 . 07 235 . 0 p = < 0 . 001 
2 . 3 l0-
5 M 
±: 0 . 36 am lnopter ln 6 4 . 47 93 . 7 p = < 0 . OS 
1.1 10-
4 M 
:: 0 . 84 a m l nopterl n 12 6 . 35 133.l p = < 0 . 005 
2 . 3 10-
4 M 
! 0 . 44 amlnopterln 12 8 . 31 174 . 2 p = <0 . 002 
TABLE 3-7 (contlnued) 
Additive and No. of Mean ± S.D % of 
Concentration Observations ng/mg protein Control Stude nt "t II test results 
l.110-3M 
+ 
amlnopterln 6 16.21 - 0.33 339.8 p =< 0.01 
-
1.1 10-SM 
pyrlmetham lne 6 4.66 + o. 36 97.7 p = > 0.1 
-4 
1. 1. 10 M 
I pyrlmetham lne 6 5.18 ± 0. 32 108.6 p = < 0.025 
.... 
1 .1 10-3M 8 
pyrlmetham lne 6 6 . 67 ± 0. 33 139.8 p = < 0 . 0025 
-4 
1.110 M 
± o . 23 trlam pterene 6 4. 72 99 . 0 p = > 0.1 
l . 110-3M 
trlam pterene 6 + 5 . 41 - 0.18 113 . 4 p = < o . 0025 
-2 
1.1 10 M + 
trlam pterene 6 7.24 - o. 23 151 . 8 p = < 0 . 001 
TABLE 3-7 (continued) 
Addltlve and No. of 
+ % of Mean - S.D 
Concentration Observations . ng/mg protein Control Student "t" test results 
2. 3 l0-4 M 
tetroxo prim 6 5.02 + 0.24 105.2 = < 0. 05 - p 
2.3 10-3M 
tetroxoprlm · 6 5.55 ± 0. 31 116.3 p = < 0.005 
2.3 10-
2 M 




trlmethoprlm 12 5.25 










trlmethoprlm 12 5.43 - o. 35 113 . 8 p = < 0. 005 
1.3 10- SM 
+ 
sulphamethoxazole 12 4 . 95 - 0. 36 103.8 P = >0.1 
1. 3 10-
4 M 




sulphamethoxazole 12 5.13 ± 0 . 33 107 . 6 p = < 0 . 01 
TABLE 3-7 (contlnued) 
Addltive and No. of Mean ± S.D % of 
Concentration Observatlons ng/mg prote in Control Student "t II test results 
-3 
1.310 Msulpha-
methoxazole + 3 .4 
-2 
10 M trlmethoprlm 12 5.25 + 1.09 110 .1 p = > 0.1 
-4 
1. 2 10 M mercapto-









10 M merca pto-
6 4 . 06 + 0.34 85 . 1 < 0. 005 purlne - p = 
1.5 
-5 
1 0 th loguan Lne 6 4 . 75 ± 0. 22 99 . 6 p = > 0.1 
-4 
1 . 5 10 M thloguan Lne 6 4.42 ± 0 . 36 92 .7 p = < 0. 05 
-3 
1 . 5 10 M thloguanlne 6 3 . 91 :!: o. 33 81.9 p = < 0. 005 
7 . 2 
-5 
10 M azathloprlne 6 4 . 91 ± 0. 27 1i4 . 0 p = < O. l 
TABLE 3-7 (continued) 
Additive and No . of Me an + % o f - S .D 
Concentration Observations ng/mg protein Control Stu dent "t II test results 
7.2 10-
4 M 
azathloprlne 6 4.28 + 0.33 89.7 p = < 0 . 01 -
7.210-3M-
azathloprlne 6 3.75 ± 0. 29 78. 6 p = < 0 . 0025 
-
8.2 l0-6M 
cyt o s lne a rabln-
+ 
os lde 6 4 . 89 - 0 . 25 102.~ p = > 0 . 1 
I 
.... 8.2 - 5 8- 10 M cytosine 
arablnoslde 6 5 .1 8 + 0 . 32 108.6 p = < 0.025 
8.2 
-4 
1 0 M cytos lne + 




















10 M theophylline 
-4 
10 M theophylllne 
-3 






+ Mean - S.D. 
ng/mg prote ln 
5.08 + o. 55 
+ 5.16 - 0.51 






Student "t" test results 
P ·= < 0. 1 
P = < 0 . 05 
P = <0.01 
TABLE 3-8 
EFFECT OF AROMATIC AMINO ACIDS ON THE IN VrTRO BIOSYNTHESIS OF BIOPTERIN 
Additive and No. of Mean + - S. D % of 
C oncentratlon Observations ng/mg prote ln Control Student llt II test results 
10-SM L-
+ tryptophan 6 4.75 - 0.22 99.6 p = > 0 .1 
-4 
10 ML-
tryptophan 6 4.49 + 0.44 94.1 < 0.1 - p = 
10-3M L-.... 








10 M L- tyro s lne 5. 11 - D. 4 7 107 . 1 p = < 0 . OS 
-3 12 5 . 55 + 0 . 42 < 0 . 002 10 M L-tyroslne - 116 . 4 p = 
The Lncubatlon tubes contalned the standard assay mlxture whlch '-'as taken as the control. The control tubes 
produced 4 . 77 ± 0.06 ng/mg proteln of blopterln and thls was taken as 100% 
TABLE 3-8 (continued) 
Additive and No. of Mean + - S.D % of 
Concentration Observations . ng/mg prote ln Control Student II t II test results 
10-S M 
+ L-phenylalanlne 12 5.18 - 0.42 108.6 p = < 0.025 
10-4 M 
L-phenylalanlne 18 5.22 + 0.52 109.4 = < 0. 01 - p 
10-3M 
I-' L-phenylalanlne 18 
+ = <0.001 0 5.38 - 0. 46 112.8 p 
'O 
DISCUSSION 
The stimulation of bio t . b' 
P errn iosynthe sis by glutamate plus 
and glucose-6-phos phate 
plus glucose-6-phosphate dehydrogenase plus 
+ NADP and the _fact that both these 
systems did not give an addltlo ,al 
increase when NADPH was also included adds to the evidence that ADPH 
is a required cofactor of de novo biopterln blosynthesls . The pcntose 
phosphate pathway and glutamate dehydrogenase are recognised routes 
of NADPH production and stimulation of these reactions wlll result ln 
increased NADPH levels which in turn, Increases blopterln production . 
(Chapter 2) Hence the availablllty of NADPH to the de novo blosyn-
thetic pathway for tetrahydrobiopterln could be a llmltlng factor on thls 
pathway's activity in vlvo. 
The inhibition of blopterin blosynthes ls by glucose was surprl slng . 
It could not be accounted for by con tarn lnatlon of the J\nalar glucose 
by lead ions which were shown to be present Ln concentrations less than 
0.033 ppm as measured by atomic absorption. (Wibberley 1978) It 
could be that addition of glucose stimulated the glycolyUc pathway rathe r 
than the pentose phosphate pathway and hence, caused decreased blop-
terin biosynthesis due to decreased NADPH avallablllty. Thls ls 
supported by the disappearance of the inhlbltlon when NADPH was added 
with the glucose. 
The increased biopterin production caused by the glycolytic 
inhibitors also points to the importance of the pentose phosphate path-
- 110 - I 
way for providing NADPH f b' 
or topterin biosynthesl s . The fate of 
glucose-6 - phos phate will d 
epend on the acttvlties of the two metabolic 
pathways: glycolysis and th 
e pentose phosphate shunt. When th 
glycolytic pathway is blocked b . h . 
Y m lb1tors the glucose-6-phospha'e 
will be channelled into the pentos h h 
. e P os P ate pathway and hence, 
NADPH production will increase. This sttmulates the biosynthesls of 
biopterin. (Chapter 2) Th e relative activities of these two major 
metabolic pathways wh' h b , tc can e asse ssed by measuring Bloom and 
Stetton ratios, (1953, 1955) could have a slgnlflcant effect on the rate 
of de novo biopterin biosynthesis. In the adult oraln the partlclpatlon 
of the pentose phosphate pathway has been shown to be small corn pared 
to that of glycolysis with Bloom and Stetton ratios close to 1. (Bloom 
1955, Sacks, 1957, Hoskin 1960). However, the pentose phosphate 
pathway makes a greater contribution ln the immature braln when more 
NADPH is needed. (Guerra, Melgar and Vlllavlncenclo 1967) 
Ascorbate caused a slgniflcant increase in blopterln blosynthesls 
which was not additive with NADPH and so the ascorbate ls sparing the 
need for additional NADPH. The ascorbate could be stablllzlng the 
NADPH or NADH present endogenously actlng Ln an antloxldant capacity. 
Alternatively the ascorbate could be actively stlmulatlng the blopterln 
biosynthesis either dlrectly or lndlrectly. If the ascorbate was acting 
directly on the biosynthetic pathway an additive result wlth the NADPH 
might be expected . Ascorbate -and methylene blue have been shown to 
increase purine biosynthesis and it was.suggested that this increase 
h mp
ounds tncrea slng the actlvlty of the pentose-
was achieved by t ese co 
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phosphate 
pathway by actlng as hydro 
gen acceptors . (Baskin nd Sperling 1978) 
Ascorbate could be actLng ln th 
e same way here to lncre s the ADPH 
production by stimulating the t 
pe n ose phosphate pathway and hence' 
increasing biopterin biosynthes ls. 
The effect of 5-methyl te trahydrofolic acld and coenzyme B12 to 
significantly increase the amount of b l t l op er n syntheslzed lndlcates 
that the fol ate status of the cell may be important ln detenn in ing the 
rate of de novo biopterin biosynthesls. Folate levels in the braln 
have been re ported to be low. (Blakely 19 69) The fact that the 
increase caused by S methyl tetrahydrofollc ac id was further increased 
when coenzyme B12 was also include d ind lcates that these reagents 
may be actlng via stimulation of the ste p lnvolvlng the loss of a one 
carbon fragment. They could however, be having an affect on some 
other step such as the dlhydrofolate reducta se step. 
N lcotinam ide increases de novo blopterln blosynthes ls most llkely 
by inhibiting the enzyme NAD nucleoslda se whlch degrades NADH (Mann 
and Quastel 1941a, Mann and Quastel 1941b) and NADPH. ( Handler and 
Klein 1942) This enzyme ls particularly plentiful ln brain extracts . 
(Mann and Quastel 1941b) Nlcotinamlde t re refore protects the NADPH 
present and this stimulates biopterln production. (Chapter 2) 
Lead acetate showed the most dramatic decrease ln blopterln b lo-
synthesis of the metals tested. 1 o -SM lead acetate, a concentration 
that is s lm ilar to that found ln normal adult bra ins (Schroeder and Tl pton 
1968) i 'f ' ant 13% decrease ln the am ount of blopterln produced . gave a s gm 1c o 
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10-
9
M gave a 6% decrease wh· h 1 h Le a t ough was only slgnlflc nt t th 
5%levelbythe 'studentt'test f't 
' t s the trend of lncreascd inhlbltlon 
of biopterin biosynthesis with l ncreased lead acetate concentrations. 
These results s.how that lead has a potent effect on this pathway . 
When a severe inhibition of tetrahydrobiopterin biosynthesls occurn such 
as in malignant hyperphenylalaninaemla due to a lesion Ln this pathway 
(Leeming, Blair and Rey 1976, Rey, Blandln-Saroja and Rey 1976, 
Kaufman, Berlow, Summer, Milstien, Schulman, Orloff, Splelbergand 
Pueschel 1978) mental retardation results. Therefore, perhaps the 
effects of lead on biopterin biosynthesis seen here could partly explaln 
neurotoxic effects of lead. A severe decrease ln tetrahydrobloplc rln 
synthesis could over a period of time , cause a reductlon ln cellular 
levels of tetrahydrobiopterin. As this ls rate-llmltlng for tyrosine 
hydroxylase (Kettler, Bartholini and Pletcher 19 74) a reduction would 
significantly reduce the activity of this enzyme which ln turn would 
reduce dopamine and noradrenallne synthesis as Lt ls the rate-llmltlng 
step for this pathway.· (Levitt, Spector, Sjoerdsma and Udenfrlend 1965) 
Reduction in the synthesis of these two central neurotransmltters could 
be related to neurological impairment. What is not clear from these 
results is on which step of the blosynthetlc route for tetrahydroblopterln 
lead is acting. 
None of the other metals tested were as potent as lead but all 
showed reductions in biopterin biosynthesls . 
cadmium are all recognised neurotoxlc agents . 
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Lead, mercury and 
(Fllnk 1975) 
Aluminium has been linked With d' . 
talysts dementia (Flendri ' Kr uls nd 
Das 19 76) and Alzheimer's dem . 
entta (Crapper, Krishman c nd Quittkat 
1976) and excess copper with 
1 
. 
convu SLons · (Schienberg and Stelnlleb 
1976) Lithium has been used t 
. 0 treat such mental disorders as mai,ic-
depres s i ve psychosis and is poisonous at really hlgh levels. 
(Schou 
1958, Schou 1968) 
So perhaps these metals are acting ln a slmllar 
way to lead but exceedingly high concentratlons would be requlred to 
produce corn parable effects. The effect of these metals on blopterln 
could not be accounted for by lead contamination ln the analar reagents . 
All the drugs which are dlhydrofolate reductase lnhlbltors increased 
the amount of biopterin produced, methotr-exate being the most potent 
doubling the amount of biopterin produced at 1.1 10-4M concentration . 
The order of increasing degree of stimulatlon for the drugs tested ls 
triam pterene, tetroxoprim, trimethoprlm, pyrlmetham lne, am lnopterln 
and methotrexate. This order correlated fairly well wlth the ablllty of 
drugs to bind rat dihydrofolate reductase as trl methoprlm and tetroxoprlm 
do not have a great affinity for the mammallan enzyme whereas metho-
trexate, am inopterin and pyrirnetharnlne have a much greater afflnlty for 
this enzyme. (Burchall 1979) , The only exception ls trlampterene 
which has an intermediate affinity for the enzyme and ls the least 
potent biopterin biosynthesis stirni:lator • It appears that thls Increase 
in biopterin biosynthesis could be related to the effect of these drugs 
on d ihydrofolate reductase which probably catalyses the flnal step In 
tetrahydrobiopterin synthesis. If these drugs lnhlblt thls flnal step 
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7, 8 dihydrobiopterin levels . th 
tn e cell wo~ild increase. Ho vever as 
the Crithidia fasciculata ass 
ay measures total biopterln Including 7' 8 
dihydrobiopterin, s, 6,7 18 tetrah . . 
ydrobtoptenn and biopterin Itself this 
should not alter the level of bio t . , . 
P enn otosynthes ls measured. The. e-
f ore , dihydrofolate reductase · h b 
tn l ltlon mu st be causing a stimulation 
of the biosynthetic pathway. The trigger for thls stlmulatlon could 
either be the reduction in S, 6, 7, 8 tetrahydroblopterln levels or an 
increase in 7, 8 dihydrobiopterin levels. ff the trigger for the 
stimulation is a reduction in cellular S, 6, 7. a tetrahydroblopterin levels, 
this could work by the synthesis pathway being under feedback lnhlblt-
ion by 5, 6, 7, 8 tetrahydrobiopterln. If there ls plenty of s, 6, 7 . 8 tetra-
hydrobiopterin in the cell it will feedback to inhlblt the synthesis path-
way but if the cellular levels of 5, 6, 7, 8-tetrahydroblopterin fall, this 
inhibition will be reduced and more 5, 6, 7 ,8 tetrahydrobiopterln wlll be 
synthesised from G. T. P. Hence the stlmulatlon observed would be due 
to reduced feedback ln~ibltlon of the synthesis pathway by tetrahydro-
biopterin. If the trigger is an increase in cellular levels of 7, 8 dlhydro-
blopterin, this would have to work by the 7, 8 dihyroblopterln stlmulatlng 
the activity of the synthetic pathway. Thismethod seems unlikely and 
feedback inhibition is a common mechanism of biological regulatlon of 
metabollc pathways. Methotrexate, pyrlmethamlne and trlmethoprlm 
Therefore wlth also inhibit dihydropteridine reductase • (Chapter 5) 
l;'llt~._'jd.A-ob, of~'" 
both reductases inhibited the cellular levels of 5, 6, 7, 8/\would certainly 
decrease. 
. • 7 8 dlhydrobiopterin levels caused by these 
The increase m , 
l crease in serum dihydro-
two effects would be expected to cause an n 
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biopterin levels which in fact ha b 
s een reported wlth patients on 
methotrexate (Leeming Blair M l'k• 
' ' e I tan and O'Gorman 1976) and In 
childre n with dihydropteridine red t d f' 
uc ase e 1clency . (Kaufman, Holtz-
man , M ilstien, Butler and Krumholz 19 75 , R ey, Harpey, Leeming, nl lr, 
Aicard i a nd Rey 1977 , Grobe, Bartholome , Mllstlen and Kaufman 1978) 
Sulphamethoxazole also increased biopterln blosynthesls . This 
drug had a slight inhibitory effect on dihydropteridlne reductase (Chapter 
5) so this could perhapsexplain this effect . This would lead to a 
small reduction in 5, 6, 7, 8 tetrahydroblopterin which could be the trigger 
for biopterin biosynthesis stimulation. Sulphamethoxazole and trimeth-
oprim a re the two active components of the pharmaceutical preparatlons, 
co-trimoxazole, bactrim and septrln. Therefore, an additive effect 
might be expected with both trimethoprim and sulphamethoxazole 
together but this was not observed. 
Of the metabolic lnh lbl tors, the pyrimidine antagonists , fluoro-
uracil and cytosine arabinoside increased the synthesis of biopterin . 
These both inhibit DNA synthesis which will probably be a major route 
for GTP utilization. If this pathway ls blocked it follows that more GTP 
will be available forbiopterin biosynthesis. The purine antagonists 
As these also Inhibit DNA and RNA 
all inhibit biopterin blosynthe s ls· 
. . lt as the pyrimidine antagonists mlght be 
synthesis, a stmtlar resu 
.bl these analogs of purines some how block GTP 
expected but presuma Y 
bi nthetlc enzymes · utilization by the biopterin osy 
They could be 
TP ite on GTP cyclohydrolase as they are 
competing with GTP for the G s 
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of a similar structure. 
Of the aromatic amino ac·d t 
L 
s , ryptophan had no effect nd phcnyl-
ala nine and tyrosine both stimulat d b ' 
e topterin synthesi s . As all three 
of these amino acids inhibited dihydropt ldi 
e r ne reducta se (Chapter S} 
all of them might be expected to stim 1 t b' 
u a e topterln blosynthesls via 
release from the feedback inhibition of s 6 7 a t h d b , , , etra y ro loptcrln ln 
the same way as methotrexate • Serum dihydroblopterln levels mirror 
closely serum phenylalanine levels (Leeming, Blair, Green and Raine 
19 76) so an effect on biopterin metabolism by phenylalanine should be 
expected . The inhibition of dihydropteridine reductase could explain 
this correlation. (Chapter S) Phenylalanine also lnhlblts pyruvate 
kinase and so could be acting in the same way as the other glycolyllc 
inhibitors to stimulate the production of NADPH by dlvertlng the flow of 
glucose down the pentose phosphate pathway. Alternat l vely tyros lne 
and phenylalanine could be acting to stimulate the blopterln blosynthesls 
by a direct method·. Normal human brain concentratlons of tyroslne and 
-4 f phenylalanine are about 10 M for both (Letendre, Nagalah and Gurof 
1980) which is the same as the concentrations used here whlch are 
producing a 7% and 9% stimulation respectively . In the case of tyrosine 
this stimulation is only a significant one lf the level s of tyrosine are 
-3 
raisedtolO M. 
lt h n here add to the evidence that NADPH ls a The resu s s ow 
h d b'opterin biosynthesis and lndlcate that required co£ actor £or tetra Y ro L 
. l thway for tetrahydroblopterln from bTP 
the activity of the bt0synthet c pa 
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can be altered de pending on th_e levels of fol ate, m t I lons 
especially lead ions, the amtno acids; phenylalanine and yrosln nd 
dihydrofolate reductase inhibitors, which probably occur vl eh ngcs In 
tetrahydrobiopterin cellular levels, suggest that the actlvlty of thl. 
pathway can be controlled by its product, tetrahydroblopterln . 
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CHAPTER FOUR 
THE ISOLATION OF DIHYDROPTE 
RtDINE REDUCTASE FROM RAT UVER 
INTRODUCTION 
The enzymatic convers. 
· ton of phenylalanine to tyrosine was shown 
to involve two essential enz (K 
ymes aufman 1957, Mltoma 1956): one 
purified from rat liver extracts (ph 1 1 . eny a anme hydroxylase) (Kaufman 
1969) and one purified from h 
s eep liver extracts (dihydropterldine 
reductase) (Kaufman 19 69) In this coupled enzyme system reduced 
n icotinamide adenine dinucleotide phos phate (NADPH) was also shown 
to be necessary. (Kaufman 1957) 
+ 
NADPH + H + phenylalanine + O 
2 
+ > tyrosine + NADP + H
2
o 
It was later shown that tetrahydroblopte rin was an essential 
cofactor for this hydroxylation and that the above equation Ls Ln fact, 
the sum of at least two reactions. (Figure 4- 1) (Kaufman 1958, 
Kaufman 19 63) The first of these reactions ls catalyzed by the 'rat 
llver enzyme' (phenylalanine hydroxy~ase) and converts phenylalanine 
t o tyrosine and tetrahydroblopterin to qu lnonoid d lhydroblopterln . 
(Kaufman 1964) The second reaction is catalyzed by 'sheep liver 
e nzyme' (dihydropteridine reductase) and converts qu lnonold dlhydro-
biopterin back to tetrahydrobiopterin and requ ires a reduced pyridine 
nucleotide. (Kaufman 1964) More recently lt was shown that a third 
t . l component for this hydroxylation If the cofactor . enzyme was an essen ta 






















Tyrosine + H2o 
form isolated from rat liver 7 8 d'h . ' ' t ydrobtopterln v:as used . Thl s 
enzyme was dihydrofolate redu t 
c ase whlch reduces 7, 8 dihydrobloptcrln 
to tetrahydrobiopterin in the 
presence of reduced nlcollnamlcie adenine 
dinucleotide phosphate. (Kaufman 19 67) This reaction serves to 
salvage the 7 , 8 dihydrobiopterin formed from the unstable qulnonold 
dihydrobiopterin by non-enzymatic rearrange t men. (Kaufman 1961) 
Dihydropteridine reductase (E .C. 1. 6 . 99. 7) utlllzes el ther 
reduced nicotinamide adenine dinucleotlde (NADH) or reduced nlcotln-
amide adenine dinucleotide phosphate (NADPH) but lt ls much more 
active with NADH. (Nielsen, Simonson and Llnd 1969) Thls enables 
dihydropteridine reductase activity to be measured slmply following the 
disappearance of NADH spectrophotometrlcally provided qulnonold dl-
hydrobiopterln could be generated. A method ls descrlbed by Cralne, 
Hall and Kaufman (1972) where they measure dlhydropterldlne reductase 
activity in this way. They used 6, 7, dimethyl 5,6, 7,8 tetrahydrop-
te rin which ·was commercially avallable lnstead of 5, 6, 7, 8 tetrahydro-
biopterin as substrate and generated the qulnonold fonn by the use of 
h orseradish peroxidase and fiydrogen peroxide. 
peroxldase 
6 , 7 dimethyl, 5,6,7,8 tetrahydropterln + H202 > qulnonoid 
6, 7 dlmethyldlhydropterln + 2 H2 O 
. . 1 (DICPIP) can also be used to generate the D1chlorophenolmdopheno 
quinonoid substrate. Sold
in Knapp Hofmann and Scrlm:Jeour 
(Cheema, ' ' 
1973) 
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Dlhydropteridine reductase has b . 
een isolated from sever l differ-
ent sources by a variety of methods. 
It was lsolated from sheep liver 
extracts by a method involv' 
mg ammonium sulphate, zlnc-eth nol nd 
alkaline ammonium s 1 h 
u P ate fractLonatLons, followed by adsorption nd 
elution from calci h 
um P osphate gel and chromatography on DEAE cellulose 
andSephadexG.lOOto · 90, 
91 ve a 10 yield and a 15 6 fold purlflcatlon . 
(Craine, Hall and Kaufman 1972) This method was modlfled by additional 
chromatographic steps to produce a yield of 2. 4% and a purlflcatlon of 
433 fold for the isolation of the enzyme from bovlne liver. (Korrl , 
Chippel, Chauvin, Tirpak and Scrimgeour 1977) A simpler method of 
chloroform-ethanol and ammonium sulphate fractlonatlons followed by 
chromatography on DEAE-Sephadex A-5O. Hydroxylapatlte and CM-
Sephadex C-5 0 was used for dihydropteridine reductase purlficatlon from 
bovine liver to give a 15% yield and a 1724 fold puriflcatlon. The 
enzyme pre pared in this way was crystalllzed both as free d lhydropter-
idine reductase and as a reductase-NADH complex. (Hasegawa 1977) 
More recently affinity chromatographic method s have been used 
to isolate dihydropteridine reductase as they are much simpler to perform . 
The enzyme was isolated from bovine kidney extracts by uslng columns 
of immobilized Cibacron Blue {Blue Dextan - Agarose) to whlch the cilhydro-
pteridine reductase bound by its dlnucleotlde (NADH) domain. Th is 
gave a 16% yield and .a 359 fold puriflcation. (Chauvln , Korrl, Tlrpak , 
S. d s · eour 1979 Scrlmgeour, Tirpak and Chauvln 1978) 1mpson an cnmg , 
d •1· · the reductase 's NADH blndlng domaln involved Another metho ut1 1zrng 
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chromatogra phy on 5 '-AMP-Se h 
P arose 48 and was used to lsol te the 
enzyme from bovlne liver and bo l d 
v ne a renal medulla giving 16% and 
17% Yields respectively. (Aksne !', Skotland, Flatmark and Ljones 1979) 
These methods are not ve ry ·f· f 
spe cL LC or dlhydropterldlnc rcductase as 
many enzymes have NADH binding domains and so stlll Involve many 
other St'ep·s to aid the Purification. An alternative method was to use 
an affinity chromatographic step involving binding to an lnhlbltor of 
the enzyme. Methotrexate-Aminohexyl-Sepharose was used to give a 
2 7% yield and 148 fold purification of dlhydropterldlne reductase from 
rat liver and similar results for sheep liver enzyme . (Webber , Delts , 
Snyder and Whiteley 19 78) As methotrexate ls also a potent lnh lb I tor 
of dihydrofolate reductase this me thod ls llkely to co-purify this 
enzyme. Use of an affinity adsorbe nt of sodium 1, 2 naphthoqulnone-
4-sulphonate, a phenylalanine hydroxylase Lnhlbltor , gave an 18% yleld 
and 404 fold purification of dlhydropterldlne reductase from human llver 
obtained at autopsy. Thls was a single s te p me thod a nd the sodlum l, 2-
naphthoquinone-4-sulphonate was be lle ved to be effective because of 
structural similarities to the qulnonold substrate . (Cotton and Jennings 
1978) 
All the above methods showed t hat the enzyme existed as a dlmer 
of molecular weight of about 40, 000- 50, 000 except the naphthoqulnone 
method whlch indicated a tetratmer of a molecular weight of about l 00, 000 . 
To date, it ls believed that the e nzymlc reaction proceeds by a 
- 12J - , 
compulsory ordered mecha . 
n1sm . (Karri, Chippel, Ch uvln, Tlrpa 
and Scrimgeour 1977 Ak 
' snes and Ljones 1980) 
It was suggested retrospectively that dihydropterldlne reductase 
deficiency may be associated wlth 
a form of phenylketonurla whlch •vas 
unresponsive to dietary control of phenylalanine and ln whlch there was 
progressive neurological illness whi h 
c was terminated by death ln early 
childhood . (Smith, Clayton and Wolff 1975) Thls theory was conflnned 
by detailed biochemical studies of similar cases . (Kaufman, Holtzman, 
Milstien, Butler and Krumholz 1975, Rey, Harpey, Leeming, Blalr, 
Aicardi and Rey 1977) Thls form of malignant hyperphenylalanlnaemla 
and the serious consequences of this inherited disease emphaslze the 
importance of dihydropteridine reductase activity. 
MATERIALS AND METHODS 
NADH, NADPH, 6,7, dimethyl 5,6, 7,8 tetrahydropterln, carbodll-:-
mlde, dithiothreitol, dichlorophenolindophenol, tetrahydrofollc acld , 
cytochrome C, =< chymotrypslnogen, equlne apoferrltln, bovlne serum 
albumin, hexokinase and dextran blue 2000 were all purchased from the 
Sigma Chemical Company. AH-Sepharose 48 and Sephadex G-150 were 
obtained from Phannacia Flne Chemlcals, Sodium L 2 naphthoqulnone-4-
s ulphonate was purchased from Cambrlan Chem lcals. Horseradlsh per-
oxldase was obtained from Calbiochem. Tetrahydroblopterln was a 
gift from Roche Products Llmlted. All other chemlcals were obtained as 
descrlbed before or from BDH and were of Analar grade. 
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METHODS 
Dihydropteridlne reductase was Isolated from r 
liver uslng a 
modified version of the ff ' 
a Lni ty chromatographic method of Cotton and 
Jennings, (1978). 
Preparation of the Affinity Adsorben t 
7 .5 9 of AH-Sepharose 4B was allowed to swell In excess O. SM 
NaCl at 4 °C Lactose and dextra n we re removed by washing the 
Sepharose in 1500 cm
3 
of 0.5 M NaCl. The Sepharose gel was then 
3 
washed in 1500 cm of distilled water to remove NaCl. 
0.375g of sodium 1,2 naphthoquinone-4-sulphonate was dissolved 
in a small amount of distilled water. This !Lgand solution was added 
to the gel and the pH of the m lxture was adjusted to between 4 . 5 - 6 . O. 
The slurry was stirred gently at room te rn perature for l hour In the dark . 
l. 86g of carbodllmide was dissolved in a s mall amount of distilled 
water and this was added dropwlse to the slurry w lth gentle stirring. 
The pH was maintained at between 4. 5 and 6 . 0 for 1 hour . This m lx-
ture was then shaken in the dark for 24 hour s . The adsorbent was then 
washed with 750 cm 
3 
of O. IM sodium ace tate buffer pH4 contalning l M 
3 3 
NaCl fallowed by 750 cm of distilled water a nd flnally w ith 75 0 cm of 
0.05M Tris/HCl buffer pH 7.6 containing 0.2M NaCl (Buffe r A) kee ping 
the adsorbent as cold as possible a nd in the dark as muc h as poss ible . 
0 
The adsorbent was stored in the la t ter buffer ln the dark at 4 C a nd 
proved to be stable for at least 12 months . It was a r ich mahogany 
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colour in Buffer A. 
Preparation of Tissue Extract 
A 20% homogenate of rat liver from freshly kllled male Wlstar rats 
was prepared in O.lM Tris/HCl buffer pH 7.6 . The homogenate w, ,s 
centrifuged at 25,000 xg for 1 hour at o0c in a M . S.E . Superspeed SO 
centrifuge• The resulting supernatant was flltered through muslln to 
remove lipids. The protein content of the supernatant was mec-sured 
using the Buiret method. (Layne 1957) The dlhydropteridlne reductase 
(DHPR) activity was measured using a modlfled method of Cralne, Hall 
and Kaufman (1972). 3 5 cm of the remalning supernatant were applled 
0 to a Sephadex G-150 column (1.5 x 25 cm) at 2 C and equlllbrated ln 
0.05 M Tris/HCl buffer pH 7. 6 . The column was eluted uslng the same 
3 
buffer collecting approximately 7 cm fractions. The protein content and 
DHPR activity of each fraction were measured as before . The most 
active fractions were pooled and made O. 8 M NaCl O .1 mM NADH and 
O .1 mM EDTA ready for application to the afflnlty adsorbent. 
Purification of DHPR by Affinlty Chromatography 
o 3 
All operations were performed at below 4 C. 10 cm of the 
affinity adsorbent were packed lnto a column and equlllbrated wlth 0.05 
M Tris/HCl buffer pH 7. 6 contalnlng O. 8 M NaCl, 0 .1 mM EDTA and 20% 
glycerol. (Buffer 1) . The prepared active Sephadex G-150 fractlons 
were applied to the column whlch was eluted wlth the followlng :-
(l) 30 cm 3 of Buffer l + 0 .1 mM NADH 
- 126 - I 
(ii) 3 
15 cm of O .1 M Na2co3 /Na OH buffer pH 10.9 con alnlng M 
Na Cl + 0.l mM NADH 
(iii) 3 1 0 c m of Buffer 1 
(iv) 3 15 cm of 0.1 M Na2 CO3/NaOH buffer pH 10.9 containing ?•i 
NaCl. 
Approx imate ly 7 cm 
3 
fractions were collected. The pH of each 
fraction wa s che cked and adjusted , lf necessary, to pH 7. 6 using M 
HCl. The protein conte nt of each fractlon was measured uslng the 
Lowry me thod (Lowry, Rosebrough, Farr and Randall 1951) and the DHPR 
activity of each fra ctlon was measured as before . The fractions were 
made 2 mM dithiothre itol and 0 . 02 mM NADH before storing In the freez-
er. The affinity adsorbent was regenerated by washing the column with 
3 
15 cm of 0.1 M sodium acetate buffer pH
4 
contalnlng M NaCl and then 
3 
15 cm of buffer 1. To prevent deterloratlon In the performance of the 
column it wa s regenerated after eve ry 4 runs us ing a dlthlothreltol treat-
ment. This consisted of washing the column adsorbent wlth Buffer l + 
2 mM dithiothreitol for 16 hour s followed by the same buffer minus the 
dithiothreitol until the colour reappeared . The adsorbent was always 
0 
stored in Buffer A at 4 C In the dark . 
Assay for Dihydropteridlne Reductase Activity 
This method wa s essentlally that of Craine, Hall and Kaufman 
(l9 72) but with the addition of sodium azlde to the buffer as a catalase 
3 
Each as saycuvette (1 cm , 1 cm path length) contained the inhibitor. 
following :-
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( l) 3 0 • 5 cm of 0 1 M T l / 4 
· r s HCl buffer PH 7. 0 containing 5. 10- M 
sodium az lde . 
( l i) 0 3 -2 . 1 cm of 1 0 M hydrogen perox lde 
(iii) 3 0 .1 cm of 80 mg/ L h orseradish peroxidase 
(iv) 3 -4 O. l cm of 10 M 6 , 7 dlmethyl 5, 6, 7, 8 tetrahydropterln 
(v) 3 0.02 cm of enzyme preparatlon 
( vi) 
3 -3 
0.1 cm of 10 M NAD H 
(vii) Distilled water to make the volume up to a total of 1 cm 3 . 
The NADH was always adde d last wlth mlxlng to lnltlate the 
reaction after the other reagents had been allowed to equlllbrate at 37°c. 
The rate of reaction was mea sured s pectrophotometrlcally by followl ng 
the decrease in optical denslty at 340 nm due to the dlsapperance of 
reduced nicotinamlde adenlne dinucleotlde (NADH) at 37°c ln a Pye 
Unlearn SP 1700 spectrophotometer llnke d to a varia ble recorder and 
constant temperature water bath. Readings of the decrease ln optical 
density against tlme were me asured directly on th_e chart recorder and 
then the enzyme actlvlty wa s calculated ln f moles NADH oxldlscd per 
3 minute per cm of enzyme. 1 unit of enzyme actl v lty ls deflned as 
that amount of enzyme whlch wlll c atalyze the oxldatlon of 1 JJ mole of 
0 
reduced pyridine nucleotlde at 37 C in 1 minute . 
Measurement of Km Values 
The effect of 6, 7 dimethyl 5, 6, 7, 8 tetrahydropterin and NADH 
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conce ntrations on the red t 
uc ase activity were examined . The Km 
value s were determine d f th 
or ose substrates by variation of the 
concentration of one subs t t 
ra e at saturating levels of the other substrate . 
Effect of Ionic Stre ngth 
The effect of diffe ring ion ic strengths on the enzyme activity was 
inve stigated by including sodium chloride In the assay mixture at a 
range of concentrations from 1 O -SM to 2M . 
Effect of pH 
The effect of pH on the enzyme activity was studied by using a 
range of buffers at different pH s in the assay mixture . 0 . 1 1"1 Tris/HCl 
-4 
buffer with 5 .10 M sodium a zide was used in the range of pH S to pH 
-4 
8.5 and 0.1 M phosphate buffer with 5 . 10 M sodium azide was used 
in the same pH range. 
Estimation of Molecular Weight 
The molecular weight of the enzyme was estimated us ing a 
Sephadex G-150 column (1.5 x 60 cm) c allbrated with the follow ing 
protein standards, molecular weight s shown in brackets :- cytochrome 
C (12,400) e< chymotrypsinogen (25,000) , bovine serum a lbumin 
(fraction V) (65,000), hexokinase (100, 000), h orseradish peroxidase 
(40,000) and dextran blue 2000 (ave rage of 2 , 000 ,000) as descri bed by 
Andrews (1966). Samples were a pplle d to the column equ illbrated w ith 
o. 05 M phosphate buffer pH 7. 0 conta ining 2 mM d ithiothreltol and 
were eluted in the same buffer, 40 x 3 ml fractions were collected . 
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Effe ct of Substrate Ty pe 
Km values were detennlned for alternatlve substrates with the 
enzyme· NADPH was used instead of NADH at a constant saturating 
concentration of 6, 7 dimethyl 5, 6, 7, 8 tetrahydropterin and tetrahyrlro-
biopterin and tetrahydrofolic acld were used in place of 6, 7 dimethyl 
5, 6, 7, 8 tetrahydropterin at a constant sat~ratlng concentration of NADH. 
Use of Dlchlorophenollndophenol (DICPIP) 
DICPIP was used as an alternative method of generating the 
quinonoid substrate fonn from the tetrahydro- form in place of the 
horseradish peroxldase and hydrogen peroxide to check the results of 
the Km values. (Cheema, Soldln, Knapp , Hofmann and Scrlmgeour 
19 73) 
RESULTS 
The results of the purlflcatlon of rat llver dlhydropterldine reduct-
ase are shown in Tables 4-1, 4-2 and 4-3 and ln flgure 4-2 . The only 
changes in experimental procedure between tables 4-1 and 4-3 are that 
for the Table 4-3 results :-
(i) a smaller volume of Sephadex G-150 peak fractions was applled 
to the affinity column; 
( l i) 
(ill) 
the affinity column was run at a slower speed and 
the afflnl ty column fractions collected were of a smaller volume, 
3 
s cm 3 lnstead of 7 cm • 
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These changes in experimental condi tions improved the puriflc tlon of 
dihy dropte rid ine reductase over the original supernatant from about 400 
fold to about 900 fold and gave a corresponding Increase In specific 
activity from 33 .5 units / mg to 55 . 1 units/mg. However, the percc>nt-
age re covery of t he activity applied to the affinity column dropped from 
61 % to 41 %. 
The e ffect of quinonold 6, 7 dimethyl dlhydropterln and NADH 
concentrations on dihydropterldlne reductase act ivity are shown ln 
figures 4-3 and 4-4 a nd gave hy perbolic velocity versus substrate 
concentration curves. Both Line weaver-Burk a nd Eadie Hofstee plots 
gave similar results for the k inetic constants . The apparent Km values 
for quinonoid 6, 7- dlmethyld lhydropterin and NADH were found to be 
-5 -5 
1.2.10 Mand 3.210 M respectively and the apparent V value 
max 
was 24.2? moles/min/ mg of prote in . 
The effect of change s ln the Lonie strength on dlhydropterldlne 
reductase are shown ln Table 4-4 a nd lt can be seen that very little 
change in activity occurs ove r the w ide range of sod l um eh lorlde con-
centrations used. 
The results of vary ing the pH of the assay buffer are shown In 
figure 4-5. There was measurable d lhydropterldlne reducta se actlvlty 
over the whole range of pH tested and with both Trls/HCl and phosphate 
buffers. As can be see n ln figure 4-5 there was a plateau of peak 
acti vl ty over the pH range of 6 • 3 to 7 · O · 
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The results of the molecular we igh t detennlnatlon are shown In 
figure 4-6. 
The dihydropteridlne reductase eluted as a single band 
from the Sephadex G-1 50 1 • co umn correspondmg to a molecular weight 
of 51,000. 
The kinetic data o:itained uslng alternative substrates for NADH 
and 6, 7 dimethyl 5, 6 , 7, 8 tetrahydropterln are summarized In Tables 4-5 
and 4-6 respectively . Table 4-5 shows that NADPH gave an apparent 
Km value which was greater than that for NADH by approximately flve 
times and an apparent V value which was about one-third that 
max 
obtained with NADH. Tetrahydrofolate gave a much lower apparent 
V value than that of 6, 7 dlmethyl 5, 6, 7, 8 tetrahydropterln and an max 
apparent Km value which was about 30 tlmes greater, as can be seen ln 
Table 4-6. However, 5, 6, 7, 8 tetrahydroblopterln gave a sllghtly low-
er apparent Km value than that of 6, 7 dimethyl 5, 6, 7, 8 tetrahydropterln 
and an apparent V value whlch was about a third more again . 
max 
Table 4-7 summarizes the kinetic data obtained when DICPIP ls 
used to generate the quinonold pterln substrate ln stead of Horseradish 
peroxidase and hydrogen -peroxide. If these results are corn pared wlth the 
corre~ponding ones in Tables 4-5 and 4-6 lt can be seen that the apparent 
Km values are all slightly elevated but the apparent V max values are 




























Total Recovery Proteln Speclflc Purlflcation 





305 .0 100 40 . 00 0 . 08 1 
115 . 6 38 1.12 8 . 60 107.S 
70 . 4 23 0.30 33 . 50 418 . 8 
TABLE 4-2 
KEY FOR FIGURE 4-2 





0.05M Trls/HCl pH 7 . 6, 0 . 8M NaCl 
0 .1 mM EDTA, 20 % glycerol buffer, 





/NaOH pH 10.9, M NaCl 
+ 0.1 mM NADH 





/NaOH pH 10.9, M NaCl 
wlth no NADH 
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FIGURE 4-2 CHROMATOGRAM FROM AFFINITY CHROMATOGRAPHY ON SODIUM 1 12 NAPHTHOQUINONE-4-SULPHONATE ATTACHED TO 
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7 9 . 69 
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Total Recovery Protein Spee lflc Purlflcatlon 





108.8 100 49.00 0.06 1 
67 . 8 62 1. 82 5 . 32 89 
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FIGURE 4-4 EFFECT OF CONCENTRATION OF NADH ON 1llE ACTIVI'n' 
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apparent Km = J.2 .10--11 
apparent Vmax = 24.2 units/mg 
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1/ [NAlli] .10-4 H- 1 
TABLE 4-4 
EFFECT OF IONIC STRENGTH ON DIHYDROPTERIDINE RI:DUCTASE ACT(V(TY 
DHPR Activity 
Concentration of NaCl Units/cm 
3 of enzyme 
pre paratlon 
10-SM 0 . 31 
10-? M 0 . 35 
10-6M 0.35 
10-SM 0.42 
10-4M 0. 46 
10-3M 0.36 
10-ZM 0 .4 3 
-2 
5. 10 M 0.39 
10-lM 0.44 
-1 
2 •. 10 M 
0.42 
-1 
4. 10 M 
0.36 
-1 







h . the normal assay mlxture 
The ionic strengt tn 















































































































SUMMARY OF K1NETrc DATA FOR RAT LIVER DCHYDROPTER[D( E RCDUCTASE 












Apparent V value max 
unlts / mg protein 
24 . 2 
8 . 3 
SUM MARY OF KINETrC DATA FOR RAT LIVER DtHYDROPTERTDINE 
REDUCTASE WITH SATURATING C ONCENTRATIONS(f NADH 
Substrate 









4. 0. 1 o-4 
5,6,7,8-
-6 
tetrahydrobiopterin 9. 2. l 0 
- 14J - , 
Apparent V vulue 
max 
un L ts/mg prote ln 
24.2 
9 . l 
32 . 8 
TABLE 4 - 7 
SUMMARY OF KINETIC DATA FOR RAT UVER DlHYDROPTERIDl E RtDUCTASt 





6, 7, dimethyl 
5,6,7,8-
Substrate 













5 . 2.10 
-5 
Apparent V max 
unlts/rr.c orot In 
24 . 1 
31.2 
24 . 1 
DISCUSSION 
The method of pur · f l t · 
L ea ion used here ls a n,odlfled version ot th t 
of Cotton and Jennings (1978). Although a slightly longer method It 
gave a higher purification of about 900 fold over the original su n . tnt 
corn pared to about 4 00 fold and a sllghtly better recovery of the nzyme 
activity in the most active fract ion of 25% compared to 18%. (Cotton 
and Jennings 1978) Like the adsorbent of Cotton and Jennings, the 
adsorbent used here could be rege nerated and used repeatedly U stored 
correctly. If the results obtained here a re corn pared to those of other 
affinity chromatographic methods of d lhydropterldlne reductase purificat-
ion, it can be seen that with a Blue Dextran-agarose adsorbent (Chauvin, 
Karri, Tirpak, Simpson and Scrimge our 1979) and a 5 ' AMP-Sepharose 48 
adsorbent (Aksnes, Skotland, Flatmarck and Lj ones 1979) 1:etter speclflc 
activities of 230 units/mg and 155 unlts/ mg respectively were obt I ned . 
These can be compared to the 55 unlts/ mg obta ined by the me thod used 
here but smaller yields of actlvlty were recorded , 16% and 17% respect-
ively. The purification was only 359 for the Blue Dextran adsorbent 
and 705 for the 5 'AMP-Sepharose 4B adsorbent . Wi th a Clbacron blue 
F3GA - agarose adsorbent, Webber and White ley obtained a better 
specific activity of 94 unlts/mg and a s imllar 26% recovery of enzyme 
activity but lower purification of 223 (1978). The results obtained 
h · 'tlar to the 62 units/ mg speclflc activity and , 27% ere are very s tm 
f t 'vity but the re was a 148 fold purlflcatlon record-recovery o enzyme ac t 
ed with a methotrexate-sepharose adsorbent. (Webber, De lts, Snyder 
and Whiteley 1978) Even though the re sults obtained here are not 
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quite as good as some of those 
recorded wl h other affinity chrom to-
graphic methods the method d h 
use as the advantage that It ls much 
shorter process consisting of 1 on Y two steps . 
Cotton and Jennings suggested that the sodium 1, 2-naphthoqi Inonc-
4-sulphonate ligand may be effective for dihydropteridlne reduct s r-
ification by affinity eh t h · roma ograp Y due to structural slmllarltles to the 
quinonoid pterin substrate. This would explain its speclflclty for 
dihydropteridine reductase and why a slngle afflnlty chromatography 
ste P gave them such good puriflcatlon results . (Cotton and Jennings 
1978) As can be seen from Figure 4-2 and Table 4-2, NADH has to be 
present for the dihydropteridine reductase to blnd to the adsorbent and 
use is made of this property in the purification by firstly binding the 
enzyme onto the adsorbent in a buffer contalnlng NADH . Then after the 
impurities have been washed off the column the enzyme ls eluted from 
the adsorbent using a buffer mlnus NADH when the enzyme ls released 
· from the adsorbent belng unable to blnd wlthout the NADH . Th is method 
also suggests that dihydropterldlne reductase may follow a compulsory 
order mechanism where the NADH has to bind to the enzyme before the 
quinonoid pterin substrate can be bound at all, hence the blndlng of the 
NADH substrate probably produces a conformational change ln the 
enzyme which then enables It to bind the qulnonold pterln substrate or 
in the case of the purification method used here, the 1, 2 sodium naph-
thoquinone-4-sulphonate. Therefore, this purlflcatlon technique adds 
more evidence to the theory of dlhydropterldlne reductase having a 
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corn pulsory order mechan · 
tsm, (Korrt, Chippel, Ch uvln, Tlr 
Scrirngeour 1977, Aksnes and 1 . Jones 1~80) as do sever l ADH-
dependent dehydrogenase and d 
re uctase enzymes such s liver lcohol 
dehydrogenase and lactate d h d 
e Y rogenase · (Dalziel 19 75, Dixon md 
Webb 1979) 
The rat liver dihydr t 'd• op en me reductase Isolated here had n pH 
optimum between pH 6. 3 and 7. 0 and thls result agrees well with those 
appearing in the literature. (Webber, Delts, Snyder and Whlt leyl978, 
Cheerna, Sold in, Knapp, Hofmann and Scrlmgeour 1973) The pH optimum 
of this rat liver dihydropteridlne reductase ls therefore near the pH 
value at which the quinonold dlhydropterln substrate ls most stable . 
(Archer and Scrirngeour 1970) 
The molecular weight of the dlhydropterldlnc reductase lsol ted by 
the method used here was 51,000 whlch again agrees well wlth the 
values quoted in the llterature which range from 48,000 (Webber, Dclts, 
Snyder and Whiteley 1978) through 49 000 (Hasegawa 1977) and 50 ,000 
(Cheerna, Soldin, Knapp, Hofmann and Scrlmgeour 1973) to 52,000 • 
(Karri, Chippel, Chauvln, Tlrpak and Scrlmgeour 1977, Aksnes, Skotland , 
Flatrnarck and Ljones 1979) In all these cases the enzyme w s found 
to be a dimer conslstlng of two ldentlca l subunits but the dlhydropter-
idine reductase isolated by the slmllar method as used here from monkey 
and human llver by Cotton and Jennings (1978) had a molecular weight of 
100,000 and was a tetramer. In all the studies the monomer molecular 
weight was found to be about 25,000 which suggests that the dlhydro-
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pteridine reductase isolated fro h 
m rat ere Is probably a dlmcr . B sed 
on the molecular weight of 51 000 ' and the spcclflc ctlvlty of SS .1 unlts/ 
mg of protein the turnover number of dlh d 3 
Y ropterldlne rcduct se ls 1.71.10 , 
(m olecules of product synthesLzed 
per minute by each molecule of 
e nzyme) 
The Michaelis constants obtalned wlth the substrates ADH and 
6, 7, dimethyl 5, 6 , 7, 8 tetrahydropterln of 3 . 2 l o-5M and l. 2 . l o-5 M 
respectively are again in good agreement with values quoted In the lit-
erature. (Webber, Deits, Snyder and Whiteley 1978, Cheema, Seldin, 
Knapp, Hofmann and Scrimgeour 1973, Webber and Whiteley 1978, Craine, 
Hall and Kaufman 1972) The higher apparent Km and lower apparent V 
max 
values obtained with NADPH suggest that the enzyme has a dlstlnct 
prefer_e nce for NADH as the cofactor. Most work on dlhydropterldlnc 
reduatase has indicated that NADH Is the preferred cofactor . (Webber, 
Deits, Snyder and Whiteley 1978, Cheema, Soldln, Knapp , Hofmann and 
Scrimgeour 1973, Cralne, Hall and Kaufman 1972, Webber and Whltelcy 
1978, Nielsen, Simonsen and Llnd 1969) except for a dlhydropterldlne 
reducta se isolated from bovlne liver by Nakanlshl and his coworkcrs 
which was shown to have a preference for NADPH rather than NADH but 
Lt ls thought_ to be a different type or form of the enzyme . (19 78) Of 
the three pterin substrates studied here, the S , 6, 7, 8 tetrahydroblopterln 
appears ~o be the most favoured substrate for the dlhydropterldlne reduct-
ase as it has the lowest apparent Km value and highest apparent Vmax 
1 b 6 7 d
. ethyls 6 7 8 tetrahydropterln has similar kinetic va ue ut , , tm , , , 
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constants. Tetrahydrofolat 
e gave a higher apparent J~ v Ju nd 
much lower apparent V value but st· 11 
max I can act s substr t for 
this enzyme. Howe h 
ver, t ese results may also be due not to tctra-
hydrofolate acting as a substrate for dlhydropterldlne rcduct se but due 
to a small amount of an impurity ln the tetrahydrofolatc which Is a 
substrate for dihydropteridine reductase such as 6 methyl tetr hydro-
pterin which has been used in assays of thl s enzyme. {Kaufman and 
Levenberg 1959, Kaufman 1975) Pollock and Kaufman suggested th t 
dihydropteridine reductase may play a role ln folate metabollsm ln the 
brain by preserving tetrahydrofola te from oxldatlon . (1978) These 
results show that tetrahydrofolate could lndeed be a substrate for 
dihydropteridine reductase but the comparatlve apparent Km values of the 
enzyme for tetrahydrofolate and tetrahydroblopterln lndlcate that the 
enzyme has a much greater affinity for tetrahydroblopterln . 
The results obtalned here lndlcate that lt ls possible to Isolate 
dihydropteridlne reductase from rat llve r by thl s two step method Involv-
ing affinity chromatography with sodium 1, 2 napthoqulnone-4-sulphonate 
as ligand and hence, inhibition studies wlth various metal Lons, 
metabolites and drugs can be performed. 
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CHAPTER FIVE 
THE EFFECT OF METAL IONS, DRUGS AND OTHER COMPOU 
LrVER DIHYDROPTER[DrNE REDUCTASE ACTIV[TY 
The cellular concent tl f ra on o tetrahydroblopterln wt 11 have 
s ignificant effect on the productlon of catecholamine neurotransmitters 
because it is present Ln rate-limit ing amounts (Kettler, Barthollnl and 
Pletscher 1974, Patrick and Barchas 1976) for the action of the rate-
limiting step, tyrosine hydroxylase. (Levitt, Spector, Sjoerdsma and 
Udenfriend 1965, Nagatsu, Ievltt and Udenfrlend 19 64) Tctrahydro-
biopterin is also an essential cofactor for the enzyme tryptophan 
hydroxylase (Hosoda and Glick 1966, Friedman, Kappelman and 
Kaufman 1972) which ls the rate-limiting step for the blosynthesls of 
another neurotransmitter, serotonin, (Costa and Meek 1974) Dlhydro-
pteridine reductase (E .C. 1. 6. 99. 7) ls the enzyme whose maln function 
ls to maintain the cellular leve ls of tetrahydroblopterln (Craine, Hall 
and Kaufman 1972) by recycling the qulnonold dlhydrobloptcrln fonned 
by phenylalanine, tyroslne and tryptophan hydroxylases ready to be 
used again. Any factor reducing the activity of dlhydropterldlne 
reductase therefore, could have serlous con sequences on neurotransmitter 
production via tetrahydroblopterln levels. 
Deficiency of dihydropterldlne reductase results ln raised serum 
biopterin levels, (Rey, Harpey, Leeming, Blalr, Alcardl and Rey 1977, 
Danks, Bartholome, c layton, Curtlus, Grobe, Kaufman, Leem Ing, 
Pfleiderer, Rembold and Rey 1978) because the qulnonold dlhydroblopterln 
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is not being reduced and th 
ere fore rearranges lo the 7. 8 di hydro lopt rln 
form which appears in the bl d 
oo and urine . (L l 9 eem ng 1 75, Le mlng 1979, 
Kaufman 19 64, Curtiu s N 'tede . , rw1eser Vlscontini. Otten, Sch ub, 
Scheibenrelter and Schmidt 1979) DLhydroxanthoptcrln Is lso det rtable 
in the urine of these patients. (Watson, Schlesinger and Cotton 1977) 
Methotrexate therapy prod · , uces a stmllar raised serum blopterln l vel and 
raised levels of biopterin in urine as well as the appearance of dlhydro-
xanthopterin . (Leeming, Blair, Melikian and O'Gorman 1976, Watson, 
Schlesinger and Cotton 1977, Cotton 1978) Methotrexate ls a potent 
dlhydrofolate reductase inhibitor (Kl below 10- 9M) (Korrl, Chlppel, 
Chauvin, Tirpak and Scrimgeour 1977) but the literature ls controversial 
on its effect on dihydropteridlne reductase. It has been shown to Inhibit 
dihydropteridine reductase of shee p liver with a KL value of 3.8. 10-SM 
and this inhibition was competltlve wlth respect to the pterln . (Cralne, 
Hall and Kaufman 1972) Inhlbltlon of beef liver dlhydropterldlne reductase 
by methotrexate which was uncompetltlve with respect to NADH and non-
competitive with respect to the qulnonold pterln substrate has also been 
described. (Chauvin, Korrl, Tirpak, Simpson and Scrlmgeour 1979) [t 
was suggested that the methotrexate could bind to either substrate slte 
but appears to bind most strongly to the qulnonold dlhydropterln slte. 
(Chauvin, Korri, Tirpak, Simpson and Scrlmgeour 1979) However, Lt has 
also been claimed that methotrexate has no effect on dlhydropterldlne 
reductase activity. (Gal, Bybee and Sherman 1979) The effect of 
methotrexate on dlhydropteridine reductase ls Important because of the 
long term side effects of methotrexate on the central nervous system which 
- 1.51 -
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have been re ported in some 
cases of childhood leukaeml . dows 
and Evans 19 76) 
Dihydropteridine reductase lnhlbltlon may be the 
cause (Cotton 1978) and th 
ese neurologlcal symptoms would then be due 
to a reduction in neurotransmitter production, as ls proposed for the .... use 
of the mental defects wh' h Lc occur In malignant hyperphenylalanlnnemla 
due to dihydropte ridine reductase deflclency. (Cotton 1978) 
rf this theory is correct then any drug which has an effect on 
dihydropteridine reductase activity will be of tm portance . 
There are many dihydrofolate reducta se tnhlbltors wh lch, llke 
methotrexate, could be dihydropteridlne reductase tnhlbltors . Amlno-
pterin and co-trimoxazole (trlmethoprlm and sulphamethoxazole) reduce 
phenylalanine clearence after an oral load as methotrexate does, (Andrews, 
Purkiss , Chalmers and Watts 1976, Leeming, Blair, Me llklan and 
O'Gorman 1976, England and Coles 1972) most probably by reduction of 
phenylalanine hydroxylation. Amlnopterln has been shown to Inhibit 
phenylalanine hydroxylation in vitro and In vlvo . (Kaufman and 
Levenberg 1959) 
Serum dihydrobiopterin has been shown to parallel serum phenyl-
alanine after oral loads. (Leeming, Blair, Green and Raine 1976) There-
fore either phenylalanine itself or a metabollte of phenylalanine may have 
an effect on the dlhydropterld ine reductase system . Phenylalanine occurs 
b t 1 o-4M In normal human brain . (Letendre, at concentrations of a ou 
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Nagaiah and Guroff 19SO) 
Langenbeck and his co-workers h v d nnln d 
by studying phenylketonurics on 
and off the phenylalanine-r strlct d dlet 
that there is a high correlat· b 
Lon etween plasma phenyl Janine levels nd 
phenylpyruvate levels whe th . 
re e rat to of am lno acld/keto acid Is abo Jt 
12 :1 at a plasma phenylalanine value of 1 . 7 mM. 
The range of serum 
phenylpyruvate was 10-SM t 1 6 -4 0 
• • 10 M ln controlled phenylketonurlcs. 
(Langenbeck, Behbehani and Luthe 1980b) The normal (non-phenylketonurtc) 
plasma phenylpyruvate concentration is about S to 8 JJM. (Langenbeck, 
Behbehani and Luthe 1980a, Langenbeck, Behbehanl and Luthe 1980b) 
Jervis and Drejza found both phenylpyruvate and o-hydroxyphenylacetlc 
acid in the plasma of every case of phenylketonurla they examlned ln the 
ranges of 10-SM to 6 . 4. 10-SM and 7.9. l0-6M to 4.0. 10-SM 
respectively. (19 66) Langenbeck 's group showed that phenylpyruvate 
appears in the urine when plasma phenylalanlne levels rise to l. lmM or 
higher. (Langenbeck, Behbehani, Mench-Holnowskl and Petersen 19 80) 
A non-linear relationship between the urlnary levels of both phenylpyruvate 
and o-hydroxyphenyl acetic acid and the plasma levels of phenylalanlne 
was also demonstrated where levels of phenylpyruvate were typlcally 5 
times higher than those of o-hydroxyphenylacetlc acid . (Langenbeck, 
Behbehani, Mench-Hoinowskl and Petersen 1980) It has been demonstrated 
that the amount of phenylpyruvate and o-hydroxyphenylacetlc acld excreted 
in the urine of patients with phenylketonurla or lts varlants Increases wlth 
age up to about z years of age with only small amounts belng excreted ln 
the first few months. Thls ls thought to be due to delayed maturatlon of 
phenylalanine transaminase. (Rey, Pellle, Slvy, Blandln-Saroja, Rey and 
- 1.5) - I 
Frezal 19 74) The lumbar b 
cere rosplnal fluid of a patient •1lth un r 
phenylketonuria had only tra f 
ces o phenylpyruvate, of bout lJJ • 
(Langenbeck, Mench-Hoinowsk l d 
an Rod-Urban 1978) An ln vlvo 
metabolic pathway in rabbit b . h 
ram as been demonstrated which 11 n d 
L-phenylalanine to phenylethylamlne d t 
an yramlne. (Mosnalm, Silk ltls 
and Wolf 1980) 
So these two metabolites of phenylalanine might b 
expected to rise in ph lk 
eny etonurla as well as the usual, quoted metaboll es, 
phenylpyruvate and 0 -hydroxyphenylacetlc acid . The concentration of 
phenylethylamine in brain has been quoted as SnM J (Fischer, Spatz and 
Heller 1972) and as 9.1. 10-
9
M ln rat brain. (Martin and Baker 1977) 
The level of para-tyramlne ln rat braln was measured and found to be 1. 3 . 
10-SM. 
5-formyltetrahydrofollc acld, whlch ls glven as a rescue therapy 
after methotrexate, (Frel, Jaffe, Tattersall, Pitman and Parker 1975) Is 
also associated with rises ln serum dlhydro:olopterln whether glven orally 
or intravenously . If the cllnlclan wished to avold the possible neurological 
consequences, then 5-methyl tetrahydrofollc acld which has no effect on 
serum dihydrobiopterin levels when glven orally m lght be a better choice 
as has been shown in the mouse. (Blalr and Searle 1970) Also 5-methyl 
tetrahydrofolic acid has been demonstrated to have no measurable effect on 
serum dlhydrobiopterin levels when adm lnlstered after methotrcxate. 
(Leeming, · Blair, Melikian and O'Gorman 1976) The effect of various 
folates on dihydropteridine reductase could therefore be of Interest. 
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As tetrahydrobiopterin plays such an lmport 
nt role ln the procluctlon 
of the ea te cholam ine neurotra . tt 
nsm i ers , dopamine and noradrenalin , 
(Kettler, Bartholin i and p le tscher 19 74 N , agatsu, Levltc nd Udenfrlend 
19 64
) it might be e x pected that t hese neurotransmitters or an lnterm dl te 
on their biosynthetic pathway or one of thelr metebolltcs may h ve a 
regulatory or controlling influe nce on tetrahydroblopterln metabollsm . 
Tetrahydrobiopterin is also involved in the productlon of serotonin 
(Friedman, Kappelman and Kaufman 19 72 , Hosoda and Gllck 1966) so thls 
neurotransmitter also may have an influence on tetrahydroblopte rln 
metabolism. Dopamine has been shown to be present in the central 
nervous system in relatively high amounts but lt Is not evenly distributed 
(Glowinski and Sversen 1966, Po pov , Pahle , Rosler and Matthies 1967) 
The neostriatum (the caudate nucleus and putamen) contains about 70-80% 
of the brain content of dopamine . (Berler and Rosengren 1959, Sano, 
Garno, Kakimoto, Taniguch, Takesada and Nichluuma 1959) The 
concentration of noradrenaline ln the ce ntral nervous system Is generally 
higher than that of dopamine. (Pal Kovit s 1979 ) [t has been shown by 
fluorimetry and electrochemical methods that whole rat brain contains 
6 -6 
about 3. 6. 1 O - M dopamine and about 2 .1. 10 M noradrenaline plus 
-7 
b 4 0 10-?M homovanillic acid and about 3 . 7 . 10 M dlhydroxyphenyl-a out •• 
acetic acid, the metabolites of dopamine • (Adams 1979, Taylor 1979) 
However the concentrations in speciflc brain areas can be greater such as 
-5 -6 
in the stria tum where there is about 5 . 0. 10 M dopam lne, 2 .1 . l O M 
-6 
noradrenaline, 5 • 5. 1 o-6M homovanllllc acid and 6 . 6. l O M dlhydroxy-
phenylacetic acid. McKellwin e t al. 1 quoted dopam lne concentrations 
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-4 
of 5. 0. 10 M iri the cereb l b -3 
_
4 
ra rain tl ssue, l . 6 . l O In the th I m JS 
and 8.0. 10 •Min the hypothalamus . (1971) 
Sc rot on In lcv ls ln 
whole rat brains have been shown t b b o e a out 1 . 8 3 . O' mat , 
Okada, Watanabe, Kawashima and Wada 1980) 
The effect of thes e neurotransmitters and thelr metabolites, 
phenylalanine and its metabolites, certaln folates and dlhydrofolate 
re ductase inhibitors plus other drugs and metal Lons associated wl th 
neurotoxicity form the basis of the results presented Ln this chapter . 
MATERIALS AND METHODS 
Folic acid, dopamine, tyramlne, phenyl pyruvic acid, phenyllac~1c 
acid, o-hydroxyphenylacetic acid, phenylacetlc acid and phenylethylamlne 
were all purchased from the Sigma Chemical Company. 10-fonnyl folate 
was pre pared in the department of chemistry, at Aston University In 
Birmingham by Dr. M. J. Connor. Noradrenallne , adrenaline, serotonin 
and L-DOPA were all gifts from Roche Products Llmlted . All other chemicals 
were obtained as listed before or from B. D . H. and were of Anal r grade . 
Methods 
The baste assay method used ln these studies was essentlally 
the same as that used by Craine, Hall and Kaufman (1972) as described 
in Chapter 4. The enzyme source was the purest fraction from the 
affinity column. Again 1 unit of enzyme actlvlty was deflned as that 
f h
'ch will catalyse the oxidation of lfmole of reduced 
amount o enzyme w L 
.: 
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pyridine nucleotide at 37oc . . tn 1 mmute . The app rent K and pp r n 
m 
V 
max values were measured d an calculated as descrlbcd ln Ch pt r 4, 
5, 6, dichlorophenolindophenol (D 
ICPIP) was used as before to check the 
results with this alternative method f 
o regenerating he qulnonold sul str tc. 
(Cheema, Soldin, Knapp, Hofrrannand Scrimgeour 1973) 
Inhibition Studies 
In addition to some of the reagents used ln Chapter 3, (Table 3-1) 
those shown in Table 5-1 were also used for lnhlbltlon studies on 
dihydropteridine reductase. 
Inhibition studies were perfonned wlth at least three different 
concentrations of the potential inhlbltor. The concentration of dlmethyl-
tetrahydropterin was varied and that of NADH was kept constant at 10-4M 
in order to determine the type of inhlbltlon with respect to NADH . Types 
of inhibition were assigned using the description s ln 'Enzymes' by Dlxon 
and Webb (3rd Edition), after plotting the results on velocity versus 
substrate plots, Lineweaver-Burk plots and Eadle-Hofstee plots . 
(Dixon and Webb 1979) 
With the potential metal ion lnhlbltors, dlhydropterldlne reductase 
activity was also measured by preincubatlng the enzyme for various 
lengths of time in the presence of various concentrations of the metal Lons 
at 37°c before the substrates were added. Appropriate controls were also 
examined by preincubating the enzyme at 37°C for various lengths of time 
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before adding the sub t t 
s ra es a nd measuring the activity In the usu I way. 
In the case of lead · h 
tons, t e removal of the lead from the dlhydro-
pteridine reductase was investigated ft h 
, a er t e enzyme had been lncubated 
-4 
with 10 M lead acetate , by d' 1 l 0 ta ys ng at 4 C for up to 72 hours ga nst 
0 • OS M Tris/HCl buffer at PH 7 or agalnst the ~ame buffer concalnlng 
-4 . 
10 M EDTA with twelve changes of buffer for each dialysis. Agaln 
appropriate controls were exam ined by dlalyslng enzyme against the same 
0 
buffers at 4 C for the same lengths of time with twelve changes of buffer. 
The Ki values were measured for methotrexate and phenylpyruvlc 
acid on the normal dihydropteridine reductase enzyme and on dlhydropterldlne 
reductase which had been incubated wlth 1 o-4M lead acetate ln order to 
see if the values were altered in the modlfled enzyme system . The effect 
of dopamine on the leaded enzyme was also lnve stlgated . 
Inhibition studies were also performed uslng the followlng mixtures 
of inhibitors to see if any synergistlc actlon could be detected :- dopam lne 
and phenylpyruvic acid; methotrexate and phenylpyruvlc acld; phenyl-
eth ylamine and phenylpyruvlc acld; doparnlne and methotrexate; and 
trimethoprim and- sulphamethoxazole . rn each case at least one of the 
inhibitors was present in concentratlons which produced maxlmal lnhlbltlon 
when used alone. 
TABLE 5-1 FORMULAE OF REAGEN'ffi USED FOR DDfi D 






CH-C - C= O 
3 11 I 
0 ONa 
CH-c-c-CH 
3 II II 3 
0 0 
- 159 - I 




























- 161 - I 
0 
0 







TABLE 5-1 continued 
Phenylacetic acid 
Phenylethylamine 
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RESULTS 
The results of sodium 1 ' 2 naphthoquinone-4-sulphon t tnhlbltlon 
are shown in Figures 5 1 and 5 2 . . and ln Table 5-2. The apparent :K 
m 
values increased with increa . d' SLng so tum l, Z-naphthoqulnone-4-sul ,on t 
concentrations but the v val max ue remained the same when ft const n 
NADH concentration of 1 o-4M was s d u e . Therefore sodium 1, 2 naphtho-
quinone-4-sulphonate is a tl compe tlve lnhibitor of rat llver dlhydropterldlne 
reductase with respect to the pterin substrate. Sodlum 1, 2 naphthoqulnone-
4-sulphonate showed mixed inhibltion wlth respect to NADH. This means 
that both the apparent V and apparent K values decreased and 
max m 
increased respectively with increas lng sodium 1, 2 naphthoqulnone-4-
sulphonate concentrations. The Dixon plot (Flgure 5. 2) showed the K l 
value for sodium 1,2 naphthoquinone-4-sulphonate to be 3 . 7 . l0-
4
M. 
Table 5-3 displays the results of inhlbltlon studles by the dlhydro-
folate reductase inhibitors. All those tested showed competltlve lnhlbltlon 
with respect to the pte rin substrate but mlxed lnhlbltlon with respect to 
NADH. The same results were obtained lf 5, 6 dlchlorophenollndolphenol 
(DICPIP) were use d in the assay system Instead of h orseradish peroxidase 
and hydrogen peroxide to generate the quinonold pterln substrate. The K1 
-5 -4 
y a lues range d from 6.4. 10 M to 5 . 8 . 10 M . Sul phamethoxazole, the 
othe r drug which appears with trimethoprlm ln the pharmaceutical preparations 
co-trimoxa~ ole , bactrln and septrln showed mlxed lnhlbltlon with respect 
to the pterin and competitive inhibitlon with respect to NADH . The K1 
-4 
value for sulphamethoxazole was 8.7. 10 M. When lnhlbltlon by both 
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trimethoprim and 1 h su P ame thoxazole was stud'ted 
he Inhibition ob In d 
by the two drugs togethe r a ppea d 
re greater than w ld be ex et d by th 
separate drugs (Table 5 . 4). For exam pie· 3 · 5 • l O - 4 M trlmethoprlm h d 
noeffectand3.9.10-4M 
sulphamethoxazole gave a 24 % lnhlbltton I ut 
together the same concentrat · f h tons O t ese drugs gave a 40% lnhlbltlon. 
This is a more than additive effe ct. However, If the concentr tlons of 
the drugs were increased this effe ct d lsappea F 1 -4. rs . or exam p e, 6 . 9 . 1 0 M 
trimeth0 Prim a nd 7 · 8 • 10-
4
M sulphamethoxazole both gave 38% lnhlbltlons 
when used separately but togethe r gave 46% lnhlbltlon . 
The results of various folates as lnhlbltors of dlhydroptcrldlne 
reductase are shown in Table 5-5. 5-methyltetrahydrofollc acid h d no 
effect on the enzyme but both folic acld and 10-formyl folate showed 
competitive inhibition wlth respect to the pter\n substrate and mlxod 
inhibition with respect to NADH. The Kl va lues for follc acld and 10-
-5 -5 
formylfolate were 7.3. 10 Mand 8.5. 10 M respectlvely . 
Table 5. 6 shows the inhibltlon re sults of the aromatlc aml no aclds 
and phenylalanine metabolites. All those detenn lned showed mlxed 
inhibition with respect to NADH. Tryptoph an, phenylalanlne , phenyllact-
ate, phenylpyruvate, o-hydroxyphenylacetlc acld, phenylacetlc acld and 
phenylethylamine displayed mlxed lnhlblt\on wlth respect to the pterln 
substrate as well whereas tyroslne and tyramlne showed non-competltlve 
inhibition with respect to the pterin. Non-competltlve lnhlbltlon ls 
h h 
t v value decre a ses and the apparent K value rem.::1lns 
w en t e apparen max m 
the same with increasing inhlbltor concentrations . Agaln the same results 
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were obtaLned for phenylala . 
nine, phenylpyruvate, phenyl) Cl t nd 
phenylethylamine when DICPIP . 
was used in the enzyme s y . There was 
a wide range of K.L values obtained wlth th'ts 
set of Inhibitors from the 
tyramine value of 1.8. 10-SM to the value for both 
phenylalanln an I 
phe nyllactate, 1. o. 1 o-3M. 
Table 5 . 7 shows the percentage Inhibition 
. -5 
whLch occurred at 10 M dimethyltetrahydropterln with v rlous concentrations 
of phenylpyruvate • It can be seen that a slgnlflcant 16% Inhibition was 
obtained with a phenylpyruvate concentration of 2 . 7 . 10 -SM . Some 
problems were encountered wlth the phenylpyruvate lnhlbltlon experiments 
at first when fractions, which were not so pure as the 900 fold purlflcatlon 
fractions, or crude supernatant was used in the studies . The phenyl-
pyruvate appeared to accelerate the dlhydropterldlne reactlon . However, 
if the pterin substrate and/or the qulnonold generatlon system were 
omitted from the reaction mixture, a rate was stlll obtained . This method 
is measuring a decrease in NADH so lt appeared that some contamlnent In 
the enzyme preparatlon was causing the phenylpyruvate to be reduced at 
the expense of the NADH. The phenylpyruvate without the enzyme 
preparation would not oxldlse the NADH so the contamlnent was not ln the 
phenylpyruvate solutions. By measuring the speclflc actlvlty of the 
dihydropteridine reductase actlvlty wlth the pterln substrate and the 
activity of the enzyme preparation to reduce phenylpyruvate at various 
stages of the purification it was determined that the reduction of the 
phenylpyruvate was not belng brought about by the dlhydropterldlne 
reductase enzyme itself. Thls was because the speclflc actlvlty of the 
dihydropteridine reductase actlvlty lncreased as the purlflcatlon was 
carried out whereas, the s . pec1fic activity of the 'ph nylpyruv t -
reducing -enzyme' decrea d se as the purification proc ded (T 
This problem W,3.s overcome at first by subtracting the r of th 
l 5-8) . 
'ph nyl-
pyruvate-reducing-enzyme, f rom the rate of dlhydropt rldln Ji duct ln 
the presence of phenylpyruvate but later the probl m did not rls th 
900 fold purification fraction from th ffl e a n l ty chrom togra phy h 
'phenylpyruvate -reducing activit y . 
d no 
The results of inhibition studies of the catecholamines nd 
serotonin are shown in Table 5-9 . Adrena llne and L-DOPA h d no effect 
but noradrenaline showed non-competitive inhibltlon and serotonin showed 
competitive inhibition with respect to the pterin substrnte and both th sc 
inhibitors showed mixed inhlbitlon with respect to NADH . The s m 
results were obtained if DICPIP was used in t he assay . The Kl values 
for noradrenaline and serotonin were 4 . 9. l0-
4




The results of dopamine inhibltlon of dlhydropterld lne reductase 
are shown in Figures 5.3, 5.4, 5.5, 5.6 and 5 .7. As can be seen from 
Figure 5. 3, in the presence of dopamine the usual hyperbolic voloclty 
versus pterin substrate concentratlon curve becomes slgmoldal ln sh, 
The symoidicity does not disappear lf DICP[P ls used to generate the 
quinonoid dimethyl dlhydropterln substrate lnstead of horseradish peroxid-
ase and hydrogen peroxide, (Flgure 5. 4) s howlng that the effect ls on 
dlhydropterldine reductase rather than the qulnonold regeneratlon method . 
The velocity versus NADH concentratlon curve also becomes slgmoldal ln 
the presence of dopamine. (Flgure 5. 5) Tpe Hlll plot (Flguro 5 . 4) 
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shows positive co- operativity forth · 
1s enzyme bee us h Hill cocfflcl nt 
determined from the slope of the "ddl 
n11 e part of the curve I" 2.26. Thi 
will approximate to 2 binding sites pe 
1 r enzyme mo ecule s here ha to 
be a whole number of binding sites. The slope at the top nd botton 
ends of the curve approach values of unity. These devl tlons from th 
theoretical linear prediction of the Hlll equatlon plot occur b c us It I 
assumed that the substrate binding does not occur In steps but In pr ctlc 
it is possible to obtain partly liganded lntermedlates . At very low Ilg nd 
concentration when proceeding from the state where no sites are occupied 
on the enzyme there would be no co-operative effect and similarly when 
only one ligand s ite remained to be filled at high levels of satur tlon 
there would be no co- operativity and hence, the values of the Hill-co-
efficient approach unity at hlgh and low level s of saturation . Th 
Scatchq.rd plot (Figure 5. 7) also shows that the number of substrate 
molecules bound per molecule of enzyme Is greater than 1, In this case , 
1. 52. 
Tables s . 10 and 5 . 11 show lnhlbltlon results wlth so~:Hum pyruvate 
and diacetyl respectively. In l;>oth cases very high concentrations of the 
compound were required In order for any Inhibition to be measured, 1. 8. 
10 -3M for sodium pyruvate and 3. 5. l o-
2
M for dlacetyl. The perc ntago 
h f these concentrations was 23% for sodium pyruv te and inhibition for eac o 
70% for d iacetyl. 
1 f ·xtures of the various Inhibitors are shown In The resu ts o mi 
Tables 5 • l 2 , 5 . 1 3 , 5 · l 4 and 5 ' l S . 
Using saturating concentrations of 
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methotrexate which d 
pro uces 83% inhibition v:i h 1 . 1. 10 " do mln 
which produces 65% inhib't" 
L ion, gave B8 % inhlbitlon tog h r nd ,.._.lth 
-3 
2 .1. 10 M dopamine wh· h 
tc Produces 80% lnhtbltlon gave 92% og th r . 
So an additive effect is being prod d 
uce . However, dopamln to tt r 
with phenylpyruvate did not produce an additive effect bee use usln 
-3 
2. 2. 10 M phenylpyruvate which produces 4 6% lnhlbitlon wlth 2 . l . 10-:'M 
dopamine only gave a ?8 % inhibltion together. Likewise, p cnylethyl mln 
with phenylpyruvate produced no additlve effect but ,ncthotre xa t at 
saturating concentrations with phenylpyruvate did produce an additive 
effect. The 83 % inhibition u sually produced by 4 . 4 . 10-4M methotrcxate 
was increased to 87% when used with 1.1. l0-3M phenylpyruve1te which 
on ly produces 43% inhibition alone and 90%wltn 2.2 . 10-3M phcnyl-
pyruvat e which only produces 46% ln hlbltlon when used alone . 
As can be seen from Figure 5.8, w 1 en dlhydropterldl ne reductase 
is incubated at 37°c with varlous concentratlons of lead acetate bofor 
measuring the enzyme actlvlty, there ls an lmmedlate lnhlbltlon . Th 
degree of inhibition depends on the length of time the enzyme Is pre-
incubated wl th the lead and the concentration of lead acetate used . 
' 
Maximum inhibition of the enzyme was obtalned by prelncubatlon for 20 
0 
minutes. If the enzyme alone ls prelncubated at 37 C for slmllar longths 
of time there is no slgnificant loss of enzyme actlvlty up to 25 mlnutes 
after which the enzyme actlvlty decreases rapldly. (Table S . 16) Table 
5 .17 and Figure 5. g show the results of lnhlbltlon of dlhydropterldlne 
d •th e of concentrations of lead acetate where the enzyme re uctase wt a rang 
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was preincubated with the 1 d 
ea for 20 minutes . An lnhlbl Ion, nlflc nt 
at the 5% level, was obtained . -6 
wi th l0 M lead acet te . As h 
concentration of lead acetat 
e was increased the level of Inhibition 
increase d up to a maximum of 54 %. h ,A tn lbltion obtained :Ith 10-,. ,11 d 
acetate. 
The same results were obtained if DICP[P .,, s us d to 9 n r te 
t he quinonold pterin substrate Instead of Horseradlsn peroxidase nd 
hydrogen peroxide. Tables 5 .18 and 5 . 19 show the results of tt mptlng 
to remove the lead by dialysis against 0 . OSM Trls/HCI buff r 1 pH 7 . 0 
and the same buffer containing 10-4M EDTA. 
enzyme activity was regained after dialysis. 
As can be seen very l lttl 
The control dlalyst. s show 
that very little enzyme actlvlty is lost because of the dialysis tecnnlqucs . 
The effect of various other inhloltors on dlhydroptcrldlne r ductase 
activity after the enzyme had been Incubated with 10-
4
M lead acctat for 
20 minutes are shown in Figure 5.10 and Table 5 . 20 . The enzym still 
displayed a slgmoidal velocity versus substrate concentration curve when 
lt was inhlblted by dopamine In the presence of lead acetate and the 
inhibition by the lead was additive to that of dopam lne (Figure 5 . 10) . The 
K. values for both methotrexate and phenylpyruvate decreased lf measur d 
l 
on the leaded enzyme so again lt appears that the lead acetate Inhi bition 
ls additive to those of methotrexate and phenylpyruvate . (Table 5 . 20) . 
Tables 5 . 21, 5.22, and 5.23 show results of Inhibition of 
dihydropterldlne reductase actlvlty by aluminium sulphate, cadm ium 
· d tlvely 2 . 10-
4
M aluminium 
chloride and mercuric chlorl e respec · 
Signl·ftcant 30 % lnhlbltlon and the level of Inhibition sulphate gave a 


















EFFECT OF SODIUM l,ZllAPHTHOJinmn - 4 - SULPHONATE ON RAT LIVER DIHYDROPTERIDINE REDUCTASE 
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no sodium 1,2 naphthoquinone-
4- Rulphonate 
I.9 x 10--1-t sodium 1,2 naphtho-
quinone - 4 - sulphonate 
J.8 x 10--1-t sodium 1,2 naphtho-
quinone - 4 - sulphonate 
9.5 x 10--11 sodium 1,2 naphtho-
quinone - 4 -- sulphonate 
4 1.9 x 10 M sodium 1,2 naphtho-
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TABLE 5-2 
SUMMARY OF KINETIC DATA FROM FrGURE 5-1 




B. 1. 9. 10- SM 
c. 3. 8. 10-SM 
D. 9. 5. 10-SM 










1.3. 10 M 
-5 
1.5. 10 M 
-5 
1.8. 10 M 
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FIGURE .2,• 2 DIXON PLOT TO SHOW THE EFFECT OF SODIUM 1 12 NAFH'IHOQUINONE - 4 - SULPHONATE ON RAT LIVER 
DiliYDROPTERIDINE REDUCTASE ACTIV!TY 
---<>-
-6 4 x 10 M - q-DHpt 
_._ 1 x 10-5 M q-DHpt 
-l:r-- 2 X 10-5 M q-DHpt 
---lr- 4 X 10-5 M q-DHpt 
I-' -4 
~ Kl • J. 7 .10 M 
0 ' 1~9 3·8 9.5 19·0 
(sodiua 1 , 2 naphthoquinone - 4 - oulphona·t.c] 
X ,10 - ,5 
TABLE 5-3 
THE EFFECT OF DIHYDROFOIATE REDUCTASE rnHIBITORS O. 
DIHYDROPTERIDINE REDUCTASE ACTlVTTY 
Apparent type of Apparent ty of 
Inhibitor inh lbitlon at lnhlbltlon at 
constant [NADH] constant [DMPH 
4
1 
Methotrexate competitive mlxcd 
Am in o pterin competitive mlxcd 
Pyrimetham ine competltlve N.D 
Tetroxoprim competitive N.D 
Trimethoprim competitlve mlxed 
N. D = not determ lned . 
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kl v lucs 
-5 
6 . 4 . J0 M 
-5 
6 . 5 . 10 M 
-5 
8 . 7 . 10 M 
-4 
1 . 3 . 10 M 
-4 
5 .8.10 M 
TABIE 5 .4. 





Enzyme Actl vlty No . of % 
unlts/mg obscrv tlons {nh lblllon 
proteln 
None 2.15 12 
3.5. 
-4 
1 0 M trimethoprim 2.15 6 0 
6. 9 . 
-4 
10 M trlmethoprlm 1. 33 6 38 
-4 1 
3 • 9 .1 o M sulphamethoxazo e 1. 63 6 24 
-4 1 7. 8. 1 0 M sulphamethoxazo e 1. 33 6 
38 
-4 
1.7.10 M trlmethoprlm 
-4 
33 + 2.0.10 M 
1.45 6 sulphamethoxazole 
-4 . 
3. 5. 1 o M trlmethopnm 
+ 3. 9. 10-
4M 
40 
1. 26 6 sulphamethoxazole 






S .9 .10-4 M trime thoprlm 
-4 
42 + 3.9.10 M 6 1. 26 
sulphame thoxazole 
6.9.10-4M trime thoprim 
+7 . 8 . 10- 4 !,1 
1. 15 
6 
sul phame th1J>:ci;l ule 
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TABLE 5-5 
Apparent type of Apparent ty of 
Inhibitor inhlbltlon at lnhlbltlon a kl v lu 
constant [NADHJ constant (DMPH 
4
1 
Folic acid Competltlve mixed -s 7.3.10 M 
10 formyl folate Com petltlve mlxed 
_ c 
8 . 5 . 10 "' • 
5 me thy 1 tetra -
-hydrofolate no effect no effect 
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TABLE 5-6 
THE EFFECT OF AROMATIC AM[NO ACIDS A.ND PHE 
ON D[HYDROPTER[D[NE REDUCTASE ACT[VlTY 
ETABOLIT2 
Apparent type of Apparent ty or 
[nhibitor inhibition at lnhlbltlon t }• l V Ju 
constant [NADHJ constant [D PH41 
Tryptophan mlxed mlxcd -4 2 . 0 . 10 M 
Tyrosine non-com petitl ve mixed -4 3 . 2 . 10 M 
-3 Phenylalanine mixed mixed 1.0 . 10 M 
Phenyllactate mlxed mixed -3 1.0 . 10 M 
Phenylpyruvate mixed mixed -5 5 .0.10 M 
o-hydroxyphenyl-
-acetic acid mixed J\: . D -4 9 . 6 . 10 M 
Phenylacetlc acid mixed N . D -4 9 . 8 . 10 M 
Phenylethylamine mixed mixed -4 8 . 5 . 10 M 
Tyramine non-competitive N . D -s 1.8 . 10 M 
N . D = not determ lned 
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TABLE 5-7 
THE EFFECT OF PHENYLPYRUVATE O E RED,JLCJA E 
ACTIVITY 
All measurements were made with l0-4M ADH nd 10-S D PH
4 
Concentration Enzyme Act I vlty % lnnlbltlon Stud nt l 
of unlts/mg t s 
Phenylpyruvate protein result 
none 2. 11 
-6 
6.1. 10 M 2.00 s P<0 . 10 
1.1. l0-
5M 1. 92 9 P <0 . l 0 
2 . 7. l0-
5M 1. 77 16 P <0 . 01 
5.4. 10-
5M 1. 69 20 p <0.005 
1.1. 10-
4M 1. 60 24 p 0.005 
2. 7. 10-
4 M 1. 31 38 P <0 . 001 
-4 
5.4 . 10 M 1.10 
48 P < 0 . 00 l 
1.1. 10-
3M 1.06 so 
p <0 . 001 
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TABLE 5-8 
THE SPECIFIC ACTIVITIES OF THE DtHYDROPTER[D[ E REDUCTASE A D 







Specific Activity of 
Dihydropterldlne 
Reductase 





- 179 - ' 
s clflc Activity of 
'phenylpyruv t -
rcduclng-cnzym ' 
fl moles NADH/mln/ 
mg protein 
0 . 0074 
0 . 015 
0.096 
TABLE 5-9 
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corn petltl ve 
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Apparent ty of 




mixed 4 .9 . 10-\i 
no eff Cl 
no effect 






















INITIAL VELOCITY VE.R3US Il'1PH4, CONCENTRATIONf PLOTS TO SHOW THE EFFECT OF OOPAMINE CONCENTRATIONS ON 
DHPR USING PEROXIDASE AND HYDROGEN PEROXIDE TO GENERATE THE g_UINONOID SUBSTRATE 
~01 /Ill/ 
-0- no dopa.mine 
_._ 5.3 .10-~ dopamine 
-4 1.1 .10 M dopamine --++-
·1 I //// 
-4 
~ 5.J . 10 M dopamine 
--+- 1 . 1 . 10- JH dopamine 
1·0 2·0 3·0 4 ·0 5·0 
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INITIAL VELOCITY VER3US Il-tFH4 CONCENTRATION PLOTS TO SHOW THE EFFECT OF OOPAMINE ON IJIPR ACTIVITY 
USING DICPIP TO GENERATE THE 9.,UINONOID SUR3TRATE 
4·0J 
no dopa.mine -0-
1.1 .10-4 M -----




o...,_ _ __________ -----_____ _ 
0·2 0·5 0 ·75 1·0 
['m m1J . 1 o 
KEY FOR FIGURE 5-5 
no dopamine 
• -4 1.1 .10 M dopamine 
5.3 .10-4 M dopamine 
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FIGU m z:.2 INITIAL VELOCITY VERSUS NADH CONCENTRATION PLOTS TO SHOW THE EFFECT OF OOPAMINE ON IHPR ACTIVITY 
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TABIE 5-10 
EFFECT OF SODIUM PYRUVATE ON RAT LtVER DIHYDROPT 
REDUCTASE ACTIVITY 
-4 -5 All measurements were made with 10 M NADH and l O D H
4 
Concentration of Enzyme activity No. of Stud nt t l ul 
sodium units/mg Observations r sults 
pyruvate protein 
None 2.05 12 
-5 
9.1. 10 M 2.13 6 p =>O . l 
-4 
4.6. 10 M 2.10 6 p = > 0 .1 
9 .1. 10-
4 M 2.03 6 p = > 0 . l 
-3 
1.8. 10 M 1. 58 6 
p = < 0 . 05 
-3 
2.7. 10 M 1.48 6 
p < 0. 01 
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TABLE 5-11 
EFFECT OF DIACETYL ON RAT LfVER DIHYDROPTERID[ t REDUCTA E 
ACTIVITY 
All measurements were made with 10-4M NADH nd 10-SM DMPH
4 
Concentration of Enzyme activity No. of 
diacetyl unlts/mg Observatlon s 
proteln 
None 2.05 12 
-3 
1.95 6 2.3. 10 M 
-3 
1.95 6 5.8. 10 M 
-2 
2.01 6 1.2. 10 M 
-2 





Stud nt t test 
results 
P-=)O.l 
P =>0 . 1 
P=>0.l 
P=>0 . 1 
p < 0 .1 
P-=<0 . 01 
TABIE 5-12 
EFFECT OF DOPAMINE ANDMETHOTREXATE O, RAT LIVER 
DIHYDROPTERIDINE REDUCTASE ACTrVITY 
-4 -5 All estlmatlons were with 10 M NADH and 10 M DMPH
4 
Inhibitor and Enzyme Actlvlty 1o . of 
concentration units/mg obscrv tlons 
protein 
None 2.93 12 
1.1. 
-3 
10 M Dopamine 1.03 6 
1. 6. 
-3 
10 M Dopamine 0 . 60 6 
2 .1. 
-3 
10 M Dopam lne 0.59 6 
3. 3. 1 a _3M Methotrexate 0.47 6 
4.4. 10-
3M Methotrexate 0.50 6 
-3 
1 • 1 • 1 O M Dopam lne + 
4. 4. 1 a- 3M Methotrexate 0.35 6 
2 .1. 10-3M Dopamine + 













EFFECT OF DOPAMINE AND PHENYLPYRUVATt Oi 
DIHYDROPTERIDINE REDUCTASE ACTIVITY 
All estimati~ns were with 10-4M NADH and 10-1-1 IMPH
4
• 
Inhibitor and Enzyme Actlvlty o . of % 
concentration unlts/mg observations lnhlbltlon 
protein 
None 2.93 12 
1. 6. 10-
3M phenylpyruvate 1. 64 6 44 
2. 2 . 
-3 
10 M phenylpyruvate 1. 58 6 46 
1. 6. 
-3 
10 M dopamine 0.60 6 79 
-3 
2 . 1 • 10 M dopamine 0.59 6 80 
-3 
1.1. 10 phenylpyruvate 0.62 6 79 
+ 2 .1. 
-3 
1 0 M dopam Lne 
-3 
2. 2. 1 0 M phenylpyruvate 0.63 6 78 
-3 + 2 .1. 1 0 M dopamine 
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TABLE 5-14 
EFFECT OF METHOTREXATE AND PHENYLPYRUVATE Q 
DIHYDROPTERIDINE REDUCTASE 
ACTIVITY 




Enzyme Actlvlty No . of % 
unlts/mg observ lions tnhlbltlon 
proteln 
None 2.77 12 
2 . 2. 
-4 
10 M Methotrexate 0. 67 6 76 
3.3. 
-4 
1 O M Methotrexate 0.48 6 83 
4.4. 
-4 
10 M Methotrexate 0.47 6 83 
-3 
1.1. 10 M phenylpyruvate 1. 73 6 43 
-3 
2. 2. 1 O M phenylpyruvate 1. 50 6 46 
-3 
1. 1. 10 M phenylpyruvate 
+ 4 . 4 . 1 O - 4 M Methotrexate 0.37 6 87 
-3 t 2. 2. 1 O M phenylpyruva e 
-4 




EFFECT OF PHENYLETHYLAMtNE AND PHENYLPYRU 'ATE O RAT LIVER 
DtHYDROPTERIDINE REDUCTASE 
ACTIVITY 
Inhibitor and Enzyme Activity o. of % 
concentration un its/mg obs rvatlon Inhlbltlon 
prote in 
None 2 . 77 12 
-4 
1.3.10 M phenylethylamlne 2.02 6 27 
-4 
6.5.10 M phenylethylamlne 1. 77 6 36 
-3 
1.3.10 M phenylethylamlne 1. 66 6 40 
-3 z . o. 1 o M pheny le thy lam lne 1. 69 6 39 
-4 t 2. 7 • 10. M phenylpyruva e 1. 72 6 38 
1 _3 _1 o-4 M phenylethylamlne 
+ 2. 7·.10 -4M phenylpyruvate 1. 69 6 39 
2 _0 _10-
3M phenylethylamlne 
-4 t + 2. 7 .10 M phenylpyruva e 1. 75 6 
37 
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FIGURE j_-8 THE EFFECT OF PREINCUBATION OF 'IRE EN2YME WITH LEAD ON RAT LIVER DIHYDROPTERIDINE REDUCTASE ACTIVITY 
so I / 




1. 0 . l 0- 5 M lead 
~ 
I I • ,0 ~ ~ 
..... ~ 307 L • --0-- 1 . 0 . 10-4 M lead ~ • 
20 
10 
0 25 5 10 IS 20 3·0 
Pre incubation Til!lC (1d.ns . ) 
TABLE 5-16 
EFFECT OF PRE[NCUBATt ON OF THEE 'ZYME AT 37°c O 










OF RAT LIVER DtHYDROPTER[D( 'E 
REDUCTASE 
Enzyme Actlvlty 1o . of 








1. 20 6 
0.83 6 
Stud nt t 
t St 
r sults 
p =>0 . 1 
p <O. 1 
p c <O.l 
p > 0. l 
p = < 0 . 05 
p < 0 . 01 
p c: < 0. 005 
TABLE 5 -17 
EFFECT OF LEAD ACETATE ON RAT LIVER DlHYDROPTERIDI 
ACTIV[1Y 
The enzyme was preincubated wlth the lead ac tat for 20 mlnut 
the enzyme activity was assayed. All estlmatlons w r 
-4 
NADH and 10 M DMPH
4 
-4 






5.0. 10 M 
-7 












1.0. 10 M 
-4 
5.0. 10 M 
-3 
1.0. 10 M 
1.0. 10-ZM 






























% Stud nt 
lnhlbltlon t t t 
r suits 
3 r > 0 . 1 
7 p > 0.1 
10 r • <0 . 1 
14 · p • <O . OS 
22 p • < 0 . OS 
28 r - 0 . 01 
46 r •<O.Ol 
54 p =<0 .005 
53 p • <0.005 
SS p • <0 . 005 
54 p • <O .005 























0 "" 162 ,c? -6 ,o ,os 164 163 
Concentl1ltion of (K ) 
TABIE 5-18 
EFFECT OF DIALYSIS ON RAT LIVER DlHYDROPTERlDl 
ACTIVITY AND LEADED RAT LIVER DlHYDROPTtRlDl 'E REDUCTASC 
ACTrVITY 
6 observations we re made for each dlalysls time excep for th 
undialysed control where 18 observations were m de . Th control w 
a mixture of buffe r and enzyme dlalysed at 4°c wlth twelve eh ngc of 
buffer. The leaded enz yme was a mlxture of buffer with enzym th t h d 
been incubated with 10-
4
M lead acetate at 37°c for 20 minutes, di ly ed 
at 4°c with twelve cha nges of buffer. The buffer used was 0 . 05 M 
Tris/HC 1 pH 7. 
Dialysis Time 
C ontrol L ded Enzym 
hrs Enzyme actlvlty % of Enzyme ctlvlty % or 
units/mg undlalysed units/mg undt lysed 
protein control proteln control 
0 (undialysed) 3.85 100 1. 75 45.S 
1 3.81 99 . 0 1. 77 46.0 
2 3'. 8 6 100 l. 77 46.0 
3 3.73 96 . 9 1. 96 50 .9 
5 3.62 94 . 0 1. 76 45.7 
93 . 0 l. 77 46.0 
8 3.58 
93 . S 1. 79 46.S 
24 3.60 
92 . 7 l.82 47.3 
48 3.57 




ACTIVITY AND LEADED DIHYDROPTERIDINE IEDUCTASE ACTIVIT! 
Dialysis Time Control Le d d Enzym 
hrs Enzyme Actlvlty % of Enzym ctlvlty % of 
unlts/mg undlalysed unlts/mg undl ly d 
protein control prot In control 
0 (undia lysed) 3 . 85 100 1. 75 45 . 5 
1 3 . 88 100.8 2 . 00 51.9 
2 3 . 81 99.0 1. 77 46.0 
3 3 . 77 97.9 1. 85 48. 1 
5 3 . 73 96.9 l.88 49 . 0 
8 3 . 54 92.0 1. 81 47 . 0 
24 3 . 58 93.0 1.85 4 8 . l 
48 3 . 58 93.0 1.81 47.0 
72 3.56 92.5 1.83 47 . 5 
FIGURE ..2,- 10 
.... 
~ 
EFFECT OF OOPAMINE AND LEAD ACETATE ON RAT LIVER DIHYDRQP'IERIDINE REDUCTASE ACTIVITY 
For the studies with lead the enzyme was preincuba.ted with the metal for 20 mins. before the enzyme 
activity was measured. 
-+- no inhibitor 
-<r- 5.3. 10-4 M Dopamine 
C"'\ 
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-+-- 5.3 • 10 M Dopamine+ 
-4 








l·O 2·0 3·0 4·0 s·-o 
( q - j)ffpt] • 10 
TABLE 5-20 









6 . 4 . 10 M 
-5 
5.0. 10 M 
-LEADED RAT LIVE 




3.8. 10 M 
For both methotrexate and phenylpyruvate the kl values for the non-le di d 
enzyme and the leaded enzyme were estlmated to be slgnlflcant at the 5% 
level (i.e. P = < 0.05 ). 
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TABLE 5-21 
EFFECT OF ALUMINIUM SULPHATE ON RAT LIVER DIHYDROPTl:RI I E 
REDUCTASE ACTtVITY 
The e nzyme was preincubated at 37°c with th lumlnlum ulph t for 
20 minutes before the enzyme actlvlty was s y d . All tl Uon 
-4 . -4 
with 10 M NADH and 10 M DMPH
4 
Concentration No.of Enzyme Activity % Stud nt 
of Observatlons unlts/mg Inhibition l t st 
Aluminium protein r sult 
sulphate 
None 12 4 . 25 
2.010- 6M 6 4.00 6 p = 0 . l 
-5 
2.0.10 M 6 3. 50 18 r • <o . 1 
.,.4 
2.0.10 M 6 3. 00 30 P • <O. OS 
-3 
2.0 .10 M 6 2.35 45 p =<0.01 
-2 
2.0.10 M 6 2.00 53 
p <0.01 
-1 
2.0.10 M 6 1.90 55 
p 0 . 005 
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TABLE 5-22 
EFFECT OF CADMIUM CHLORIDE O RAT LlVER DIHYDR TJ.:Rlru.J_ 
REDUCTASE ACT{ TY 
The enzyme was prelncubated at 37°c with the cadmium chlorld fo 20 
minutes before the enzyme actlvlty was assay d. All 
-4 -4 
with 10 M NADH and 10 M DMPH
4 
C oncentratlon No . of Enzyme Activity % Stu nt 
of Observatlons units/mg lnhlbltlon t .St 
Cadmlum protcln r ults 
Chloride 
N one 6 4.62 
- 6 
1.0. 10 M 6 4 . 61 0 r c:> O. l 
-6 
5.0. 10 M 6 4.63 0 r •> O. l 
-5 
1.0. 10 M 6 4 . 57 l r-=<O . l 
-5 
5.0. 10 M 6 3.97 14 pa <O. OS 
1.0. 10-
4M 6 3. 19 31 pc<Q . 05 
5. 0. 10-
4M 6 2. 31 so p <o. 01 
-3 




EFFECT OF MERCURIC CHLORCDE O RAT LIVER DIHYDR 
REDUCTASE ACTIVITY 
The enzyme was preincubated with the mercurlc chlorld t 37°c for 20 
minutes before the enzyme actlvlty was assayed. All stlm tlo 
-4 -4 
with 10 M NADH and 10 M DMPH
4 
Concentration No. of Enzyme Actlvlty % Stud nt 
of Observations unlts/mg (nhlbltlon t t t 
Mercurk proteln r ults 
Chloride 
None 12 4.25 
2. 0. l0-
6M 6 4.08 4 p >O . l 
2.0. 10-SM 6 3.15 26 r 0 . 05 
2.0. 10-
4 M 6 1. 91 55 r - 0 . 01 
-3 








' .0 -➔ N i ~ 
"1t. 
80 
THE EFFECT OF PREINCUBATION OF mIE ENZYME WITH GALLIUM CHLORIDE ON RAT LIVER DIHYDROPTERIDINE 
REDUCTASE ACTIVITI 
4 -2 --o- 1 •• 10 M Gallium chloride 
-+- 7.2. 10-J M Gallium chloride 
-fr- 1.4. 10-J M Gallium chloride 




Preincubatlon Tii=c (nins . ) 
increased as the level of alum· 1 in um sulp lncr d. C tum 
mercuric chlorides produced simlla t 
r pa terns with sl ntflc n SO 
inhibitlonat5.0.10-
4
Mforcadmlum hl ld d c or e an a slgnlflc nt 2 % 
inhibltion at Z.10-
5
M for mercuric chloride nd th d r of lnhlblt o 
de pending on the concentration of the metal Ion. fl c. 11 h h gur ~. ow t 
result with gallium chloride where the enzym w 
with various concentrations of the metal Ion for differ nt l ngth of tlm 
before the enzyme activity was assayed . f:i.s wlth l d, n 
immediate inhlbition which increased as the prelncub tlon tlm Iner d 
up to a levelling off at 15 minutes . The amount of Inhibition d ncJ don 
the concentration of galllum chlorlde used and 1 . 4 . l0-
4
M nd gr t r 
concentrations of galllum ions produced significant (P < 0. 01) lnhlbltlons 
with pre incubation times of 5 minutes or more . 
DISCUSSION 
Sodium 1, 2 naphthoqulnone-4-sulphonate was shown to 
competitive inhibltor of dihydropteridlne reductasc wlth r spect to lh pt rln 
substrate. These results explain why this compound prov d to 
uch e 
good ligand for the affinity chromatographic preparation of dlhydro t rldln 
reductase. It obviously does have a 3-D structure v ry slmll r to th 
d h It ls a competltlv Inhibitor qu inonoid dihydropterln substrate an ence , 
and a good tool for the isolation of the enzyme . 
All the dihydrofolate reductase Inhibitors tested wcr 
hown to 
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inhibitors of dihydropteridi d 
ne re uc as which •,•er c-om 
pterin substrate and showed m. d l h 
txe n lbitlon with r 
apparent K. value for methotrexate 6 )I -5 t was , "t , 10 hie 
't d -5 magnt u e to the 3.8. 10 M obtained byCr 
In et 1., w o 
Th 
ll r 
that the inhibition was tl compe tlve with respect to qulnonold y roblori rln. 
(C raine, Hall and Kaufman 1972) Chauvin et 1. , found n thotr 
-5 
have a Ki value of 7 .0. 10 M but to be non-compctltlv •Ith r 
to 
et to 
the pterin. (Chauvin, Karri, Tlrpak, Simpson and Scrlmg our 1979) Th 
increasing inhibitor potency of the dlhydrofolate rcductas Inhibitor t t d 
for dihydropteridine reductase lnhlbltlon ls as follows :-
tetroxoprim; pyrimethamlne; amlnopterln and methotr x t 
trim thoix-lm: 
Thi ord r or 
potency is the same as that for these inhi bitors for inhibition of r t 
dihydrohlate reductase. (Burchall 1979) The ap rent ri v lu for mlno-
-5 
pterin was 6.5. 10 M which can be favourably comp red with th t obtain d 
-5 
by Cheema et al., of 2.0. 10 M however, they found amlnopt rln to 
non-competltive with respect to the pterln substrate . (Che ma, Soldln, 
Knapp, Kaufman and Scrlmgeour 1973) The apparent K1 v lu s for 
-5 -4 
pyrimetham ine and trimethoprim were 8. 7. 10 M and S . 8 . l 0 M 
respectively whereas, Cheema et al., could not d tect Inhibition or 
dihydropterldlne reductase by e ither of these drugs v n t cone ntr tlon 
as hlgh as 1o-3M. {Cheema, Soldln, Knapp, Hofm n nd Serini our 1973) 
It seems that dihydrofolate reductase lnhlbltors do in fact lnhlblt dlhydro-
pteridine reductas~ but the concentratlon s at which they r eH ctlv 
much higher than those needed for dlhydrofolate reduct s lnhlbltlon. 
S ldln Knapp Hofmann and Scrlmg our 1973) (Burchall 19 79, Che em a, o , ' 
- 2o6 -
Sulphame thoxazole al so lnhlblts dlhyaropt rldl 
r due g 
a competitive inhlbitor Wlth res t 
pee to ADH nd ml d lnhl llor th 
respect to the pterin . 
It has an a pparent K
1 
v lue of 8 . 7. lo -
Sulphamethoxazole has also been shown to be an Inhibitor of col 
dihydrofolate reductase be lng com pe tl tlve with th ub 
, dlhydrofol t 
and having a K. value of 2. O. 1 o-3M 
l • (Poe 1976) Th lit r 
controversial as to the mechanism by whlch sulpham thox zol nd 
trimethoprim produce a synerglstlc lnhlbl tory effect on E . coll . Po 
argues in favour of the synergism of these two drugs du to slmult n ou 
binding to dihydrofolate reductase, (Poe 1976 , Poe 1977, L, c y 1979) 
whereas Burchall and Then are ln favour of a sequent! I blockad of 
dihydrofolate reductase by trimethoprlm and dlhydroptcro tc synth t by 
sulphamethoxazole as being the mechanism of s ynerg ism . (Burch II 1977, 
Burchall 1979, Then 1977) The results shown here do sc m to ugg t 
that trimethoprim and sulphamethoxazole have a synergistic off et on 
dihydropteridine reductase and because the y dcmons tr te compctlt lv 
inhibition to the different substrates, trlme thoprlm to the pt r ln nd 
sulphamethoxazole to NADH, Lt ls possible to envisage th t thli, l 
produced by simultaneous binding to the enzyme , 
5-methyltetrahydrofolic acid had no effect on dlhydroptcrldln 
d h fol ·c acid and 10-fonnyl fol a tc both Inhibited th re uctase w ereas L 
· t to the ptc r ln and with mix enzyme competitively wtth respec d Inhibition 
-5 
with respect to NADH with apparent Kl values of 7. 3. 10 M and 8 . 5 . 1 o-
5 11 
respectively . lts agr
ee with those of t eem Ing on dthydrop rldln These resu 
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reductase whereas the unreduced form i hi 
1979) Cheema et al ., found folic a c id lo b 
dihydropteridine reductase with a n app 
Ki v tu o 2. 
i.s greater than the value obtained he r by b 
out 3 old. 
The metabolites of phenylalanin and ph nyt 
shown to be inhibitors of dihydropteridin r duct 
) 
w r tryp 
ll 
and tyrosine (Chapter 5). These results confhcl with tho o L ml 
(1979) which showed phenylalanine and o rtho- hydroxyph nyl d to 
have no effect on dihydropteridine reductas and ph nylpyru t to 
stimulate the enzyme activity . It seems likely th t th tlmul w 
in fact due to the same 'phenylpyruvate-r duclng ' c ivlty th t w o ln d 
here with unpurified enzyme extracts as only rat br in up r-n l nt 
mos t potent inhibitors were phenylpyruva tc and tyr m n wllh p r r 
-5 - 5 
K values of 5 .0. 10 Mand 1 .8. 10 Mr wP ctlv ly. tnt lb ll no 
i 
dihydropteridine reductase by phenylala nin nd i "' r'r'I t bollt 
phenylpyruvate, tyramine, phenylethyla min could r ult In r d l 
of dihydrobiopterin in the cell due lo inc r ased non- nzy le r 
m e nt from quinonoi.d di.hydrobiople rin and h nc re. I cl run 
,.. 
l e ve ls. It is possible that phenylalanine and it m 
the a gents responsible for the recorded r,se in 
seen in hyperphenylalaninaemia · (Leeming 1979 ' 
m1n • Bl r, r n 
a nd Raine 1974) 
. d L DOPA had no effect on dihyd 
Adrenallne a n -
r1din r du 
1-ne dopamln nd but the neurotrans mitters noradrena 1 ' 
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,.. n 
inhibited it . Noradrenaline and seroto ln h 
4 9 10 -
4 
M d 1 2 - 3 
. . an .. 10 M respectively . So nor dr n lln 
r 
at concentrations which ')uggest that lt be 
m y lnvolv d tn db C 
inhibition on dihydropterldlne red t l 
uc ase n order to control ll o n 
production because d lhydropterldlne reduct s ls r sponsl 
for t tr hy ro-
biopterin Production (Craine, Hall and K ufm n 1972) nd t trahy ro lo-
pterin ls rate -limiting for the flrst enzymatlc ste for nor dr n lln 
biosynthesis • (Kettler, Barthollnl and Pletscher 1974, Levitt, S ctor, 
Sjoerdsman and Udenfrlend 1965, Musacchio, D'Angclo, nd n 
19 71) Dopamine gave s igmold velocity versus substr t cone ntr tlon 
curves (both for pterin and NADH substrates) t 11 concentr lions of 
dopamine used and whatever the system for the g n r tlon of th 
qu inonoid substrate used. These s lgmold curves prompted th plotting 
of a Hill plot to see if the enzyme, whlch ls known to b subunit nzym 
(Craine, Hall and Kaufman 1972, Cheema, Soldln, Knapp, Hof n nd 
Scrimgeour 1973, Webber, Delts , Snyder nd Whiteley 1978, H soo w 
1977) demonstrated any co-operatlvlty. The Hlll plot did In f et 
demonstrate a positive co-operative effect. Thls lmpll th t binding of 
the substrate increases the affinity of the enzyme for ubs qu nt mol cul 
of the substrate (L. e . a homotroplc effect) . Tho ff et of dof)llmln would 
presumably be a heterotroplc effect of co-operatlvlty wh r th blndln 
of the dopam lne decreases the afflnl ty of the nzym for subs qu nt 
molecules of the substrate, and hence causes an Inhibition. A Scatch rd 
plot confirmed that each molecule of enzyme had mor than one ubstr t 
in fact' that each molecule of enzym h d h o sub tr t binding site , 
binding sites which fits the dat 
which how th 
dihydropteridine reductase to be dimer. (Cr In 
19 72, Cheema , Sold in Knapp H f 
' ' 0 m nn nd Scrim 
ol 
H II n 
our 1 7 b r, 
Deits, Snyde r and Whiteley 1978) The Inhibit on of dlh~•drop r din 
reductase by dopaml 
ne occurred at concentr tlon w} lch u t th It 
is involved in a feedback mecha I h n sm on t ls nzym , II. nor dr n lln , 
to inhibit its own synthesis via control of tetrahydroblop rln I v l 
available for use by tyrosine hydroxylase, the r te-llmltlng t for 
catecholamine synthesis. (Nagatsu, Levitt and Ud nfrl nd 196 , vltt, 
Spector, Sjoerdsman and Udenfrlend 1965) 
Studies with dopamine and methotrcx te tog th r d mon tr t d 
that an additive effect was produced. Methotrexat h b n hown to b 
quinonoid dihydropterin for the pterin active sit of th nzym . Th 
additive effect obtained with saturatlng lnhibltlon cone ntr tlon of 
methotrexate used with dopamine Indicated that th do mln w prob bly 
binding to another part of the enzyme other than th pt rln ctlv It In 
order to bring about its inhibitlon. Therefore , dopamtn p n 
allosterlc inhibitor of dlhydropterldine reductase. Allostcrlc Inhibitor 
and/or activators have been found for all enzym s known to b co-o r tlv 
enzymes , (Dixon and Webb ' 19 79) so an allosteric Inhibitor of dlhydro-
pteridine reductase which demonstrates co-oper tlvlty l not urprl In . 
No additive effect was obtained using saturatlno do mln cone nt tlon 




phenyleth Ylamine so it seems likely th t the c hr e lnhlbl or bind 
to the same part of the enzyme mole 1 cu e . Ho,vever, ddltiv ff cts 
were obtained with saturating concentr tions of methotrexate •lth p 1 nyJ-
pyruvate add ing to the evidence that phenylpyruvate binds to the s 11 
site on the enzyme as dopamine which ls a different slt to th pterln 
active s ite of the enzyme . 
The inhibition of dihydro pterldlne reductase by lead was time-
de pendent which raises the pos s lblllty of the Inhibitor being lrreverslble 
although the time-dependent lnhibltlon curves did appear to level off as 
if it was corning to an equlllbrium for each lead acetate concentration . 
(Figure 5. 8) Dialysis of the leaded enzyme against trls buffer and trls 
buffer conta ining the chelating agent EDTA with no recovery of enzyme 
act ivity confirmed the irrevers ibility of lead lnhlbltlon . Alumlnlum, 
cadm ium and mercuric salts all lnhiblted dlhydropterldlne reductase after 
preincubation of the enzyme with the metal presumably Ln an lrreverslble 
manner like lead. Gallium chloride also Lnhlblted dlhydropterldlne 
re ductase and this inhibition was time-dependent so Lt was most probably 
an irre versible inhlbltion. The lnhlbltlon results wlth lead, alumlnlum, 
cadm ium and mercuric salts are at similar concentrations to those obtained 
by Leeming. (1979) The most likely cause of the heavy metal Lnhlbltlon 
is attachment to a thlol group on the enzyme by those meta ls as lead and 
mercury are known to act in thls way . (Ferdinand 1976, Dixon and Webb 
19 79) If dopamine was used with the leaded enzyme, the velocity versus 
s ubstrate concentration curve remained slgmoldal in shape lndlcatlng that 
I 
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the modlflcation of the enzyme by lead ld not< ff et do mln 's 
allosteric inhibition effect. The apparent K values for both phenyl-
! 
pyruvate and methotrexate with the lead-modlfled enzyme were less th n 
the corresponding values on the unmodified enzyme. This lndlc t, s 
that the inhibition ls increased In the presence of Jead whlch Infers th t 
the lead is not blocking the pterln actlve site to whlch mctholrcx te binds 
or the allosteric site to which phenylpyruvate appears to bind. rt the 
lead did block either of these sites, no further lnhlbltlon on ddltlon of 
these inhibitors would occur. The time dependence of the lnhlbltlon, 
however , implies some protection from lead inhlbltlon by one of the 
substrates . As the pterin site appears to be unaffected, the NADH s lte 
seems the most likely target for lead attack. 
The results presented In thls Chapter add to the evidence that 
dihydropteridine reductase can be Inhibited by dlhydrofolate reductase 
Inhibitors and indicate that dihydropterldlne reductase dls plays co-
operati vity . It is shown that dopamine ls likely to be an allosterlc 
inh ib itor of th i s enzyme . Dihydropterldlne reductase can also be 
inhibited by a range of metals, a range of phenylalanine metabolites, 
aromatic am ino ac ids and certain neurotransmitters which probably act as 
feedback inhibitors of this enzyme In order to control their own blosynthesls 
by lim it lng t he cellular levels of tetrahydrobiopterln . 
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CHAPTER srx 
GENERAL DISCUSSION 
Tetrahydrobiopterln (Figure 6-1) ls widely dlstrlbuted ln tlssu s 
(Rembold and Gyure 1972) and lts cofactor role In phenylalanlnc, 
tyroslne and tryptophan hydroxylases is now flrrnly establl shed . 
(figurt: 6-1) 
(Kaufman and Fisher 1970, Lloyd and Welner 1971, Friedman , Kappelman 
and Kaufman 1972) Tyroslne hydroxylase converts tyrosine to L-DOPA 
and is the rate-limiting step for dopamine and noradrenallne blosynthesls . 
(Levitt, Spector, Sjoerdsma and Udenfrlend 1965, Nagatsu, Levitt and 
Udenfriend 1964, Patrlck and Barchas 197 6) Tryptophan hydroxylase 
ls responsible for the conversion of tryptophan to 5 hydroxytryptophan 
and ls the rate-llmltlng step for the blosynthesls of serotonin . 
(Hosoda and Glick 1966, Frledman, Kappelman and Kaufman 1972) 
Cellular tetrahydroblopterln levels are rate-llmltlng for tyrosine hydroxy-
lase actlvlty (Kettler, Barthollnl and Pletscher 1974) and may also be 
limltlng for tryptophan hydroxylase actlvlty although tryptophan 
concentrations are probably the major rate-llmltlng factor for the 
activity of this enzyme. (Costa and Meek 1974) Therefore, tetra-
hydroblopterln concentrations wlll have slgnlflcant effect on the 
productlon of the catecholamine neurotransmitters; noradrenallne and 
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dopam lne and possibly on serotonin production, o a less r ext nt. 
Tetrahydrobiopterln levels are maintained In the cell by two 
processes: the de novo blosynthettc pathway (Figure 6-2) (Brown 
1971, Rembold and Gyure 1972, Gal, Nelson and Sherman 1978) end 
the dlhydropteridlne reductase salvage pathway. (Flgur 6-3) (Craine, 
Hall and Kaufman 1972) The blosynthetlc pathway serves to synthesize 
dihydrobiopterln from GTP by a serles of reactions catalysed by three 
enzymes : dihydroneopterln trl phosphate synthetase or GTP cyclohydro-
lase; an enzyme whlch converts dlhydroneopterln trlphosphate to 
sepiapterin and sepiapterln reductase. Dlhydroblopterln ls then 
converted to tetrahydroblopterln by dlhydrofolate reductase. (Figure 
6-4) (Abelson, Spector, Gorka and Fosburg 1978, Pollock and Kaufman 
1978) Dihydropterldlne reductase regenerates the actl ve tetra hydro 
form of the cofactor from the qulnonold dlhydroblopterln formed ln the 
hydroxylase reactions. The lm portance of tetrahydroblopterln ls 
demonstrated by the severe neurologlcal consequences whlch occur ln 
mallgnant hyperphenylalanlnaem la. There are two causes of thls 
disease. The flrst ls a deflclency ln one of the enzymes of the tetra-
hydrobiopterln blosynthetlc pathway. (Leeming, Blalr and Rey 1976, 
Rey, Blandln-Saroja and Rey 1976, Kaufman, Berlow, Summer, Mllstlen, 
Schulmann, Orloff, Spielberg and Pueschel 1978) The second Ls a 
deflclency of dihydropterldlne reductase. (Kaufman, Holtzman, 
Milstlen, Butler and Krumholz 1975, Rey, Harpey, Leeming, Blalr, 
Alcardl and Rey 1977, Grobe, Bartholome, Mllstlen and Kaufman 1978, 
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Koslow and Butler 1977, Milst1en, Holtzman, O'flynn, Thom s, Bu J r 
and Kaufman 1976 B tl • , u er, Koslow, Krumholz, Holtzm n nd J'aufm n 
1978) 
The aim of the work presented Ln this thesis was to examine he 
tn vitro tetrahydrobiopterin production by these two pathways and to 
see how they can be altered by various reagents, some of which may . 
effect tetrahydroblopterln levels Ln vlvo . The results were then to be 
corn pared to those of published Ln vivo studles, (Leeming and Blair 
1980a, Leemlng and Blair 1980b, Leeming 1975, Leeming 1979, Leeming, 
Blair, Melikian and O 'Gorman 1976, Danks, Bartholome, Clayton, 
Curtius, Grobe, Kaufman, Leeming , Pfleiderer, Rembold and Rey 1978, 
Kaufman 1978, Watson, Schlesinger and Cotton 977) to see If the 
observations made Ln vitro could be related to them with a vlew to 
explain lng the ln vi vo observations . 
The results of the study of t~e blosynthetlc pathway from GTP 
must be interpreted wlth caution, firstly because the whole pathway was 
studied as one process so Lt Ls dlfflcult to tell exactly which step a 
particular reagent Ls acting on. Secondly, the blosynthetlc pathway 
probably only provldes minor amounts of tetrahydroblopterin in the 
normally- active cell to replace any tetrahydroblopterln lost by conversion 
to 7, 8 dihydroblopterln. The blosynthetlc pathway wlll only play a 
major role in tetrahydroblopterln metabollsm when the normal metabolism 
Ls upset such as in the congenital deflclency of dihydropterldine 
reductase, (Kaufman, Holtzman, Milstlen, Butler and Krumholz 1975, 
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Rey ' Harpey ' Leeming, Blair , Ai card I and Rey 1977, Grobe, B rtholome, 
Mllstie n and Kaufman 1978, Koslow and Butler 1977, Mlls ten, 
Holtzman , O'Flynn, Thomas, Butler and Kaufman 1976, Bu ler, Koslow, 
Krumholtz , Holtzman and Kaufman 1978) or when dthydrop erldlne 
re ductase is inhi!:> ited . 
The results of the blosynthettc work show that the tetrahydrobtopterln 
biosynthetlc pathway is present ln rat brain ttssue and that guanoslne 
triphosphate (GTP) is the best precursor. (Chapter 2) Thls Is as other 
workers have s hown In dlfferent mammalian tissues: hamster llver; 
(Fukushima, Eto, Saliba and Shlota 1975) mouse lung and kidney, rat 
lung, hamste r lung , kidney, brain and llver; (Fukushima, Eto, Mayuml, 
Richter, Goodson and Shlota 1975) and rat braln. (Gal and Shennan 
1976, Lee, Fukush ima and N lxon 1978) The results also demonstrate 
that NADPH ls requ ired for the blosynthetlc pathway, also as other 
workers have shown. (C hapters Zand 3) (Lee, Fukushima and N lxon 1978, 
Fukushima, Eto , Mayuml, Richter , Goodson and Shlota 1975, Fukushima , 
Eto, Saliba and Shlota 1975 , Eto, Fukushima and Shlota 1976) The 
methods used to demonstrate that NADPH ls required are somewhat 
different t o those utllize d by other workers , although straightforward 
NADPH addltion wa s used. They conslsted of protectlon of NADPH by 
the NAD nucleosidase lnh lbltor , nlcotlnamlde, (Mann and Quastel 1941a, 
Mann and Quastel 1941b) and stlmulatlon of production of NADPH by 
glutamate dehydroge nase and the pentose phosphate pathway, elther 
directly or Indirectly by glycolytlc lnhlbitlon . The most llkely point 
ln the biosynthetlc pathway where NADPH wlll be required would seem 
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to be the conversion of sepiapterln to 7' 8 dlhydroblopterln. (figure 
6-2) This reaction has b h 
een s own to be catalysed by seplapterln 
reductase, (Nagai 1968, Matsubara, Katoh, Aklno and Kaufnan 1966) 
which does require NADPH . NADPH has been shown to be r qulred for 
this conversion in pterln blosynthesis in a variety of animal syst •ms. 
(Brown, Kri vi, ·ran and Unnasch 1978, Eto, Fukushima and Shlota 19 76, 
Tanaka, Ak ino, Hagi and Shlota 19 78) However, NADPH has also 
been shown to be required for the conversion of dlhydroneopterln 
triphosphate to seplapterln. (Brown, Krlvl, Fan and Unnasch 1978, 
Tanaka, Akino, Hagi and Shlota 1978) but there ls no evidence of NADPH 
being required for the conversion of guanoslne trlphosphate to dlhydroneo-
pterin triphosphate. (Fukushim a, Richter and Shlota 1977, Fan and 
Brown 1976, Gal, Nelson and Shennan 1978) Magnesium lons have 
also been shown to be stlmulatlng for the biosynthetlc pathway actlvlty . 
(Chapter 2) (Eto, Fukushima and Shlota 1976, Lee, Fukushima and 
Nixon 1978) It has been demonstrated that mageslum Lons are required 
for the conversion of dlhydroneopterln trlphosphate to seplapterln ln the 
presence of NADPH. (Tanaka, Aklno, Hagl and Shlota 1978) 
Magnesium Lons (Fukushima, Richter and Shlota 1977) and other 
divalent ions (Fan and Brown 1976) have been shown to lnhlblt the 
conversion of guanosine trlphosphate to dlhydroneopterln trlphosphate 
(Brown 1971) but the enzyme GTP-cyclohydrolase A-II isolated from rat 
brain which converts guanoslne trlphosphate to 2-amlno-6-(5-trlphosphor-
ibosyl)-amlno-5-formamldo- 6-hydroxypyrlmldlne was shown to have an 
absolute dependence on magnesium Lons. (Gal, Nelson and Shennan 
19 78) 
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The dihydrofolate reductase lnhlbitors exhibit he sam order of 
degree of inh ibition on both dlhydrofolate reductase and tctrahydroblopterln 
biosynthesls. (Chapter 3) {Burchall 1979) Dlhydrofolate r ductase 
is capable of reducing dlhydropterlns and Is postulated as the flnal step 
in tetrahydrobiopterin blosynthesls. {figure 6-4) (Kaufman 1967, 
Pollock and Kaufman 19 78 , Abelson, Spector, Gorka and Fosburg 1978, 
Spector, Fosburg, Levy and Abelson 1978) It appears that these drugs 
are acting on dihydrofolate reductase , thus causing a decrease ln the 
tetrahydrobiopterln produced and increasing dlhydroblopterln levels. 
As the Crithidia fasclculata assay measures both reduced fonns of 
biopterin and biopterln itse lf , this lnhlbltlon should not be detected 
using this method. The increases recorded must therefore be due to a 
stimulation of the biosynthetlc pathway due to dlhydrofolate reductase 
inhibition. The most likely explanation of thls ls Lf the blosynthetlc 
pathway is under the control of feedback lnhlbltlon by lts product. 
Then when the tetrahydrobiopterln levels fall due to dlhydrofolate 
reductase lnhibltlon, the feedback lnhlbltlon would be reduced and the 
activity of the biosynthetlc pathway would increase as seen . The 
obvious target for this feedback lnhlbltlon would be the flrst enzyme 
of the pathway, guanos lne trl phosphate cyclohydrolase or dlhydro-
neopterin triphosphate synthetase depending on the notation used . 
This ls because the first enzyme ln a pathway c ommits the precursor 
to that particular pathway rather than any other, for example, DNA 
synthesis in the case of GTP. It ls therefore the best place for feed-
back control. GTP cyclohydrolase from E . coll was shown not to be 
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subject to feedback inhibition by a range of folatc molecules but tr -
hydrobiopterin was not tested. (Burg and Brown .9 68) Dlhydron op rln 
tri phosphate, the product of thl s reaction, has been shown to be th k y 
intennediate in the biosynthesls of pterlns so the GTP cyclohydrolnsc 
step is an important reaction of this pathway. (Brown and ran 19 75) 
However, GTP cyclohydrolase is a common enzyme for both pterln and 
folate biosynthesis, (Figure 6-5) (Brown 1971) so the next enzyme ln 
the pathway which converts dlhydroneopterln trlphosphate to seplapterln 
may be a more suitable control point for tetrahydroblopterln feedback 
inhibition, so that folate blosynthesls ls not tnhlblted at the same time . 
The final product, tetrahydroblopterln ls slmllar ln structure to dlhydro-
neopterin and so could act by competlng for the pterln site on this 
enzyme. As stated previously, these results must be treated tentatively 
until further studies are done on the Individual enzymes of the blosynthet-
ic pathway. 
The purine antagonists, mercaptopurlne, thioguanlne and 
azathioprine all inhibited biopterln blosynthesl s probably by corn petlng 
with GTP for the GTP slte on GTP cyclohydrolase as they are of slmllar 
structure. (Chapter 3) The pyrlmldlne Lnhlbltors, cytosine arabinoslde 
and fluorourasil both Increased blopterln blosynthesls . (Chapter 3) 
This could be due to their inhibition of other pathways utlllzlng GTP 
such as DNA blosynthesis which would Increase the avallablllty of GTP 
for biopterin biosynthe s ls. 
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Other lnteresting res It f h 
u s o t e blosynthctlc wor · wer thos of 
the metal ion inhibitlo ti 1 n par cu arly the lead results . (Ch pt r ) All 
th
e metals te sted produced signlficant lnhlbltions of th pathw y but 
lead was most interesting because of its signlflcant 13% lnhlbltlo1 at a 
concentration a s low as 1 o-8M. (Chapter 3) 
A maximum 4 6% 
inhibition was obtained with 10-4M lead. 
[t has been suggested that 
lead does cause neurotoxic effects and behavioural changes at low 
concentrations. (Grandj ean, Arnvlg and Beckman 1978, Needleman, 
Gunnoe, Leviton, Reed, Pees le, Maher and Barrett 1979, Rutter 1980) 
although this idea is controversial. The inhibitions at low concentrat-
ions of lead demonstrated here (Chapter 3) could explain these 
observations. Lead is known to cause hyperactl vl ty, behavioural 
changes and neurotoxicity in man when blood levels are greater than 
80 pg/dl. (about 4. 10-
6
M) (David , Clark and Voeller 1972, Baloh, 
Sturm, Green and Gieser 1975, Beevers, Erskin I, Robertson, Beattle, 
Campbell, Goldberg, Moore and Hawthorne 1976, Chisolm 1971, 
Byers and Lord 1943) If tetrahydrobiopterin levels are depleted by 
chronic inhibition of the blosynthetlc pathway this would decrease 
catecholamine neurotransmitter biosynthesls due to the absolute 
dependence of the rate-llmltlng step, tyrosine hydroxylase, on tetra-
hydrobiopterln, (Levitt, Spector, SJoerdsma and Udenfrlend 1965, 
Nagatsu, Levitt and Udenfriend 1964) whlch ls rate-llmltlng for the 
activity of this enzyme. (Kettler, Barthollnl and Pletscher 1974) 
Mercury, cadm Lum, copper and alumlnlum have also been suggested 
as neurotoxic agents. Mercury is associated with loss of memory and 
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severe central nervous system t .. 
ox1c1ty wher s c dmlum poisoning 
produces headaches and neurological disturbanc s . 
(F lln · 1975) 
Copper toxicity causes 1 con vu slons (Schelnberg and S lnll b l 97 6) 
and aluminium has bee h 
n s own to be responsible for dialysis derne tta 
(Alfrey, LeGendre and Kachny 1976) and to be associated with 
Alzheimer's dementia. (Crapper, Krishman and Qulttkat 1976) The 
effect on tetrahydrobiopterln metabolism of these metals could be a 
contributing factor in the same way as lead. The effect on neuro-
transmitter production could only occur with chronic exposure to the 
metals because the dihydropterldlne reductase system should be abl to 
provide the majority of t he tetrahydroblopterln required by the hydroxylase 
enzymes. 
5 methyl tetrahydrofolate a lone Increased blopterln blosynthesls 
and with coenzyme B
12 
increased lt to 300% of nonnal . (Chapter 3) 
This suggested that the folate may be stlmulatlng the step Involving 
the loss of the one carbon fragment by removing the one carbon fragments 
as soon as they are ellmlnated from the molecule and so causing the 
equilibrium of the reaction to be ln favour of dlhydroneoptcrln trlphosphate 
formation. rt ls known that B
12 
deflclency ls associated wlth neuro-
logical defects such as occur ln pernlclous anaemia. (White, Handler 
and Smith 1973, Guyton 1971) 
The work on dlhydropterldlne reductase should be eas ler to Interpret 
and correlate with clinical studies because only one enzyme ls belng 
studied rather than a corn plete pathway. (Figure 6-3) Al so the 
'tsolated from rat liver ln a relatlvely pure fraction so the enzyme was 
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effects demonstrated are unlt'·el t be 
' Y o rtHact du to cont mln tlo 
by other enzymes . 
Such an Isolation do s r sult In s udytng th 
enzyme in an 'artiflclal' environment. Many st ps re t • n to 
provide the enzyme with all the conditions for optimal actlvl y bu he 
conditions used will probably not be exactly like those which occur ln 
the cell, in vivo . 
The affinity chromatography method using sodium 1, 2 naphtho-
Q.l.J.inone-4-sulphonate as a ligand to Isolate dlhydropterldlne r ductase 
from rat liver resulted in an enzyme fraction purlfled about 900 fold 
over the original supernatant wlth a specific activity of 55 unlts/mg 
protein and 25 % recovery of enzyme activity in the most active fractlon . 
(Chapter 4) These results compare favourably wlth those using other 
methods of isolation by afflnlty chromatography (Chauvin, Korrl, 
Tirpak, Simpson and Scrimge0trl979, Aksnes, Skotland, Flatmorck and 
Ljones 1979, Webber and Whiteley 1978, Webber, Delt s, Snyder and 
Whitel'ey 1978) and the same method. (Cotton and Jennings 1978) 
This affinity method gave purlflcation results near to tho e of the more 
traditional methods of enzyme isolation involving many fractlonation 
steps (Hasegawa 1977, Cheema, Soldin, Knapp, Hofmann and 
Scrlmgeour 1973, Korrl, Chlppel, Chauvin, Tirpak and Scrlmgeour 1977) 
but because the ligand was so specific for dihydropterldlne reductase, 
had the advantage of consisting of only two steps. The afflnity gel 
proved to be a useful tool for lsolatlon of this enzyme and could be 
regenerated and used repeatedly if stored correctly as Cotton and 
Jennings have shown (1978) . The sodium 1, 2 naphthoqulnone-4-
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sulphonate proved to be so efflclent a dlhydrop rldln r duct 
isolation be c au se it ls a corn petltive Inhibitor or h nzym ilth 
respect to the pterin substrate . (Chapter 5) [t h s a 'I v lu of 
-4 
3 · 7 · 1 O M and must re semble closely the qulnonold dlhydroblopt rln 
substrate in structure in order that the enzyme binds to h affinity 
a~sorbent. The enzyme will onl y blnd to the gel wh n ADH Is 
present (Chapter 4) which presumably causes a confonnatlon l change 
in the enzyme in order to allow the pterln to bind or In this case the 
sodium 1, 2 naphthoquinone-4-sulphonate Inhibitor . This also Indicates 
the ligand resembles the qulnonold substrate very much or ll would blnd 
to the enzyme in the absence of NADH . Th is observation also im plles 
that the enzyme follows a corn pulsory ordered mechanl sm which has 
been suggested in the literature . (Korrl, Chippel , Chauvin, Tirpak and 
Scrimgeour 1977, Aksnes and Ljone s 1980) 
The affinity chromatography me thod used here for the enzyme 
purlflcatlon also gave a similar pH optimum range (6 . 3 to 7 . 0) (Chapter 
4) as those quoted ln the literature. (We bber , Delts , Snyder and 
Whiteley 1978 , Cheema, Soldin, Knapp, Hofmann , and Scrimgeour 1973) 
This pH optimum ls near the pH value at wh ich the qulnonoid dlhydro-
pterin substrate is most stable which ls t he most efficient pH for thls 
enzyme. (Archer and Scrlmgeour 19 70) 
The molecular weight of dlhydropterldlne reductase was demon-
strated to be about Sl, 000 (Chapter 4) whlch ls ln good agreement wlth 
values obtained by other methods whlch were all shown to be dimers , 
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(Webber, Deits, Snyder and Whiteley 1978, Haseg 
1977, Ch m , 
Soldin, Knapp, Hofmann and Scrlmgeour 1973, }'orrl, Chlppel, Chauvin, 
Tirpak and Scrimgeour 1977' Aksnes, Skotland, FI mark nd Ljon s 
19 79 ) but is about half the value obtained by Cotton nd Jennings t y a 
similar method of 100 ,000 . (1978) They showed th nzyme molL•cul 
to consist of a tetramer where each mononier subunit was 25,000 
molecular weight. This was about the same monomer subunit molecul r 
weight as obtained for the dlmers. (Webber, Delts. Snyder and 
Whiteley 1978, Hasegawa 1977, Aksnes, Skotland, Flatmark and 
Ljones 1979, Cheema, Soldln, Knapp , Hofmann and Scrlmgeour 1973, 
Korri, Chippel, Chauvin , Tlrpak and Scrlmgeour 1977) Solt ls probable 
that the enzyme isolate d here ls a dlmer wi th a similar monomer subunit 
molecular weight. The differences ln value of enzyme molecular weight 
and number of subunlts per enzyme molecule between thls study and 
that of Cotton and Jennlngs who used a similar method cou ld be because 
these results are for rat liver dlhydropteridlne reductase and those of 
Cotton and Jennings were for monkey and human llver dihydropterldlne 
reductase that ls a species dlfference . Or Cotton and Jennings c la im 
that they obtained a tetramer structure, which they bclleve to be the 
native form of the enzyme due to the simple one-step method of lsolatlon 
used whereas ln the other methods the tetramer becomes broken down 
tnto dimers due to the lsolatlon procedures. If thls ls so, the dimer 
obtained here may have been obtained on the Sephadex G-150 fractlonat-
ion step which Cotton and Jennings did not perform . 
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The turnover number of 1 . 71. l 0-3 (molecul s of oduct 
syn thesized per mlnute by each molecule of enzym ) o t ln d nd h 
apparent Km values for qulnonoid dimethyl dihydropterln of 3. 2. l 0-S ~ 
and for NADH of 1 1 l 0-SM · · are again In good agr cm nt with lit I ture 
values . (Chapter4) (Webber, Deis, Snyd rand 'hit ley 1978, 
Cheema, Seldin, Knapp, Hofrrannand Scrlmgcour 1973, Wehbcr nd 
Whiteley 1978, Cralne, Hall and Kaufman 1972) NADH w s shown to 
be a better substrate than NADPH for the enzyme although bo h cou Id 
function as substrate, also as demonstrated by other workers. (Chapter 
4) (Webber, Deits, Snyder and Whiteley 1978, Chccma, Soldin, Knapp, 
Hofmann and Scrimgeour 1973, Craine, Hall and Kaufman 1972, Webber 
and Whiteley 19 78, Nielsen. Simonsen and Lind 1969) Qulnonoid 
dihydrobiopterin, the natural substrate, was the best ptcrln substrate 
studied but quinonoid dimethyl dihydropterin wa s nearly as active ond 
the enzyme did display some activity with quinonoid dlhydrofolate 
(Chapter 4) although this may have been due to an impurity present Ln 
the tetrahydrofolate such as 6 methyl tetrahydroptcrin, the qulnonoid 
form of which is active as a substrate for dihydropterldlne r ductase . 
(Kaufman and Levenberg 1959 , Kaufman 1975) However, Llnd has shown 
that quinonoid dihydrofolate can act as a substrate for dlhydropteridlne 
reductase. (19 72) 
All these general properties of the enzyme which are simllar to 
the characteristics of dihydropterldine reductase quoted ln the lltcrature 
show that this affinity chromatography method of lsolatlon ls a good 
- 2JO -
and reliable method for purlfyln th" 
g 1s enzym 
The inhibition studies on dihydropterldlne rcductas 
several interesting results . 
lso produced 
The end-products of neurotransmitter blosynthese which lnvolv 
tetrahydrobiopterin , noradrenaline, dopamine and serotonin all Inhibit d 
dihydropteridlne reductase activity. (Chapter 5) Noradrenallne and 
serotonin had Ki values of 4.9. l0-4M and 1.2. 10-JM respectively 
and a Ki value for dopam ine cannot be calculated due to the sigmoid 
curve obtained for the ve locity versus substrate concentration plots. 
The concentration of noradrenaline in the whole brain ls 2.1. l0- 6M. 
(Taylor 1979) ln the hypothalamus, 6.4 . 10-GM (Westerlnk 1979) and 
-6 in the nucleus accumbens , 4.1. 10 M (Westerlnk 1979) whereas the 
concentration of serotonin in the whole brain ls 1.83. l0- 6M, (Kamaka, 
Okada, Watanabe, Kawashima and Wada 1980) In the hypothalamus, 
7.5. 10-
6
M (Cummings .. James, Soeters, Keane, Foster and Fischer 
-6 
1976} and in the midbraln, 5.3. 10 (Cummings, James, Soeters , 
Keane , Foster and Fischer 19 76) These neurotransmitters could there-
fore, be involved in a feedback inhlbl tlon of tetrahydroblopterln 
production by dlhydropterldine reductase es peclally as the neurotrans-
mitters are probably concentrated In the terminal vesic les of the 
neurones . However, these feedback lnhlbltors probably work by 
different mechanisms as the serotonin ls a competltlve lnhlbltor and 
noradrenaline is a non-competltlve lnhlbltor of dlhydropterldlne 
reductase with respect to the pterln. Therefore, seroton In lnh lblts 
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by competing with the qulnonoid dlhydropt rln for he P rln sit on 
dihydropteridine reductase a d d 
n nor a rena Hne binds to some oth r It 
on the enzyme, most prob bl h 
a Y t e same site as dopamine due to Its 
structural similarity , that Is, to the allostcrlc site. Dopamine lls If, 
gave sigmoid velocity versus substrate concentra Ion curves for bo h 
the pterin and NADH. (Chapter 5) This led to the discovery that 
dihydropteridine reductase exhibited positive co-operatlvlty. Thls 
implies that binding of a substrate molecule to one subunit of the 
enzyme induces a conformational change ln the enzyme which makes 
the other subunit more readily bind substrate molecules. The results, 
that there are two binding sites per enzyme molecule (The scatchQ.rd 
plot, Chapter S) is expected from the molecular weight studies which 
indicate that the enzyme exists as a dimer but provides evidence that 
each subunit of the dimer possesses an active site . -4 1.1. 10 M 
dopam lne gave a 4 6% Inhibition at a pterln substrate concentration of 
10 pM and 5 7% at 2 0 pM which are concentrations of dlhydroblopterln 
which can occur In vivo. Inhibition studies with dopamine and 
saturating concentrations of the pterln-competltlve Inhibitor, methotexate 
indicated that these two inhibitors bind to different sites on the enzyme 
molecule as both together gave an additive Inhibition. (Chapter 5) 
Therefore, dopamine binds to an allos terlc s I te. Dopamine Inhibits 
dihydropterldine reductase at concentrations which occur ln vl vo as 
-6 
the concentration of dopamine ln whole brain ls 2.8. 10 M (Taylor 
-5 
1979), in the nucleus accumbera, 3.3. 10 Mand ln the strlatum, 
s.o. 1o-5M (Westerlnk 1979) Therefore Lt ls a good candidate for 
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feedback inhibition 
of the dthydropterldlne r "duct s o rcduc c 11-
ular tetrahydrobiopterin and he d 
nee ecrcase catccholamln synlhesls 
from tyrosine . 
These results suggest that dlhydropt rldlne r ductase 
may be a regulatory enz yme responslble for control of dopamln 
biosynthes is. This has already been suggested, (Musacchio, D'Angclo 
and McQueen 1971) but only lndlrect evidence was presented wher an 
assay system for the hydroxylatlon of tyrosine hydroxylase was utlllzed, 
which contained dihydropteridine reductase as well as the tyrosine 
hydroxylase. It was shown that DOPA formation could be controlled by 
the concentration of dlhydropterldlne reductase present and that the 
feedback i nhlbi ti on of tyrosine hydroxy lase can be an tag on I sed by 
increasing the concentration of dlhydropterld lne reductasc. (Musacchio, 
D'Angelo and McQueen 1971) However, no dlrect effect of catechol-
amines on dihydropterldine reductase has been demonstrated before . 
Dopamine biosynthesls ls known to be controlled by feedback lnhlbltlon 
of catecholamines on tyrosine hydroxylase (Nagatsu, Mlzatanl, Nagatsu, 
Matsura and Sugimoto 1972, Nagatsu, Levltt and Udenfrlend 1964, 
Kuczenzkl and Mandell 1972) where the catecholamines compete for the 
pterin site on tyrosine hydroxyla se. As this feedback lnhlbltlon can 
be opposed by increaslng the concentratlon of letrahydroblopterln as a 
result of increased dlhydropteridine reductase actlvlty (Musacchlo, 
D 'Angelo and McQueen 1971) Lt seems likely that ln order to control 
dopamine biosynthesls more efficiently, the dopamine levels should 
control the amount of tetrahydroblopterin available to tyrosine hydroxy-
lase as well as tyroslne hydroxylase actlvlty. Recently Lt has been 
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shown that the lnh'b't 
L L ion of tyrosine hydroxyl se by do mln l 
greater in synaptosome preparations than In soluble • 
(Waggoner, McDermed and Leighton 1980) Thcs wor · rs •1 r unable 
to explain these result b t s u suggested that this pheno11enon could 14? 
explained if d opam ine were capable of lowering the r due d cof ctor 
(tetrahydrobiopterin) levels in some way as well as dlrectly inhibltlng 
tyrosine hydroxylase as tnls would Increase tne competitive lnhlbltlon 
by dopamine. The results presenled here explain t. ese observ lions 
by showing that dopamine does indeed Inhibit tetrahydrobloptcrln form-
ation. Dihydropteridine reductase therefore has a possible role In 
dopamine biosynthe sis regulation. 
Dihydropterldine reductase ls lnhlblted by phenylalanine and 
metabolites of phenylalanine. (Chapter 5) The Kl values for these 
-5 -5 
corn pounds range from 1 . 8. 10 M for tyrem lne and 5 . 0 . 10 M for 
-3 
phenylpyruvate to 1. O. 10 M for phenylalanine and phen}ilactate . The 
concentrations of these compounds are also very variable ln health ancl 
disease with normal human brain levels of phenylalanine belng about 
1.0. l0-4M, (Letendre, Nagalah and Guroff 1980) normal human serum 
-6 
levels of phenylpyruvate belng about 5. 0. \ 0 M (Langen beck, Behbehanl 
and Luthe 1980a, Langenbeck, Behbehanl and Luthe 1980b) the nonnal 
rat brain levels of phenylethylamlne belng about SnM (Fischer, Spatz 
and Heller 1972) and the normal rat brain levels of tyramlne being about 
1. 3. 1 o-8M. However ln phenylketonurla and its varlants the levels 
of phenylalanine and its metabolites are much higher. (Jervis and 
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Drejza 1966, Blckel, Gerrard and Hid· ,1 ns 1953, Ud nfrl nd 1961) 
V 1 f - 5 -4 aueso 10 Mtol.6 . 10 Mforhum n scrum ph nylpyruv l 
(Langenbeck, Behbehanl and Luthe 1980b) and 7.9. 10-G 1 to 4.0. 10 
for human serum o-hydroxyphenylacetlc acid (Jervis nd DreJ?.a 191,6) 
have been measured. This Ls due to reduced phenylalanln hydroxy-
lase activlty due to the deficiency of the enzyme Itself In norm I ph nyl-
ketonurla and due to a deflclency of tetrahydroblopterln In mallgn nt 
hyperphenylalanlnaem las . Therefore, Instead of being converted to 
tyrosine by phenylalanine hydroxylase, the phenylalanine accumulates 
and more of its metabolltes such as phenylpyruvate and o-hydroxy-
phenylacetic acid are produced. (Part lngton 19 78) 
It was suggested that the mental defects which occur In phenyl-
ketonuria were due to the increased levels of phenylalanine or Its 
metabolites. (Blckel, Gerrard and Hlckmans 1953, Udenfrlend 1961) 
This ls supported by the fact that a low-phenylalanine diet appears to 
reduce the neurologlcal damage of phenylketonurla. (Bickel , Gerrard 
and Hickman 1953) It ls usual for phenylketonurlc chlldren to be put 
on the low-phenylalanlne diet as soon as possible so that the posslbll-
ltle s of mental defects are kept to a m lnlmum. The chlldren are then 
kept on this reglme untll the age of about five or slx when the dlet ls 
relaxed because the phase of ra pld braln development ls flnlshed at the 
age of about two years. (Dobblng and Sands 1973, Smlth, Lobascher, 
Stevenson, Wolff, Schmldt, Grubel-Kaiser and Blckel 1978) However, 
there is evldence now that children ln whom the diet Is relaxed or whom 
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are given complete freedom of diet h v r I.Q. m u m n th n 
eh i ldren who are kept on the diet I h od 1 w go con ro • (B rry, O'Gr dy 
Perlmutter and Boflnger 1979, Brown and W rner 1976, Smith, Lob sch r, 
Stevenson, Wolff, Schmldt , Grubel-Kalser nd Blc ·el 1978, C b ls· , 
Duezynska, Borzymowska, Korska, Koslocz-rolg and Bozkow , }l177, 
Dobson, Willlamson, Azen and Koch 1977, Partington and Lcverty 1978, 
Williamson , Koch and Berlow 1977). Nowadays phcnylketonurlc women 
who wish to have chlldren are recommended to return to the phenylal nlne-
restricted diet before conceptlon In order to avold neurologlcal dam ge 
to the fetus which might be normal as such defects have been reported 
to occur. (Smith , Erdohgl, Macartney, Dlncott, Wolff, Brenton, Biddle, 
Fairweather and Dobblng 1979, rarquhar 1979, Smith and Wolff 1979, 
Buist, Lls, Tuerck and Murphey 1979) This ls evidence that, not only 
does the phenylalanine or lts metabolltes cause damage to the 
developing brain, but probably causes some damage after brain maturallon 
is complete. Many suggestion s have been made as to why phenylalanine 
and/or lts metabolites cause neurologlcal damage. One theory ls that 
phenylpyruvate ls responsible because lt Inhibits the transport of 
pyruvate lnto mitochondria ln the brain and hence lnhlblts pyruvatc 
oxidation and upsets braln functlon. The concentratlons of phenyl-
pyruvate used to produce this lnhlbltlon were 2. 5 to SmM . (Halestrap, 
Brand and Denton 1974) Phenylpyruvate ls formed In the brain by 
transarhlnation of phenylalanine and It has been suggested that this 
causes a depletion of<::.< ketoglut1Arate In the brain which then has 
consequences on the Krebs cycle leadlng to defectlve braln metabollsm 
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(Korey 1957) Alternatively he depletion of to IUl\AC- t m • s I 
unavailable for essential transamlnatton of oth r mlno cld g ln 
leading to braln dysfunctlon . (Jervis and Dr J 1966) Th s hypo-
theses are supported by the decreased urln ry output of • glu 1oL ate 
in phenylketonurics . (Jervl s and Drej ?.a 19 66) It has also en 
suggested that the neurologlcal defects ln phenylk tonurl re due to 
phenylpyruvate lnhibltlon of aromatic amino acld decarboxyl tton 
which leads to depletion of catecholamlnes Ln the braln whlch has also 
been reported in phenylketonurlc patients (Davidson and Sandler 1958, 
Boylen and Quastel 19 61, Wolley and Van der Hoeven 1964) One of 
the most popular theories ls that the Increased phenylalanine levels 
inhibit the entry of other amlno aclds Into the braln as they all have 
to compete for common membrane carrlers for transport. (Pratt 1980, 
Banos, Dan le i Moorhouse, Pratt and Wllson 19 74) 
The lnhlbltlon of dlhydropterldlne reductase by phenylalanlne nd 
Its metabolltes could also be responslble for the neurological defects 
which occur In phenylketonurla. Much evidence supports thls theory. 
Inhlbltlon of dihydropterld lne reductase would lead to reduced cellular 
tetrahydrobiopterln levels and thls would then result In less dopamine 
and noradrenallne belng synthesized from tyroslne and perhaps less 
serotonin being produced from tryptophan. This theory explains the 
reduced brain catecholamlnes and serotonln reported In phenylketonurlcs . 
(Butler, Koslow, Krumholz, Holtzman and Kaufman 19 78) Therefore 
the mental defects are due to a lack of tetrahydroblopterln . Treatment 
- 2J7 - I 
of malignant hyperphenylala 1 n na mlcs us lly lnvolv ., glvlng L-D A 
and serotonin which bypass the 1 slon. (Curtlu • d rwl r, 
Viscontlni, Otten, Schaub, Schelb nrelter and Schmidt 1979, Sch ub, 
Daum ling, Curtlus, N lederwleser, B rtholomc, Vlscontlnl, Schlrcl 
and Bierl 1978, Danks, Bartholome, Cl yton, Curtlus, Gro • •· ufm n, 
Leeming, Pfleiderer, Rembold and Rey 1978) Chlldr n wlth ph nyl-
ketonuria have higher than nonnal scrum dlhydroblopt rln l v ls which 
in fact parallel the serum levels of phenylalanine. (L mln , BI lr. 
Green and Raine 1976) Serum phenylpyruvate levels can be corr l tcd 
with serum phenylalanine levels. (Langcnbeck, Bchbehanl nd Luthe 
1980b) Inhibition of dlhydropterldlne reductase by phenyl pyruv te and/ 
or phenylalanine would explaln these observatlons because there would 
be an accumulation of qulnonold dlhydroblopterln In the c 11 whlch would 
rearrange to give the increased levels of scrum dlhydroblopterln r cord d. 
It has been reported that there Ls a slgnlflcant Inverse corrcl tlon between 
I . Q. measurements and serum phenylalanine levels. (Berry, O'Gr dy, . 
Perlmutter and Boflnger 1979) It has also been shown that taking 
phenylketonurics off the low phenylalanine diet causes I. Q . to decrease 
(Smith, Lobascher, Stevenson, Wolff, Schmidt , Grubcl-K Lscr and 
Bickel 19 78) and that phenylketonurlc children on phenylalanlnc-
restricted diets had I. Q. measurements more than one standard deviation 
below those of famlly members. (Berry, O'Grady , Perlmutter and 
Bofinger 1979) Phenylketonurla heterozygotes are alsomlldlyhyper-
phenylalaninaemic and have lowered I.Q. measurements compared to 
normal children. (Bessman, Williamson and Koch, 1978) Not only 
- 2J8 - ' 
have lowe r I. Q. measurements In mild hy perph nyl 1 nln mlc child n 
been correlated with higher serum phenyl 1 n n l v Is but lso with 
higher serum dihydrobiopterin levels too. (Rey 1980) A, rum 
dihydrobiopterln and serum phenylalanine levels correlat Inv rs 1 with 
_r · Q • measurements and serum phenylalanine and phenylpyruv t l v l 
also correlate with each other, plus th t Inhibition of dlhydropt rldln 
reductase by phenylalanine ~nq/or phenylpyruvate caus s lncre s d 
serum dihydrobiopterin levels, then it could be said th t Inhibition of 
dihydropteridine reductase correlated Inversely wl th r. Q . measurements. 
So that inhibition of dihydro pteridine reductase causes deer ascd I. Q. 
measurements in young chi ldren . All the phenylalanine metabolites 
tested were shown to lnhiblt dihydropterldine rcductase but at dlff rent 
concentrations. (Chapter S) Obviously the most potent Inhibitors, 
tyramine, (Kl value= 1.8. 10 -5M) phenylpyruvate (Kl value= 5 . 0. 10-SM) 
-4 and phenylethylam lne (Kl value = 8 . 5 . l O M) are the most likely causes 
of the ,neurological defects ln phenylketonurla and concentrations of 
-4 
phenylpyruvate in phenylketonurlcs of 1. 6. 10 Mare known. 
(Langenbeck, Behbehanl and Luthe 1980b) Phenylalanine (Kl value = 
1. o. 1 o-3M) could also contribute as high phenylalanlne concentrations 
do occur in untreated phenylketonuria . (Jervis and Drejza 19 66) 
Lowering phenylalanine levels by the recommended diet lowers the 
phenylalanine metabolite levels as well and so will reduce the neuro-
logical damage. Thls theory ls supported by the fact that ln malignant 
hyperphenylalanlnaemla the mental defects are not relieved by a phenyl-
alanine-restricted diet. In these chtldren the phenylalanine hydroxylase 
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enzym · 
e ts normal but cellular t tr hydroblopt 
The leslon here ls in tetrahydroblopterln m t bollsm I 
alanine restriction wlll not elevlate the symptom 
phenylketonurla . The fact that the neurologtc J d m 




treated wlth tetrahydroblopterln also adds to the vld nc th t th braln 
damage is due to lack of tetrahydroblopterln . (Curtius, d rwl s r, 
Viscontinl, Otten, Sc haub, Schelberecter and Schmidt l 979, Sch ub, 
Daumllng, Curtlus, N Lederwleser, Bartholome, VI scontlnl, Schtrcks and 
Bieri 1978) It is of course, possible that the neurological defects 
occurring in phenylketonurla are a result of all these postul ted theories 
of the effects of phenylalanlne and lts metabolites actlng together rather 
than one theory alone. 
This proposed model for the cause of mental retardation in phenyl-
ketonuria has other wide-reachlng consequences . [t could be xt nded 
to suggest that any agent that Lnhlbl ts dlhydropterldlne rcductas could 
cause neurological damage due to reduced tetrahydroblopterln levels In 
young chlldren. 
Thls theory may also explaln why the levels of serum dlhydrobiopterln 
parallel so closely the serum levels of phenylalanine In phenylalanine 
load ing tests. (Leemlng, Blalr, Green and Ralne 1976) As the levels 
of serum phenylalanine rise, the lnhlbltlon of dlhydropterldlne reductase 
lncreases and so the levels of serum dlhydroblopterln wlll Increase as 
the quinonoid dihydrobiopterln is converted to the tetra-hydro form . 
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Dihydropteridine reductase lnhlbl Ion by nyl 
phenylethylamlne has been shown to occur by th s r 
t he same site on the enzyme as dopamtn th t Is, th 
nd 
g nr binding to 
llo t rlc It • 
(Chapter S) It is assumed that phenylalanln nd I oth r m t bollt 
t yram ine and noradrenaline for example, also bind to th allost rte stt 
b ecause of s imilari ties of structure. A comparison of eh dcgr c of 
inhib ition by t hese reagents wlth consideration or th lr structur s chould 
giv e an indication of the kind of structure required to produc lnhlbltlon 
at the allosteric site . Dopamine (flgure 6-6) Is likely to be the 
natural inhibi t or w ith noradrenallne (Figure 6-6) being another posslblllty. 
A Ki va l ue for dopam ine could not be derived due to the sigmoid curves 
it produce d. -4 N oradrenaline had a Kl value of 4 .9. 10 M (Chapter 5) 
and has a very similar structure to dopamine having only an additional 
hydroxyl group on t he side-chain . This group must prevent noradrenaline 
being as potent an inh ibitor as dopamine . Adrenaline {Figure 6-6) has 
an additional methyl grou p at the end of the slde-chaln to noradrenaline 
but had no effect on dihydropteri dlne reductase. Llkewlse L-DOPA 
(Figure 6-6) which has an addltlonal carboxyl group on the slde-chaln 
also had no effect on the enzyme . tt can be concluded from this that 
the addition of a large group such as a methyl or a carboxyl to the side-
chain prevents the se compounds binding to the allosterlc site. or the 
phenylalanine metabolites, ty ramlne (Figure 6-6) and phenylpyruvate 
(Figure 6-6) were the most potent lnhlbltors of dlhydropterldlne 
reductase followed by pheny l ethylam lne (Flgure 6-6). Ty ram lne ls 
like dopamine except f or the absence of one hydroxyl group from the 
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benzene ring system and so Is quit 
po nt lnhlbl or of dlh}• ro rldln 
reductase . PhenylethYlam1ne Is structur lly II· do mln xc t for 
having no hydroxy l groups on the benzene ring Y 
like phenylethylamlne has no hydroxyl gro 
also has an entirely different side chain which, fr 
Ph nylpyruv t 
nz n rtn t J 
th r ults wl h 
adrenaline and L-DOPA mlght be expected not to flt at II In th 
allosteric slte . However, If the structure Is written as ln f'lgur 6-7, 
it begins to resemble the dopamine structure mor closely and h nc Its 
potent inhibition effect might be explained. Phenylacellc acid, o-hydroxy-
phenylacetlc acld and phen;llactate (Figure 6-6} ar even less potent 
inhibitors of dlhydropterldlne reductase and their structures re even 
less like that of dopamine . If the structure of phenyllactate Is written 
as in Figure 6-7, lts structure ls more llkc that of dopamine and phonyl-
pyruvate but unlike them, phenyllactate does not possess the double 
bonds to keep the dlhydroxyl group conflguratlon In a planar arrangement 
and so still would not flt the a llosterlc slte as well as dopamine nd 
phenylpyruvate. Sodium pyruvate and dlacetyl were tested to sec lf 
they would lnhlblt because their structures were llkc part of the 
dopamine structure and they were found to lnhlbll only at extremely high 
concentrations. It is concluded that the structural properties Important 
for binding to the allosterlc site are the benzene ring structure, a planar 
dicarbonyl group and an amine group . DI carbonyl corn pounds such as 
1, 2 cyclohexanedlone are known to attach to the amlne groups at the 
end of the side-chains of arglnyl residues on protelns. (Ferdlnand 



























of dihydropteridine reductase. Th mtno c-ld, r inln w roun 
when the amino acid corn position of dlhydrop rid In r duct .,,.. 
determined. (Cheema, Soldln, l'napp Hofm nn and Sering our 197, 
Craine, Hall and Kaufman 1972, Has g wa 1977, Ak n , S.ol ncl, 
Flatmark and Ljones 1979, Korri, Chlppel. Ch uvln, Tlr k nd 
Scrimgeour 19 77) 
Inhibition of dlhydropterldlne reductase by l d and oth r m t ls 
was probably by irreversible lnhlbi tlon .(Chapter S) The time d pendent 
inhibition by lead and gallium suggested irreversible tnhiblllon but the 
inhibition levelled off as lf an equi llbrlum were being set up. How-
ever dialysis studies with the leaded enzyme produced no recovery 
of activity and so confirmed that the Inhibition was irreversible. Such 
irreversible inhibition s of enzymes by metals are common and usually 
the heavy metal attaches to a thiol group on the enzyme. (F rdlnard 
1976) The amlno acid composltlon of dihydropterldlne reduct se has 
been determined by several groups from different sources . (Korrl, 
Chippel, Chauvin, Tirpak and Scrimgeour 1977, Cheem , Soldln, Knapp, 
HofmannandScrimgeour 1973, Craine, Hall and Kaufman 1972) Of 
these only two groups measured cystelne residues which ls the amlno 
acid residue with a thlol group on Its slde-chatn. Craine et al. 
showed the sheep liver enzyme to contain one cystelne per subunit and 
Aksnes et al., showed that the bovine llver enzyme had three cysteines 
per subunit. (Craine, Hall and Kaufman 1972, Aksnes, Skotland, 
Flatmarck and Ljones 19 79) So assuming the rat liver enzyme also 
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has at least one f 
ree cystelne r slduc, th n th lnhlbl Ion by h vy 
metals · l'k 1 b 
ts L e Y Y attachment to the hlol group If th cy t In occurs 
in an accesslble posltlon on the enzyme mol cule nd h r suits 
obtained suggest this Is so. They also suggest th lh thlol gro p 
is not in or near the pterln active site or the llost ric sit to which 
dopamine binds as, when methotrexate, phenylpyruv te nd do mln 
were used with the fully-leaded enzyme further lnhlbltlon occurred . 
(Chapter 5) However, the tlme dependence of the le d and g Ilium 
inhibitions suggest that one of the substrates Is c using partial or whole 
protection of the enzyme from lead inhlbl lion. The pterln ~1.1bstrate 
does not appear to be fulfllllng this prq:>erty or further Inhibition on top 
of the maximum lead lnhlbltlon would not be expected to occur with 
methotrexate whlch obvlously blnds to the pterln active site bccausP. It 
is a competltlve Inhibitor. So It ls probably the NADH which Is protcctlng 
the enzyme from lead lnhlbltlon suggestlng the cystelne residue to which 
lead attaches is ln or near the NADH site . Alternatively there ls a 
possibility that the thlol group ls not near the NADH active slte but that 
the attachment of lead to the thlol group causes a conformational change 
in the enzyme molecule which prevents the NADH from binding so 
readily. Other workers have looked for the presence of thlol groups on 
dihydropteridlne reductase to see lf they are required for enzyme actlvl ty. 
Aksnes et al., could not detect any free thl ol groups using S '5' dlthlobls-
(2-nitro-benzolc acld) In the absence of denaturing agents but upon 
denaturatlon of the bovine liver enzyme wlth sodium dodecyl sulphate, 
they found three free th lol groups and concluded a free thlol group was 
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not part of the active site. (A· n s,S o 1 nd, rl trn rck and Ljon 1979) 
However, Webber and Whiteley found r ltv r dlhydropt ridln r due 
to be strongly Inhibited by both mercuric chlorld and p chlorom rcurl-
benzoate and that the loss of activity could b h d ho gh not 
restored by addltlon of NAOH. (1978) Cheem o ho ,ed 
that sheep liver dlhydropterld lne rcduct se was also Inhibit d by the 
two reagents , but that lodoacetlc acid g v no Inhibition . Th y too 
discovered the partlal protection from Inhibition f!orded by NADH. 
(Cheema, Soldln , Knapp, Hofmann and Scrlmgeour 973) It Is concluded 
that a thlol group ls Involved In the malntenanc of dlhydropt rldlnc 
reductase actlvlty. tnhlbltlon of dlhydroptcrldlnc r ductase by 1 ad Is 
significant at concentrations of 10-GM or greater. (Chapter 5) This 
inhibition could lead to the same mental defects as phenyloyruvatc Is 
thought to cause by decreasing the tetrahydroblopterln levels In the 
cells . Similarly, Inhibition of thls enzyme system by any of thes 
metals could cause neurologi ca l damage. The dlhydropterldlnc 
- 4 
reductase Inhibition by aluminium Is slgnlflcant at 2. 10 M (Chapter 
S) and the brain levels of aluminium quoted for patl nts with dialysis 
dementia were 1.18. l0-
4
M (McDermott, Smith Ward, Parkinson and 
Kerr 1978) and for patients wi th Alzhelmcr's dementla were 2.8-4.3 fg/g. 
-4 4 
(Approximately 1 O -1. 6 . 10 M) tnhlbltlon of dlhydropterldlne 
reductase has already been suggested as a cause of dialysis dem ntla . 
(Leem Ing and Blair 19 79) 
The effects of agents on tetrahydroblopterln metabollsm can be 
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examine d us ing the cllnical da a av ll bi from h 
indica te wha t mi ght be the ln vlvo ff et of ihos 
In vlvo 
g n s . 
udt s o 
If Figure 6-8 is used for rcfercnc nd eff c s of alt rln th rat 
of the various metabolic pathways of tetrahydroblopt rln r co I< r d, 
a model for te trahydroblopterln metabolism c n b built up. fnhlbltlon 
or decreasing the rate of the dlhydropterldlne r ductase alv g th-
way would result ln increased qulnonold dlhydroblopt rln lev ls, which 
would lead to lncre ased le ve ls of 7, 8 dlhydroblopterln which could b 
measured ln the se rum and urine and decreased tetrahydroblopterln 
levels which would lead to decreased tyrosine hydroxylese acllvlty and 
hence, decreased productlon of the catechol neurotransmitters. The 
biosynthetic pathway for tetra hydroblopterln wou Id probably not manage 
to provide enough tetrahydroblopterln to keep the tyrosine hydroxylas 
activity at the normal rate eve n though the blosynthetlc pathway would , 
be stimulated by reduced feedback lnhlbl tlon by tetrahydrobloptorln. 
Inhibition or decreased actlvlty of any step Including dlhydrofolate 
reductase on the blosynthetlc pathway for tetrahydroblo pt rln would 
reduce the tetrahydroblopte rln gradua lly b cause the cellul r levels 
would no longer be belng topped up. The 7, 8 dlhydroblopterln l vels 
would fall because the dlhydro pterldlne reductase would convert most 
of the qulnonold dlhydroblopterln to the tetrahydro-{orm leaving less to 
rearrange to 7, 8 dlhydroblo pte rln . Inhlbltlon or decreased actlvlty of 
tyrosine hydroxylase would resu lt ln lowered qulnonold dlhydroblopterln 
levels and hence, lowered 7, 8 - dlhydroblopterln levels In the cell, serum 
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The levels of tetr hydroblopL rln o Id 
would probably feedbac: to lnhl It th 
biopterln . 
lo }'n h tic ro 
Inhibitlon of dlhydropterldlnc rcduct s C n re 
d n 
for r h • ro-
In 
Similar to that form of malignant hyper nyl J n mla wh th r 
deficlency of dihydropteridlne reductas Th sc wo ff et should 
therefore, give slmllar clinlcal symptoms. In his fonn of m llgn nt 
hyperphenylalanlnaemla there are the predicted high r then nonnal 1 v ls 
of serum and urlne dlhydroblopterln (Danks Bartholomc, Clayton, 
Curtlus, Grobe, Kaufman, Leeming, Pfleiderer, R mbold nd R y 1978, 
Leemlng and Blair 1980b , Kaufman 1978) The hy rphenylalanlna ml 
results from lack of tetrahydroblopterln whlch results In decre sed 
phenylalanine hydroxylase actlvlty because the re ctton Is absolut ly 
ceperdmt on tetrahydroblopterln (Curtlus, Zag lak, Baerlocher, Sch ub, 
Leimbacker and Redweik 1977, Kaufman 1978) These chlld n lso 
have increased levels of urlne 7, Bdl)vdroxanthoptcrln which ls thought 
to be derlved from reduced blopterln derivatives, (Watson, Schlesinger 
and Cotton 19 77) and reduced amounts of do pain lne and serotonin. 
(Brewster, Moskowltz, Kaufman, Berlow, Mllstlen and Abroms 1979, 
Butler, Koslow, Krumholz, Holtzman and Kaufman 1978, Danks, 
Bartholome, Clayton, Curtlus, Grobe, Kaufman, Leeming, Pfleiderer, 
Rembold and Rey 1978) They also suffer from neurological damage. 
Their response to a phenylalanine loading test varies from the nonnal 
response and that of typical phenylketonurlcs In that the serum dlhydro-
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bi opterln concentrations rise high r. 
Aicardi and Rey 1977) 
(Ry Hr y In , I l r, 
Inhibition of the tetrahydrobtopt rln blo yn h le th ~ y c n 
regarded as being slmllar to that Conn o! m llgn n rph nyl 1 , In-
aemia where there ls a deficiency of the blo ynth oft tr hydroblop1 rln. 
Again these two effects should produce slmll r clinic I syrn pto 
There ls hyperphenylalanlnaemla , agaln du to th lac•: of t r hydro-
b iopterln as ln the other form of malignant hyperph nylal nln ml 
(Kaufman, Berlow, Summer, Mllstlen, Schulman, nd 
Pueschel 1978) The response to a phenyl lanln loading t st Is dlff r nt 
to that of normal patients and typical phenylketonurlcs b cau th 
serum dihydroblopterln levels do not Increase. (K ufm n, 8 rlow, 
Summer, Mllstlen, Schulman, Orloff, Splclb rg and Puesch 11978, R y, 
Harpey, Leemlng, Blalr, Alcardl and Rey 1977) The catechol mine 
concentratlons ln these chlldren have also been found to b low , nd 
they suffer neurologlcal defects (Danks, Bartholome, Cl yton, Curllus, 
Grobe, Kaufman, Leemlng, Pflelderer, Rembold and Rey 1978) nd It has 
been determlned that they excrete large amounts of n opt rln nd small 
amounts of dlhydroneopterln and dlhydroxanthopterln but no traces of 
biopterlns ln their urine. (Curtlus, Nlederwclser, Vlscontlnl, Ott n, 
Schaub, Schelbereicter and Schmldt 1979) These children also hav 
the predlcted lowered serum dlhydroblopterln levels. (Danks, 
Bartholome, Clayton, Grobe, Kaufman Leeming, Pfleiderer, Rembold 
and Rey 1978, Leemlng and Blair 1980b, Kaufman 978) 
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Therefore these two types of m llgn nl hy 
can be distlnguished by their different s rum nd ur n 7 8 dlhy ro 
concentrations, different urine dih d h y rox nt opt rln I 
responses when presented with an or I ph nylalanln lo d. 
d dlH r, n 
I l h f 
recently been sugges ted that ratios of neopterln to blopt rln XCfi d In 
the urine can also be used to distinguish between th s two yndrom s . 
(Nixon, Lee, Milste in, Kaufman , Bartholomc 1980) (l should 1 o 
possible to distinguish between inhibitions of the v rlous , et bollc 
pathways of tetrahydrobiopterln by looking for these symptom . 
For example, in typical phenylketonurla, there Is ad flciency of 
phenylalan i ne hydroxylase w hlch leads lo increased lev ls of phenyl-
pyruvate which inhibits dihydropterldine reductase ctlvlty . (Ch pt r S) 
This gives rlse to lncreased qulnonoid dlhydrobioptertn which r rr ng s 
to give the increased levels of 7, 8 dlhydrobiopterln, soon in typlc 
phenylketonurla . (Leeming, Blalr, M elikian and O'Gonnan 1976) 
· 7, 8 dihydroxanthopterln has also been found In the urine of untreated 
phenylketonurics but not ln those under good di t ry control (W tson, 
Schlesinger and Cotton 19 77) A phenylalanine loading test In phenyl-
ketonurlc patients also produ ces ri ses in serum dlhydroblopt rln 
concentrations greater than in normal patients. (Leeming, Blair, Green 
and Raine 19 76) If untreated, phenylketonurics are severely mentally 
retarded . (Bickel, Gerrard and Hlckmans 1953) The symptoms pr dieted 
from the model of tetrahydroblopterln metabollsm for inhibition of 
dihydro'p~eridine reductase are in fact found In this case . 
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The results presented in thls th sis lndlc t th m tho fi X l 
should also cause lncreased serum 7, 8 dlhydroblopt rln 1 
it too inhibits dlhydropterldlne reduct se nd such high rum 1 v 1 
have been recorded ln patients on methotr xate . (Leeming, Blair, 
Melikian and O'Gonnan 1976} Methotrexate h also b n shov:n to 
increase the time taken to clear a phenylalanln lo d (Goodfrl nd nd 
Kaufman 1961) and chlldren with acute lymphoblastlc I uk cmla tr t d 
with methotrexate have been reported as suffering from neurological 
damage . (Eiser 1978 , Meadows and Evans 1976) This might also b 
predicted from the model set up and t t has been suggested that these 
children might benefit from neurotransmitter replacement therapy 
(Leeming, Blair 1978, Cotton 1978) shown to help the malignant hyper-
phenylalaninaem ics. (Curtius Nlederwlcser, Vlscontlnl, Ott n, Schaub, 
Scheibere iter and Schm ldt 19 79, Schaub, Daum llng, Curtlus, 
Niederwieser, Bartholome , Vlscontlnl, Schrlrks and Bierl 1978) lf th y 
are to escape severe neurologlcal defects. 
Folic acid and 5 formyltetrahydrofollc acld following doses of 
methotrexate also raised serum 7, 8 dlhydroblopterln levels whereas 
s methyltetrahydrofollc acld dld not. (Leeming, Blalr , Melikian nd 
O 'Gorman 1976) Thls also agrees wlth the predlctlon that can be made 
from the model and the results presented ln thls thesls as follc acld and 
1 o formyl follc acld lnhlblted dlhydropterldlne reductase (Chapter S) and 
5 methyltetrahydrofollc acld dld not. These corn pounds shou Id there-
fore lncrease the serum concentrations of dlhydroblopterln when glven 
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alone but they do not. (Leeming B1 lr, 
l i I n nd O Gonn n 19 7 ) 
It is possible that alone these compound r rapldly r boll d nd 
hence, ln vl vo have no effect on di hydro pt rldln r duct 
Trimethoprlm and sulphamethox zol tnhtblt d dlhydropt rldln • 
reductase both alone and together, wh n th y g v yn rgl tie ff et. 
(Chapter 5) These drugs would be expect d to Iner a rum dlhydro-
biopterin levels and phannaceutlcal preparations cont lnlng both of th m 
such as co-trimoxazole, septrln and bactrln would b ex et d to glv 
more than additive increase of scrum dlhydrobloptcrln cone ntr tlons . 
Co-trlmoxazole has indeed been shown to cause abnonn l phenyl l nine-
tolerance tests ln patients and slight phenylalanine lntol I nc occurr d 
when the drugs were glven lndlvldually which suggested that the drugs 
in combination had a synergistic effect on phenyl Janine tol r nc . 
Patients on co-trlmoxazole also had raised fasting scrum ph nylalanln 
levels. (England and Coles 1972) Recently s rum 7,8 dlhydroblopt rln 
concentrations ln volunteers who took trlmethoprlm or/and sulph methoxazol 
have been measured and wlth trlmethoprlrn alone ther was a significant 
rise of about l. 88 )-19/ml, sul phamethoxazole alon there was a small 
insignificant rlse of about 0. 06 ]19/m 1 whereas together these drugs g ve 
a slgnlficant rise of about 3.44 fg/ml. (Leeming 980) So th s 
results also flt the predlctlons from the model well. tt h s also been 
claimed that trlmethoprlm lnhlblts the conversion of 7, 8 dlhydroblopterln 
to tetrahydroblopterln by dlhydrofolate reductase (Stone . 976) and this 
would also add to increased serum 7, 8 dlhydroblopterln levels and low r 
tetrahydrobiopterin levels . 
This would 1 0 Y. et d fr h r ul 
presented ln this thesis of the bi h l 
osyn et c stud! . (Ch pt r ) 
Patients wl th blood lead levels great r than l 00 
have Significantly lowered serum 7, 8 dihydroblopt rln 1 v ls of O. ·•S JJ /L 
corn pared to the nonnal 1. 75 pg/L (Leeming and Bl lr 1980 ) nd one 
child with lead poisoning had a serum level of 0.8 f9/L Inst d of th 
nonnal 1. 78 )lg/L . (Leeming and Blair 1980a) This fits well with th 
data presented ln thls thesis that lead Inhibits tctr hydroblopterln 
synthesis from GTP. (Chapter 3) There Is ex rlrnen al evidence from 
in vivo rat studies that also supports thls hypothesis. (Hilburn 1979, 
Leeming 1979) 
The correlation of the Ln vlvo results with the predictions th1't 
can be made from the tetrahydroblopterln metabolism model and th 
in vitro results obtained suggest that other diseases where blopterln 
levels are found to be abnormal may also be explained In a _si milar 
manner. However the effects on tetrahydroblopterln metabolism could 
be a secondary effect of the disease and not the primary cause . Care 
must be taken when considering serum dlhydroblopterln l vels because 
they are the result of tetrahydroblopterln metabolism In all tissues nd 
not just brain metabollsm. 
7, 8 dlhydroblopterln levels ln the serum have been shown to rlse 
with age belng l.95fg/L compared to the normal lev ls of l. 60/19/L. 
(Leemlng and Blalr 1980a Leeming and Blair 1980b) Tyrosine hydroxy-
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lase activ i ty has been shown to dee 
r 1978, 
Bonati, Brunelle and Ponzio 1977) h 
as v o mln nd nor d n lln 
levels, (Austln, Connole , Kett and Collin 1978) 
of d ihydroneopterin tri phos phate would glv Iner 
and decreased serum d lhydroblopterln cone ntr •lo 
lnhlblllon 
which h v 
measured. (Leeming and Bl alr 1980a, Le mlng, BI lr, 11 I n nd 
O'Gorman 1976, Rokos, Rok os, Frlslus nd l'lrst d · r 1980) 
n 
V l 
Schlzophrenlc pati ents have b en shown to h v low s rum 
dihydrobiopterin level s (Leeming , Blair, Mellki n nd O'Gorm n 1976) 
and significantly high fastlng le vel s of phenylalanine . (Polsn r 1960) 
Urinary excretion of phenylethylamlne has been r ported to b lgnlflc ntly 
higher in paranoid chronic schizophrenics corn r d to norm l tl nts . 
(Potkin, Karoum, Chatang, Cannon-Spoor , Phillips nd Wy tt 1979) 
Dopamine levels in schizophrenia are ra i sed . (0 . H . E. 1979) Do mine 
feeds back to inhibit tyroslne hydroxylase (Nag tsu , Mlz t nl, N g tsu , 
Matsuura and Sugimoto 19 72, Musacchio , D 'Angel o nd M cQu en 1971) 
and limits its own product Lon from tyrosine nd this cou Id expl In th 
lowered serum dihydrobiopterln l evel s observed whereas the results 
presented in this thesls suggest that the dlhydroblopterln level ln th 
serum should be high due to Inhibition of dlhydropterldlne rcduct so by 
dopamine. rn a volunteer who took a monoamlne oxldase lnhlbltor, 
Nardi!, which should Lncrease dopamlne concentrallons, the serum 
dihydroblopterln concentrations decreased wh i ch agrees wlth the 
observations made ln schlzophrenl c patlents . 
In Parkinson 's disease he dopamln 
19 66, Horynykiewlcz 1973) and admlnistr 
or 
or L-DOPA have been found to be bcneficl l ln m ny ll n . 
(Cotzias, Van Woert, Schiffer 1967 Gey nd Pl t eh r 19 ) 
are also given monoamlne oxldase Inhibitors which prolo g th 
no c d 
P l n 
c Ion 
of dopamine by lnhlbltlon o f lts breakdown. L v l of rum dlhydro-
biopterin in Parkinson 's disease were found to b no tgnlflc n ly 
different from those of normal patients. (Le mlng, 81 lr, Ilk! n nd 
O'Gorman 1976) However all these patlents wer m dicat d xc pt on 
in which the levels were hlgher than normal at 5. 2 )Jg/L. In m die l d 
patients the drugs increase dopamine levels which Inhibit tyrosln 
hydroxylase and reduce dlhydroblopterln levels. B caus the rurn 
C 
leve ls ln Parkinson 's disease are higher than normal anyw y, th over 11 
effect is that the serum levels of dlhydroblopterln r not lgntflc ntly 
different from those of normal patients. 
There ls a difference ln serum dlhydroblopterln lcv ls b twe n th 
sexes, normal males havlng hlgher levels (l. 75 JJ9IL) than normal 
females (1. 53 pg/L) wlth the greatest differences occurring betw nth 
ages of 21 and 30 whlch lndlcates there may be n hormonal Involvement 
in tetrahydrobiopterin metabollsm. (Leemlng and Blalr 1980a, Leeming 
and Blair 1980b , Leeming 1979) Women not taking oral contrac ptlvcs 
show a distinct cycllc pattern of serum dlhydroblopterln lev ls through-
out the menstrual cycle whereas women talc Ing oral contraceptlv s do not. 
(Leeming and Blair 1980a Leeming 1979) If th first day of m nstruatlon 
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is taken as day one of the cycle, the v lu 
in women not taking oral cont ceptlvcs dee 
of 
lowest value occurs at around day twclv Th n th 
about day twenty and the values then rls steadily t th nd of th 
·cycle to the hlghes~ value on day twenty-eight just for th on t of 
menstruation. These changes in levels c n be loos 
the changes in levels of oestrogens throughout th m nstru l cycl . 
(Guyton 1971) Tyrosine hydroxylase activity has also b n shown to 
vary throughout the menstrual cycle (Voogt, Carr and Levin 1979) nd to 
increase following ovarlectomy ln rats (Beattle, Rodgers and Soyk 
1972) whereas oestrogen replacement therapy In ovarl ctomlz d r ts 
has been shown to decrease tyrosine hydroxylase activity ln the 
substantia nigra. (Lulne, McElwen and Black 1977) The hypoth lamus 
is capable of convertlng oestrogens to catechol oestrog ns such s 
2 hydroxyestradiol and 2 hydroxyestrone (Flshman and Norton 19 75, 
Fishman 1976, Paul, Axelrod and Dlllberto 1977) nd th se have been 
shown to inhibit the actlvlty of tyroslne hydroxylase. (Lloyd nd 
Welsz 1978, Foreman and Porter 1980) The catechol oestrogens ar 
similar ln structure to dopamine and hence could Inhibit dlhydropt rldlne 
reductase as dopam Lne does. (Chapter S) Thls would result ln high 
serum levels of dlhydroblopterln when the levels o( catechol o strogens 
are high, and hence would explaln why the serum dlhydroblopt rln 
levels correlate wlth oestrogen levels throughout the menstrual cycl 
A form of depresslon known as premenstrual tension occurs at the Um 
of the paramenstruum (Dalton 1971, Dalton 1964, lckham 1958) and 
this is the time f hi h 0 g scrum dlhydroblopt rln co n ra o . l 
therefore probably a time of d d 
ecre s do mln nd nor 
biosynthesls due to decreased tyrostn hydroxyls ctlvt y c u 
of decreased cellular tetrahydrobtoptertn cone n ratton . 1111 co Id 
explain the depression and ln-attentlveness s n In pr m nstru n Ion. 
(Dalton, 19?la, Dalton 1964, Wlckm n 1958, D lton 1970, Dalton 19 O) 
Levels of serum dihydrobl opterln have lso b n hown to v ry In 
pregnant women, being low at week 38 (1 . 01 }19/L) and rl Ing r pldly 
post-partum. (Leeming and Blair 1980c) Post-p rtum depr slon Is 
also common. (Dalton 1971a, Dalton 1971 b) The worn n po t-p r•um 
could be divided into two groups; i) those who bee m d pr s d and 
ii) those who did not. The flrst group had a greater serum dlhydrohlopterln 
than the second group (Leeming and Blair 1980c} which lndlcat s again 
that high levels of serum dihydrobiopterln are correla t d with d pr slon . 
Finally patients diagnosed as suffering from depr sslon also had 
significantly high serum dlhydrobiopterln levels corn pared to normal 
patients, and this was in both male (2 . 26 f9/L) and female {l . 87 JJ9/L) 
depressives. (Leeming 1979) 
It seems therefore that the model of tetrahydroblopt rln m tabollsm 
can be used to explain the differences ln serum dlhydrobloptcrln 
concentrations in dlsease where these have been found to alter. 
Increased serum dlhydroblopterln levels can b explained as d er as d 
dihydro"pterldine reductase actlvlty but decreased s rum dlhydroblopt rln 
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levels are more difficult to t ribu 
0 d f C nl fur r 
ments and observations are m d e. This I C U er d 
de novo biosynthesis of tetrahydrobtopt rln nd d er 
d yro n 
hydroxylase activity can lead to this condltlon. 
Th l tr hydro 
metabolism model explains the situation occurrln tn both h 
certain well-defined disease states such s ph nyl. tonurl 
p rln 
malignant hyperphenylalanlnaemlas so It can b d l nntn d th t c llul r 
tetrahydrobiopterin le vels are closely malnt lned by two proc , th 
dihydropterldine reductase salvage pathw y and th d novo t tr hydro-
biopterin biosynthetic pathway but the activity of th hydroxyl 
reactions also has some effect. [nterference of these pathw ys up .. t 
the balance of cellular tetrahydroblopterln and b c use It Is requlr d 
for catechol neurotransmi tter production, the bal nc of thes n uro-
transmitters as well. This can lead to ment l de! cts nd th approprlat 
disease syndrome develops. 
In order to further understand the control and lnt ractlon or th so 
pathways, further study Is required and their activities should b 
related to various disease states. The blosynth tic pathway, P rllcularly 
requires more consideration by the Isolation of each enzyme lnvolv d 
and these being studled lndlvldually In order to discover which 
particular step ls effected by the reagents . The m surcments of 
serum dihydroblopterln, tyrosine and phenylalantn concentrations ln 
t t eds to be related to actlvltles of enzymes oft trahydro-dlsease s a es ne 
biopterin metabolism. Dlhydropterldlne reductas ctl vl ty can now b 
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measured in platelets, lymphocytes nd gr nulo y 
obtainable from blood samples, so m king th d r cl y or tht 
lly 
enzyme from patients with disease s e sy . (rtrgulr , Co o nd D n · 
1979, Abelson, Gorka and Beardsley 1979) Compound u et I of 
being the agent responslble for Inte rference w th tr hydroblopt rln 
metabolism such as the catechol cstrog ns tn th m nstru l cycl c n 
be tested on the in vitro systems suc h a s those v:hlch hav b n tup 
for the work presented in this thesis and a ls o on In vlvo nnlm l rno 
or volunteers. 
By co-ordinating the results from all s uch s tudies, answ rs to 
many of the problems of tetrahydroblopterln me taboll sm may be obta1n d . 
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